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Thesis Abstract 
Background  
Randomised control trials (RCTs) are capital-intensive projects and demand substantial 
human and capital resources. Therefore, proper planning, precise research questions and 
adequate thoughts are required in areas such as acceptability of the intervention, participant 
recruitment, and selection of measurable outcomes. Ensuring all these are possible before 
delving into the main work can be forecasted through pilot trials. They help in determining the 
feasibility of the intended critical endpoints and ensure the applicability of the result findings. 
However, no matter how noble and vital the results are, improper reporting can make them 
unusable. 
The thesis brings to the fore the importance of pilot trials in low- and medium-income countries 
and how they can help make a case for more extensive definitive trials. It then focuses on how 
subgroup analysis can be used as an essential statistical tool for fully understanding clinical 
trial results and can be used to unearth non-apparent results in RCT. In the thesis, we highlight 
the need for accurate, systematic and complete reporting of pilot trials, by critically appraising 
the literature on abstract reporting in heart failure. The thesis discusses several aspects of 
pilot trial processes to understand better its unique role in helping refine the components of 
RCT, to make the running smooth and findings affirmative. Leveraging on the experience of 
working as a clinical research fellow in the second Investigation for Management of Pericarditis 
in Africa (IMPI-2) trial, the lessons learnt in planning, designing, implementation, recruitment 
and reporting of the IMPI-2 pilot forms the nucleus of this thesis. The experience acquired in 
the process and how they can help in planning future definitive studies are discussed in 
different sections of the thesis. 
Methodology 
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The thesis uses the experience gained in critical appraisal of the literature, participation in 
preliminary planning and active participation in a multicentre randomised control trial to 
understand the importance of some issues during an RCT. These areas include the need for 
specific objective setting, identification of research participants and collaborators, the 
acceptability of research intervention, proper identification of possible outcome measures, 
retention of participants and quality reporting of research findings. 
It begins with an overview of pilot trials, subgroup analysis and tuberculous pericarditis which 
is the primary disease focus of the IMPI project. Each subsequent chapter of the thesis is 
presented either as a published manuscript or prepared for submission as a manuscript.  
The quality of reporting of pilot trials is then examined by systematically surveying the reporting 
of abstracts of pilot trials in heart failure using the checklist of the Consolidated standard for 
reporting of trials (CONSORT) extension for pilot trials. A subgroup analysis of IMPI-1 trial 
planned a priori on the modification of the effect of prednisolone by baseline pericardiocentesis 
status of trial participants is used to highlight the role subgroup analysis can play in unmasking 
the group effect in the randomised control trial. The thesis then goes on to present the 
preliminary report of the IMPI-2 pilot study, highlighting the lessons learned and aspirations in 
need of refining. 
Retention of study participants is essential to achieve success in clinical trials, one way of 
ensuring this is by letting the study participants understand the objectives and processes of 
the research and gaining their confidence. Thus, in chapter six, we piloted the use of the 
University of California San Diego Brief Assessment of Capacity to Consent (UBACC), a 
screening tool for evaluation of informed consent (IC) comprehension as a training tool for 
iterative learning and evaluation of consent comprehension among IMPI-2 pilot trial 
participants. 
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Results and Conclusion 
Enormous resources expended in clinical research can yield good returns before the main 
work commences, a well-planned micro trial run in the form of a pilot study is undertaken. Our 
systematic survey of abstracts of pilot trials in heart failure showed that reporting of abstracts 
of pilot trials is currently suboptimal. Deciding ahead of time on what to report by systematically 
identifying the different sections needed to inform the audience can improve the quality 
adequately. Planning subgroup analysis during the design of main studies can help reveal 
unsuspected findings. The subgroup analysis result showed that pericardiocentesis, despite 
its essential use among patients with pericardial effusion, did not significantly influence the 
effect of prednisolone on the primary critical outcomes among IMPI-1 participants. The 
preliminary report of IMPI-2 trial was designed as a two-phase study; phase 1 results showed 
that at 50mg, intrapericardial alteplase was safe in facilitating complete pericardiocentesis, 
while phase two showed that it was feasible to recruit, randomised and follow up patients in 
line with the study protocol. However, we identified participant retention as a considerable 
challenge. The result of the pilot revealed that more effort should be expended on participants’ 
education on the clinical condition, the reason for the trial and the need for follow-up 
adherence. There is also a need to make adequate provision for the use of field workers for 
contact tracing to reduce the dropout rate. In the main trial protocol, there may also be a need 
to reconsider the patient's selection and use of fibrinolysis in malignant effusion, judging from 
the high rate of 3 months mortality in this group of patients. 
The results of the informed consent study showed that an improved level of comprehension 
followed the use of iterative learning, a higher level of education and non-use of interpreters 
during informed consent delivery. These finding led us to conclude that every effort should be 
made to ensure that research participants entirely buy into the research they are asked to be 
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part of through thorough information delivery. Doing so can help improve participants 
adherence to the trial follow-up. 
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Overview of The Thesis 
In this PhD thesis I set out to achieve the following: 
1. Critically appraise the literature on pilot trials, subgroup analysis and tuberculous 
pericarditis - the building blocks for the works for the research 
2.  Systematically evaluate the quality of pilot trial reporting by focusing on heart failure 
pilot trials and, in that process, get familiar with the crucial items in reporting of pilot 
trials. Complete itemised reporting can help avoid missing out any detail and, 
ultimately, improve the conduct of the definitive main study. The exercise is part of the 
preliminary preparations for reporting of the findings of the second investigation of 
management of pericarditis in Africa (IMPI-2) pilot trial. 
3.  Understand how to conduct, analyse and report subgroup studies in RCT and, by so 
doing, show how subgroup analysis can further reveal RCT results. 
4.  Report the two-phase IMPI-2 preliminary study comprising of dose-finding (Phase 1) 
and IMPI-2 feasibility study (Phase 2) in preparation for the main trial and use the 
report to practically implement concepts already discussed in the introduction. 
5.  Present a pilot report of a tool for informed consent comprehension and show how this 
can help us improve participant adherence in the main trial. 
6. Describe how piloting, subgroup analysis and the strategies outlined in  1-5 above can 
be used collectively to the improve the efficacy and yield of clinical trials using the IMPI 
trials as a reference example 
7. Through use of different research methodologies in the chapters, the thesis to explored 
pilot trial designs and subgroup analysis for randomized clinical trials. The experience 
of the investigation for management of pericarditis (IMPI) trial is used in understanding 
how to improve the conduct and report of RCT. 
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In many resource-limited environments such as sub-Saharan Africa, the funding, infrastructure 
and resources required to invest in the conduct of large randomised controlled studies and 
other resource-intensive clinical studies are often not available. Researchers in these regions, 
therefore, find it difficult to conduct such studies and, when they do, several limitations make 
their results non-generalizable. Two essential research tools which are underutilised to aid 
and facilitate research and address important questions are pilot trial and subgroup analyses 
of randomised controlled studies. Used efficiently they have the potential through their findings 
to provide the rationale for the conduct of larger more capital-intensive studies, train human 
resources and attract collaborators for bigger works, as well as boost funders’ confidence in 
the ability of the sites for more extensive studies. 
Pilot trials allow clinician/researchers the opportunity, to test the feasibility of conducting 
clinical trials; to test the safety of the investigational product and conducting the study; to 
identify protocol related factors that make the study work or not work and, more importantly, 
to recognize items and issues that can or cannot be modified.  
Subgroup analyses of already conducted randomised controlled studies are another critical, 
efficient and effective mechanism for answering important clinically relevant questions, 
especially where resources and capacity to conduct studies are not available. However, for 
the information from sub studies to be meaningful and useable, there is a need to have a clear 
understanding of the strengths and weaknesses of substudies, when they are indicated and 
acceptable methodological approaches to conducting them.   
The thesis provides an in-depth examination and exploration of the role of pilot trials in a 
resource-limited environment by using literature review, critical appraisal of the literature and 
practical example of a pilot trial which the researcher contributed to its design and conduct. In 
doing this, the focus is laid on the pilot trial protocol development, abstract publication and 
ability to inform the successful design and conduct of a more extensive study. In the thesis, 
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we also provide a practical example of a subgroup analysis from a randomised controlled 
study designed to help address an important clinical question which may influence clinical 
practice and patient outcomes.    
Chapter one is made up of introduction and review of the literature designed to summarize the 
following essential topics, all of which are core to the thesis and its objectives: i) Pilot Trials; 
ii) Subgroup analyses; iii) Tuberculous pericarditis, its management and outcomes; iv) The 
IMPI trial experience v) Informed consent comprehension and tools to improve the process. 
Chapter two is a protocol for critical appraisal of the quality of pilot trial, published as a way of 
illustrating the importance of high-quality protocols, to informing the subsequent design and 
development of modifiable methods of conducting a larger trial.   
Chapter three is a published critical appraisal of the quality of abstracts of pilot trials using 
heart failure related studies as the subject of focus and a systematic survey as the methods. 
In the survey, 92 out of 228 retrieved publications met the inclusion criteria. Pharmacological 
interventions were associated with better reporting. However, the overall quality of reporting 
of abstract, based on the Consolidated Standard for Reporting of Trials (CONSORT) extension 
for reporting of abstract of pilot trials, was suboptimal.   
Chapter 4 addresses a subgroup analysis of the IMPI-I trial. In it, we evaluate whether the 
effectiveness of adjunctive steroid therapy on the primary composite outcome of the trial is 
modified in the subgroup of patients who have had pericardiocentesis before the use of 
steroids. The analysis illustrates how subgroup analyses when performed and used correctly 
can be a useful tool to answer important questions, without having to repeat expensive large 
trials, to understand the limitations to the interpretations drawn from the conclusions.  
Chapter 5 was designed as a two-phased study (a dose-finding study and a feasibility study). 
In it, we present a practical example of the use of a pilot trial to inform the design and conduct 
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of a larger trial on patients presenting with large pericardial effusion. It is on the use of tissue 
plasminogen activator, compared with conventional pericardiocentesis to reduce combined 
primary outcome of death, repeat effusion with tamponade and pericardial constriction. The 
results show that the use of 50mg of alteplase is safe in facilitating complete drainage and 
recruitment is feasible. However, the high dropout rate in the pilot demands modification of 
protocol to ensure adequate follow-up. One way to address this is the focus of the next chapter 
of the thesis. 
In Chapter 6 we show that informed consent comprehension is key to ensuring autonomy and 
confidence of study participants. This chapter presents the results of a feasibility study on the 
use of University of California San Diego Brief assessment of capacity to consent 
Questionnaire (UBACC) as a training tool to improve consent comprehension among 
participants of the IMPI-2 pilot trial. The results of the study may allow for the implementation 
of an informed consent process that ensures better participant comprehension.  
In the 7th and final chapter, we present a summary and discussion of the major conclusions 
from the thesis, lessons learned, limitations and the essential take-home messages of the role 
of pilot trials and subgroup analyses to answer clinically relevant questions in resource-limited 
and other environments.   
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Chapter 1: Introduction and Literature Review 
1.1 General Comments  
Randomised control trials (RCTs) are a vital source of evidence that shape clinical practice. 
Proper planning and preparations go into the conduct of RCTs for them to effectively play this 
role. Pilot studies provide essential building blocks for RCTs by serving as “crystal balls” to 
peep into the processes of main studies and help prepare the team ahead of time. 
The first investigation of pericarditis (IMPI-1) trial, a randomised control trial on the use of 
adjunctive steroids and immunotherapy raised discussions on how the use of these 
interventions affect short term complications such as tamponade requiring 
pericardiocentesis, hospitalisation, and long-term complications such as the risk of 
malignancy, death and constrictive pericarditis.  The main conclusion from the trial was that 
adjunctive steroid and immunotherapy did not have any effect on the primary composite 
outcome of all-cause mortality, tamponade requiring pericardiocentesis and 
pericardiocentesis; they also led to increased incidence of HIV-related malignancy. Use of 
prednisolone resulted in a reduction of secondary outcomes of hospitalisation and 
constrictive pericarditis. However, these IMPI-1 trial conclusions were based on the entire 
study population; there is a need to examine further their consistency through evaluation of 
the robustness of the overall results and seeing how the intervention effects differed based 
on individual population characteristics. In IMPI-1, provision was made for this interrogation 
of the RCT results through a priori subgroup analysis to explore if there was any difference 
in the effects among the subgroups; one such subgroup was pericardiocentesis status at 
baseline.  
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In the second investigation for management of pericarditis (IMPI-2) trial, percutaneous 
drainage facilitated by intrapericardial fibrinolysis will be compared with routine 
pericardiocentesis, so the lessons from this subgroup analysis on the influence of 
pericardiocentesis will aid our understanding of the results of the RCT better. It will also 
contribute to the planning of the pilot trial and ultimately the next phase of the IMPI study. 
The experience garnered in understanding the different research methods involved in the 
IMPI trial and using the knowledge in planning the execution of the current phase of the trial 
form the crux of this thesis. 
1.2 Pilot trials, their roles in directing clinical research 
1.2.1 Definition 
Pilot trials refer to small preliminary studies which aid researchers in deciding on starting larger 
confirmatory trials (Arain et al. 2010a; Conn et al. 2010; Thabane et al. 2010) They are made 
up of a distinctive group of randomised controlled trials which are often referred to as pilot or 
feasibility studies, which do not have effectiveness or efficacy as their primary focus (Eldridge 
et al. 2016). They are a version of the main study run in miniature form to determine if the 
components of the main study can work (Glossary 2013). Pilot trials are not by nature designed 
for testing of hypothesis but rather should emphasise confidence interval estimation 
(Lancaster 2015; Lancaster, Dodd, and Williamson 2004a) and are usually set up to support 
the development of a future definitive RCT (Anderson and Prentice 1999). 
Pilot trials in their design are used to lay the foundation for a larger trial. They provide 
information for planning and justification of randomised control trials and often, their results 
can lead to changing of study design (Arain et al. 2010a). They are usually focused on 
ensuring of the smooth running of the processes in the main study such as recruitment, 
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randomisation, treatment, flow and follow up assessment (Leon, Davis, and Kraemer 2011; 
Ross‐McGill et al. 2000).   
Pilot trials are a form of a feasibility study in that they test the feasibility of conducting the main 
trial (Whitehead, Sully, and Campbell 2014; Thabane et al. 2010). They provide training and 
experience in the running of the main study by highlighting identified problems so that they 
can be corrected before the main research begins. To distinguish pilot trials from pilot works 
or pilot studies, one paper referred to pilot trials as stand-alone pilot studies incorporating a 
randomisation procedure (Arnold et al. 2009). 
 
1.2.2 Features of Pilot trial 
For a study to qualify to be designated as a pilot trial, such a study must have a strict study 
methodology, such as sample size justification and a clear intention for further work must be 
stated up front.  There should be clear understanding that it is a small version of the main 
study with aspects such as randomisation and use of control as is expected in the main work. 
Also, the intention should be a focus on the trial process rather than outcome. Since pilot trials 
mimic main studies, the sample size should be representative of the target population for the 
main study and should aid the assessment of feasibility by having an adequate sample to 
provide such information. A pilot trial must also, among other things, be clear on the criteria 
for success based on the feasibility objectives. These attributes are essential as they serve as 
a check to lead investigators and reviewers on the four broad feasibility outcomes/conclusions 
of every pilot trials which are: stop (main study not feasible), continue but modify protocol, 
continue without protocol modification but monitor process firmly and continue without change 
(Thabane et al. 2010). 
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A well-structured pilot trial is made up of certain critical elements such as sample size 
calculation, the integrity of study protocol, testing of data collection tool/questionnaire, 
identification of source of participants, procedure involved in randomisation, processes such 
as recruitment and consent, how acceptable is the intended intervention and ensuring the 
most appropriate primary outcome measures are selected. These key elements have been 
referred to as reasons for the pilot trial and grouped into four broad sections, namely; process, 
resources, management and scientific bases (Van Teijlingen et al. 2001; Van Teijlingen and 
Hundley 2001). Before commencing a clinical trial, advance estimation is necessary on three 
classes of parameters. These issues involve administration, process and effect of the 
treatment; pilot trials address the first two adequately (Wittes and Brittain 1990). The 
administrative readiness is evaluated by such parameters as the number of participants 
expected to be identified, the willingness of these participants and their physicians to be part 
of the trial, and the rate of recruitment, randomization, compliance with the protocol as well as 
ability to identify events of interest and follow-up related to the process. The dose-finding 
phase constitutes the scientific bases of the trial hypothesis. It evaluates the dose and safety 
of the study medicine. Some argue that though it is part of the feasibility, it may not strictly be 
part of the pilot as already described (Lawrence Gould 2005).   
 
1.2.3 Goals of Pilot trial 
Pilot trials, as already defined, guide the planning of larger trials, they assess the safety of 
interventions, recruitment potentials, the feasibility of international collaboration, multisite 
coordination, increase experience with study drugs, evaluation of data collection tools and 
surrogate markers (Leon, Davis, and Kraemer 2011). These various aspects test the 
preparedness of the study team for the main trial and boast funders’ confidence in approving 
funds for the main study. 
5 
 
Through conducting a pilot trial, an opportunity is created to formulate consistent practice that 
can enhance data integrity and human subject protection (Leon, Davis, and Kraemer 2011). 
Pilots are focussed on the process of the main study such as recruitment, randomisation and 
follow-up. If data from the pilot phase contributes to the final analysis, this is termed internal 
pilot; however, if it is set aside and not included in the main trial data, it is called external pilot. 
The pilot phase is usually used in an internal pilot to describe the initial phase in the protocol. 
In such instances, the investigator estimates the parameters of interest at the end of the pilot 
and recalculates the sample size (Wittes and Brittain 1990). All observations are treated as if 
they come from a single study during data analysis at the end of the trial.   
A pilot trial could be critical in the training of research personnel through the provision of 
needed experience, thereby strengthening the competencies and skills needed for conducting 
the investigation with accuracy and precision (Whitehead, Sully, and Campbell 2014). It can 
function as a test (and if successful a safeguard) for the investigators and grant agencies to 
ensure that a future trial is designed optimally and can be implemented in practice (Arnold et 
al. 2009). It can also provide an opportunity to apply and examine the feasibility of an adverse 
event reporting system (Leon, Davis, and Kraemer 2011).  
 
1.2.4 Analysis of Pilot Trial 
A descriptive analysis should be used for pilot studies, with an emphasis on confidence interval 
estimation (Burrows et al. 2001) because hypothesis testing requires a power sample size 
calculation which is usually not available in the pilot. There are instances where the pilot trial 
has been used to generate sample size calculation (Thabane et al. 2010); however, the use 
of pilot trial in estimating treatment effect can be biased because of the limited sample size. In 
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such a situation, caution needs to be applied as a pilot trial can potentially mislead sample 
size or power calculation (Kraemer et al. 2006). 
External pilots which are stand-alone studies, however, can be hypothesis testing driven, but 
the interpretation of this should be cautious and the results treated as preliminary (Stevinson 
and Ernst 2000; Whitehead, Sully, and Campbell 2014). Safety efficacy and effectiveness are 
not evaluated in pilot trials. The temptation not to proceed with main studies when significant 
differences are found should be avoided. 
  
1.2.5 Limitations of Pilot trial 
Janet Wittes, in her paper on the role of internal pilot trials in increasing efficiency of clinical 
trials (Wittes and Brittain 1990), recounted the teaching of WG Cochran in which he listed pilot 
trials among undesirable practices; describing the proponents of pilots as mischief makers 
and concluding that pilots often lead to regret. According to WG Cochrane, when pilots show 
statistically or nearly significant results, the treatment effect could prevent one from embarking 
on a large-scale study, as administrators could ask, ‘Why should you perform a large study 
when a small one sufficed? A small study would not be persuasive enough to influence medical 
practice.' Whereas a pilot study that showed no effect would also prevent one from initiating a 
large study because the administrator would challenge, ‘Why should you embark on a major 
investigation when the pilot did not appear promising?' According to Cochrane, "The power of 
such a small pilot would be too low to exclude even significant differences among treatments" 
(Wittes and Brittain 1990). 
This opinion is still held by some publishers who insist that most pilot trials rarely act as 
precursors to bigger studies, while other journals discourage publishing of pilot studies 
because they consider them less rigorous compared to main studies (Arain et al. 2010a). The 
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only way pilot trials can break these stereotypes and lead to progression to definitive trials is 
by having clear methodological rigours. 
Inadequate publicity due to poor methodological approach is, therefore, a significant drawback 
for pilot trials. Though pilots could be used in sample size calculation, however, as already 
stated, they should not be used to estimate treatment effect due to their limited sample size. 
Doing so has the potential to mislead sample power calculation for the main study.  Labelling 
studies as a pilot for the wrong reason is another major drawback - identified reasons for doing 
this may include lack of funding, editor's suggestion, and single-site study (Thabane et al. 
2010). Finally, the perception of some publishers and journal editors is another limitation to 
pilot trials. 
 
1.2.6 How should Pilot trials be reported? 
Every research endeavour merit being communicated to the reading public to achieve the 
desired impact, which is knowledge dissemination leading to change in practice. Pilot trials, 
by their small and exploratory nature, run the risk of non-reporting especially following negative 
results. Some publishers, as a policy, do not publish pilot trials claiming that they lack 
methodological rigor. However, if pilot trials are to fulfil their role of informing the processes 
and development of larger trials, then efforts should be expended in systematically reporting 
them. Doing so will discourage repeat of the same errors, as well as help in the planning of 
main trials. The Consolidated Standard for Reporting of Trials (CONSORT) was developed in 
1996 to bring uniformity in ways RCTs are reported (Hopewell et al.).  The CONSORT 
extension for reporting of pilot trials was released in 2016 to include pilot trials reporting. It is 
a good guide on things to include in the report of pilot trials. Journals can insist that publications 
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adhere to the use of such tools as included in the CONSORT checklist to improve the 
completeness reporting of pilot trials (Eldridge S 2016). 
In the IMPI-2 trial, certain key features of the CONSORT extension for pilots were added to 
address pilot trial. These included emphasising to the patients that the major objective was 
feasibility, stating prespecified parameters to assess success of the objectives, and clearly 
having prespecified criteria used to judge whether, or how, to proceed with future definitive 
trial. The randomization technique was also perfected in this internal pilot as we plan to use 
it in the main trial. In accordance with the CONSORT extension, the findings of the pilot are 
presented in this thesis as stipulated by guideline. 
 
1.3 The role of subgroup analysis in clinical research: An overview 
1.3.1 Introduction 
Randomised control trials are usually set up to determine the benefits and harm of 
interventions but are not powered enough to detect heterogeneity (Collins 1996). The 
magnitude of these benefits or harm is often dependent on the baseline characteristics of the 
individual participant. Subgroup analysis is used to investigate the consistency of these 
treatment effects across groups to ensure correct interpretation and to avoid attributing such 
importance to heterogeneity in treatment which could have been by chance.  
Subgroup analysis can, therefore, be defined as an analysis that explores whether intervention 
effects (experimental versus control) differ according to the participant's characteristics 
(Kasenda et al. 2014). They investigate the consistency of heterogeneity of treatment effects 
across the group based on baseline characteristics, bearing in mind that the observed 
heterogeneity in treatment effect can arise by chance due to the partitioning of the population. 
It, therefore, in ensuring that the broad range of effects of intervention in a trial is captured, 
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plays an essential role in the interpretation of clinical trial findings. Relative risk, odds ratio or 
arithmetic difference is used to estimate the treatment effect [a comparison between treatment 
groups] (Wang et al. 2007). 
Evaluation of consistency of the trial conclusions among the different population, as defined 
by each baseline characteristic, is the reason for undertaking subgroup analysis (Wang et al. 
2007). The result of RCTs are often complex and made up of pulled results which often are 
based on several generalizations. Subgroup analysis are used to unpack these results by 
focusing on group characteristics. By doing this, they may help draw attention to previously 
unacknowledged findings.  However, inappropriate subgroup analysis not supported by 
scientific rationale can give rise to over-stated and spurious misleading results either by 
coincidence (multiple testing effect) or by unintended patient selection mechanism (Yusuf et 
al. 1991; Assmann et al. 2000; Sleight 2000; Lagakos 2006).  These situations are rife in post 
hoc subgroup analysis (where the intention only come after the data is inspected) and such 
concerns are justified (Alosh et al. 2017). However, there are numerous instances where 
subgroup analysis has led to discoveries of a new treatment or revising of initial 
recommendations based on general population results due to the finding out of the beneficial 
effect of treatment in specific subgroups (Rédei 2008; Bachynsky, Infeld, and Shah 2008). 
Subgroup analysis can be categorised into (1) exploratory in cases where the overall effect is 
not established in the whole study population, and the aim is to find out if there is a positive 
effect in the groups. Here the findings are hypothesis generating and the results require 
confirmation in future trials;  (2) supportive analysis where positive impact has been shown, 
and the further analysis wants to establish consistency of these findings among the various 
subgroups; (3) inferential analysis where the aim is to determine treatment efficacy in a 
predefined targeted subgroup (Alosh et al. 2017). 
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1.3.2 Indications for subgroup analysis 
Subgroup analysis could be could be used to explore the effect two potential treatment 
heterogeneity - either effect related to risk or effect related to pathophysiology (Rothwell 2005). 
It may also be due to reasons of essential clinical questions related to the practical application 
of treatment or under-utilisation of treatment in routine clinical practice due to uncertainty about 
the benefit.   
Several motivations have been reported to drive these indications such as the need to 
evaluate the robustness of the overall result across subgroups and evaluation of the risk-
benefit profile of treatment on the different subgroups. Others are the requirement of 
explaining the variation in treatment effects, because pulling results from a heterogeneous 
population can increase the risk of missing significant effects. Also, the observed general 
effects may not be precise for individual patients. It can also aid in drug labelling. 
 
1.3.3 Method and guideline in conducting subgroup analysis 
In subgroup analysis, study samples are broken down into a subset of participants based on 
shared characteristics, with the goal of exploring the differences in how people respond to the 
intervention. In doing this, variables should be limited to baseline characteristics to ensure that 
they were not affected by the study treatment. To avoid ambiguity, the objectives must be 
defined upfront from the onset and the reasons for the subgroup explained scientifically based 
on sound hypothesis and reporting of findings should include all the subgroups and not a 
selected few. Statistical methods for conducting exploratory subgroup analysis include use of 
marginal structural modelling and propensity matching. 
Due to the crucial role well-conducted subgroup analysis could play in trials, many regulatory 
bodies encourage their use by researchers to investigate the consistency of treatment effects 
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and the impact of such findings on the interpretation of clinical trials (Group 1999; Alosh et al. 
2015; Wang and Hung 2014; Maggioni et al. 2007). However, subgroup analysis remains a 
controversial issue with many protagonists and antagonists drawn between clinicians and 
statisticians, a situation that has previously been referred to as the “clinicostatistical” tragedy 
(Feinstein 1998). There is every need to ensure adherence to laid down guidelines in 
undertaking and reporting subgroup analysis in order to avoid the pitfalls.  
Subgroup analysis can aid the design of future trials; therefore there is a need to reinforce the 
foundation on which researches are built through ensuring uniform reporting (Wang et al. 
2007). In a bid to encourage a more explicit and more complete reporting of all aspects of 
RCT, including subgroup analysis, the CONSORT guidelines were proposed in 1996 and 
subsequently edited in 2001 (Altman et al. 2001). Despite these efforts, review of several 
publications show that most researchers do not obey these rules. These flagrant downplaying 
of the set guidelines are the reasons while many commentators oppose the use of subgroup 
analysis while others refer to them as attempts at data mining. 
Planned subgroup analysis should be documented in the trial registry at the stage of protocol 
development and ensure adherence to the guidelines for protocols of RCTs, such as the  
Standard Protocol Items Recommendations for Interventional Trials [SPIRIT] (Chan et al. 
2013). It has also been canvassed that journals request access to a protocol of statistical 
analysis plans for reviews. 
The robustness of subgroup analysis can be significantly enhanced by considering multiple 
factors rather than individual baseline characteristics. Risk of disease outcome calculated from 
prespecified externally validated formula can be used to categorise them into separate groups 
by incorporating several baseline characteristics. 
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Results of subgroup analysis should be exploratory because significant testing in it is 
inappropriate unless alpha levels needed to achieve significance is attributed to a comparison 
of interest in advance. Forest plot with the level of baseline factors is the most appropriate way 
of presenting information about plausible treatment effects (Cuzick 2005; Wactawski-Wende 
et al. 2006). The confidence interval in such a plot should not be used to indirectly assess 
statistical significance based on whether they exclude a null effect; doing so is the same as 
using subgroup analysis to look for significant testing (Hayward et al. 2006; loannidis and Lau 
1998). 
If the effect of intervention varies in the subgroup, this is referred to as effect modification of 
the intervention on the outcome due to the additional presence of subgroup variables. Tests 
of interactions like multivariable modelling are used to test the significance of these 
differences. The credibility of subgroup analysis is improved if confined to the primary outcome 
and a few predefined subgroups based on biologically plausible hypothesis including factors 
used to stratify randomisation (Assmann et al. 2000). 
 
1.3.4 Limitations to using subgroup analysis and ways to avoid them 
Patients in a trial have multiple characteristics simultaneously. However, in subgroup 
analyses, these characteristics are erroneously considered one at a time. One glaring 
consequence of this is multiple testing which could lead to type 2 error (false negative result). 
Also, in doing several subgroup analyses, there is the problem of reduced sample size and 
loss of statistical power to detect any effect.  Embarking on post hoc analysis after inspection 
of data most likely leads to error, and this has led to the conclusion held by some that reporting 
of subgroup analysis is characterised by poor practice (Parker and Naylor 2000; Pocock, 
Hughes, and Lee 1987; Pocock et al. 2002; Yusuf et al. 1991).  
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Suggestions have been made on ways to avoid the dangers in subgroup analysis, and this 
begins at the stage of planning before randomisation (Cook, Gebski, and Keech 2004). The 
subgroups need to be defined a priori, stating reasons for selection. The appropriate test for 
hypothesis should be employed, interaction used to test for heterogeneity, and adequate 
adjustment should be made for multiple testing. 
In interpreting the result, the general trial findings should be explained, rather than the 
subgroup, since it has less power to detect a therapeutic effect, the discussion should be done 
considering biological knowledge and findings from an independent study.  
In evaluating the results of a subgroup analysis attention should be paid to the chance of 
association, biological gradient, consistency of findings with previous works, the presence of 
confounders and the plausibility/coherence of report.  
The validity of subgroup analysis results can be evaluated through some criteria: Is the noticed 
difference suggested by comparison within or between the group, what time was the 
hypothesis generated? Before data inspection (a priori) or after (post hoc); how large is the 
magnitude of the effect and if it was statistically significant.  Also,  the other results should 
confirm the same findings seen reported by the indirect evidence to support the subgroup 
effect (Oxman and Guyatt 1992). 
 
1.4 Overview of tuberculous pericarditis with relevance to the IMPI trials 
1.4.1 Introduction 
Tuberculosis (TB) is a  prominent health concern globally and a leading cause of mortality and 
morbidity in low- and medium-income countries [LMICs] (WHO 2013). It is now the world’s 
leading cause of death from infectious diseases, exceeding acquired immune deficiency 
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syndrome (HIV/AIDS) and malaria. The World Health Organization (WHO) 2018 report 
estimates about 10.4 million new cases of and tuberculosis worldwide, and 1.674 million 
deaths yearly (1.3 million HIV negative and 374,000 HIV positive) from the disease, with 
approximately 95% of these patents residing in LMICs (WHO 2017). 
Tuberculous pericarditis is a disease caused by infection/inflammation of the pericardial 
covering of the heart by Mycobacterium tuberculosis. Pericarditis is the most common disease 
of the pericardium in clinical practice and refers to the inflammation of the heart covering; it is 
responsible for 0.1-0.2% of all hospital admissions (Kyto, Sipila, and Rautava 2014; Lange 
and Hillis 2004) and the cause of about 5% of emergency room presentations for chest pain 
without myocardial infarction. The aetiology of pericarditis is based on the local epidemiology, 
in Europe, the majority of cases are idiopathic (mainly viral) or from malignancies, with 
tuberculosis accounting for about 4% (Imazio, Brucato, et al. 2010).  However, in Africa and 
India, tuberculosis is responsible for 70-80% (in HIV negative) and up to 90% (in HIV positive) 
cases of pericarditis (Adler, Charron, Imazio, Badano, Barón-Esquivias, Bogaert, Brucato, 
Gueret, Klingel, Lionis, et al. 2015; Imazio, Brucato, et al. 2010). This report makes 
tuberculosis the most prominent cause of pericarditis in Africa and other parts of the world with 
a high TB burden. 
According to WHO report, the high morbidity and mortality from TB is mostly contributed to by 
the difficulty in diagnosis and delayed initiation of treatment in tuberculous pericarditis and 
other forms of extrapulmonary TB (Mayosi et al. 2008a; Larrieu et al.).  The reason for this is 
the paucibacillary nature of extrapulmonary TB leading to the low yield of Mycobacterium TB 
required for culture, which is the gold standard for the confirmation of the diagnosis of TB. The 
delayed diagnosis results in a long time before the commencement of treatment, which may 
affect the outcome.  
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1.4.2 Epidemiology  
The incidence of pericardial involvement following pulmonary TB is estimated to be 1-8% 
(Lorrel 1997; Denk et al. 2016). Autopsy studies done before the HIV/AIDS  era show that 
there is pericardial involvement in up to 1-2% of patients known to have had pulmonary TB 
(Fowler 1991; Trautner and Darouiche 2001).  
The epidemic of HIV/AIDS has led to an increase in the morbidity and mortality of TB and 
consequently of TBP; this can be attributed to the fact that the 10% lifetime risk of TB in an 
immunocompetent adult exponentially increases to 10% per year and, in cases of severe 
immunodeficiency, it is estimated to be 30% per year.  During the pre-antibiotics era diagnosis 
of tuberculosis led to certain death with a reported mortality of 80-90%. However, the 
introduction of anti-tuberculous drugs led to a reduction in case fatality to 8-17%, but with the 
scourge of HIV/AIDS has resulted in a significant pushback in the success achieved, with a 
reported mortality of 17% in HIV negative patients and 40% in HIV positive patients in an 
African multinational study (Mayosi et al. 2008a). 
Tuberculous pericarditis (TBP) contributes to the increased mortality of tuberculosis and is the 
most frequent cause of constrictive pericarditis in Africa and Asia (Mayosi, Wiysonge, Ntsekhe, 
Volmink, Gumedze, Maartens, Aje, Thomas, Thomas, Awotedu, et al. 2006). It is responsible 
for 50%-70% of pericardial disease, and 7% of cases of heart failure in Africa (Mayosi, 
Wiysonge, Ntsekhe, Volmink, Gumedze, Maartens, Aje, Thomas, Thomas, Awotedu, et al. 
2006). The incidence of TBP in Sub Saharan Africa is increasing because of HIV epidemics, 
as it is leading the resurgence of TB. Large pericardial effusion occurring in up to 90% of HIV 
infected patients living in Tuberculous endemic areas are caused by tuberculosis (Reuter, 
Burgess, and Doubell 2005; Cegielski et al. 1994; Maher and Harries 1997). In the Sub-
Saharan Africa Survey of Heart Failure (THESUS–HF), conducted in 9 African countries 
between 2007-2010, pericardial effusion with tamponade was the cause of acute heart failure 
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in 6.8% of the patients (Damasceno et al. 2012). Approximately 65.6% of the cohorts in the 
first investigation of the management of pericarditis (IMPI-1) trial drawn from  South Africa, 
Malawi, Mozambique, Kenya, Nigeria, Sierra Leon, Uganda, Zimbabwe were HIV positive 
(Mayosi et al. 2014).  In a study from Malawi more than 60% of patients with pericardial TB were 
HIV positive (Maher and Harries 1997). Tuberculosis is responsible for 37% of patients with 
large effusion in Kuwait (Uthaman et al. 1997), while in the United Kingdom the immigrant 
communities account for 26% of pericardial effusion (Gibbs et al. 2000).  
 
1.4.3 Pathogenesis 
The occurrence of pericarditis follows inoculation of the bacteria into the pericardial space, 
resulting pathologically in polymorphonuclear leucocytosis (Figure 1.1) with abundant bacilli 
and granular formation (Spodick 1956). The bacilli gain access to the pericardium either by 
retrograde lymphatic spread from the mediastinum, paratracheal or parabronchial lymph 
nodes, through the hematogenous spread (common in immunosuppression). Direct 
contiguous spread from adjacent structures such as lungs, pleura and spine could be another 
rare route (Spodick 1956). The pathological changes seen in TBP are because of the body's 
immune response to Mycobacterium TB as it penetrates the pericardium, and this stimulates 
lymphocyte to release lymphokines which activate macrophages leading to granuloma 
formation. TH-1 lymphocytes have been shown to engineer the hypersensitivity reactions that 
lead to the development of effusion as demonstrated by the elaboration of the cytokine profile 
(Burgess et al. 2002). Also anti-myolemma antibodies mediated cytokines aid the exudation 
of fluid in TBP as shown by complement-fixing anti-myolemma and anti-myosin type 
antibodies seen in patients with tuberculous pericardial effusion (Maisch, Maisch, and 
Kochsiek 1982). In the literature, there are four pathological phases of tuberculous pericarditis 
and the clinical pictures seen in practice follow these phases (Table 1.2). 
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Figure 1.1: Pathophysiological changes in pericarditis  
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Table1.1: Stages of Tuberculous pericarditis (Ntsekhe and Mayosi 2013a)  
 
(Adapted with permission from Springer Nature Science. Ntsekhe M, Mayosi BM. Tuberculous 
pericarditis with and without HIV. Heart Failure Reviews. 2013;18(3):367-73) 
1.4.4 Clinical Presentation 
Stage 1 
• Pathological bases 
 
 
 
 
 
 
• Pathological 
manifestations 
• Clinical manifestation 
Fibrinous exudation predominates, occurrence of 
polymorphonuclear leucocytosis is first seen with 
relatively abundant mycobacteria. There is loose 
organization of macrophages and T cells with early 
granuloma formation (HIV patients with low CD4 T 
cells with fewer granuloma due to low immune 
response). 
Dry stage (the least common form seen). 
 
Patients present in acute pericarditis with chest pain, 
pericardial friction rub and widespread ST elevation 
without effusion. 
Stage 2 
• Pathological bases 
 
 
• Pathological manifestation 
• Clinical manifestation 
There are predominantly lymphocytic exudates with 
monocytes and foam cells; Presence of 
serosanguineous effusion is seen. 
Effusive stage (most common form seen)  
(1) Patients present with features of heart failure and 
/or cardiac tamponade due to moderate to large 
pericardial effusion. 
(2) Effusive constrictive pericarditis with coexistence 
of visceral constrictive pericarditis and simultaneous 
compressive pericardial fluid. The former become 
obvious following pericardial drainage. 
Stage 3 
• Pathological bases 
 
 
 
• Pathological manifestation 
• Clinical manifestation 
At this stage there is absorption of effusion, 
granulomatous caseation becomes organized and 
pericardial thickening occurs due to fibrin, deposition 
of collagen and ultimately fibrosis. 
Adsorptive stage 
Symptoms and signs compatible with constrictive 
pericarditis but radiological and echocardiographic 
evidence of thick fibrinous fluid around the heart. 
Stage 4 
• Pathological bases 
 
 
 
 
 
• Pathological manifestation 
• Clinical manifestation 
Constrictive scarring (the fibrosing visceral and 
parietal pericardium contracts on the cardiac 
chambers). Calcification leads to encasing of the 
heart in a fibrocalcific skin. Diastolic filling is impeded, 
causing the classic syndrome of constrictive 
pericarditis. 
Constrictive stage 
Constrictive pericarditis symptoms and signs 
predominate; and echocardiography confirms the 
diagnosis with no residual fluid in the pericardium. 
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Clinical presentation depends on the stage of the disease; however, some patients can be 
asymptomatic and the diagnosis of TBP made incidentally following presentation for other 
reasons. The Tygerberg score (Table 1.3) was developed to aid accurate and prompt 
diagnosis of tuberculous pericarditis in resource-limited settings where TBP is endemic 
(Reuter, Burgess, et al. 2006a). A total of 6 and above has a sensitivity of 86% and a specificity 
of 85% in reaching a diagnosis of TB pericarditis (Reuter et al. 2007). 
 
Table 1.2: Tygerberg score 
Clinical Parameter No of Point.  
1. Weight loss 1 
2. Night Sweats 1 
3. Fever 2 
4. Serum globulin >40 g/l 3 
5. Blood leukocyte count <10 × 109/l 3 
              Total  
      A total score of 6 or more is highly suggestive that tuberculosis is the cause of the 
pericarditis. 
 
 
About 3 - 8% of patients with TBP can present as acute pericarditis (Mayosi, Wiysonge, 
Ntsekhe, Volmink, Gumedze, Maartens, Aje, Thomas, Thomas, and Awotedu 2006; Mayosi 
et al. 2014), with complaint of pleuritic chest pain, finding of pericardial friction rub, 
electrocardiographic ST-T wave changes and PR depression, with or without new/worsening 
pericardial effusion [at least two of these can be used to make the diagnosis] (Klein et al. 2013; 
Imazio et al. 2014; Imazio 2012). Other signs and symptoms could include evidence of 
systematic inflammation, fever and raised markers of acute infection such as white cell count, 
ESR and C-reactive proteins. This condition has been attributed to the inoculation of tubercle 
bacilli into the pericardium, said to be characterised pathologically by polymorphonuclear 
leucocytosis with abundant bacilli and granuloma formation (Fowler 1991; Spodick 1956). The 
diagnosis is suggested in TB endemic areas by finding of constitutional symptoms, lack of 
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response to conventional antibiotics and resolution of symptoms following anti-tuberculosis 
medications (Mayosi, Burgess, and Doubell 2005). 
Two broad mechanisms drive the other clinical presentation of pericarditis; fluid accumulation 
around the heart, referred to as effusion, which may lead to the restraining of contraction of 
the heart (tamponade) or thickening of the pericardium without effusion which results in 
restriction of the pumping action of the heart (constriction) [Figure1.1 &1.2]. These two 
scenarios can usually present in three clinical forms: pericardial effusion, and its 
complications, constrictive pericarditis or a combination of effusion and constriction (effusive-
constrictive pericarditis).  Despite the discussion of these as separate clinical entities, there is 
much overlap in their manifestations (Mayosi, Wiysonge, Ntsekhe, Volmink, Gumedze, 
Maartens, Aje, Thomas, Thomas, Awotedu, et al. 2006; Syed and Mayosi 2007). 
 
 
Figure 1.2: Natural history of Pericarditis 
 
1.4.4.1 Pericardial Effusion 
21 
 
The pericardial sac usually contains 10-50 ml of plasma ultrafiltrate that lubricates the 
pericardial layers; the body homeostasis ensures that this quantity of fluid remains constant. 
However, alteration of this standard regulatory mechanism can lead to an increase in 
pericardial fluid. This can be due to reduced absorption (transudate), as seen in the situation 
of increased systemic venous pressure like the congestive cardiac failure or pulmonary 
hypertension or from inflammation (exudate) as in Mycobacterium tuberculosis, bacterial 
infection or neoplasm. Development of pericardial effusion can be insidious depending on 
such factors as rapidity of accumulation of fluid, pressure-volume balance and the underlying 
cardiac pathology status (Spodick 2003); symptoms are also non-specific and can include 
fever, night sweats, fatigue and weight loss (Hageman, D'Esopo, and Glenn 1964). 
 If fluid accumulation is rapid as is seen in trauma or during cardiac interventions, small acute 
pericardial effusions can lead to the dramatic development of tamponade physiology; with 
increased diastolic filling pressure, resulting in systemic and pulmonary congestion, leading to 
tachycardia, hypotension typical of cardiac tamponade (Spodick 1997). However, 
hemodynamically, slowly accumulating moderate-sized or even large pericardial effusions can 
be well tolerated. In this situation, pericardial effusion presentation is usually subacute or 
chronic if fluid collection is slow and in cases with adequate cardiac compensatory 
mechanisms, large pericardial fluid may be asymptomatic and findings incidental (Ivens, Munt, 
and Moss 2007). Therefore, the signs and symptoms of pericardial effusion are determined 
by the rate of accumulation of fluid, magnitude of pericardial fluid induced compression, 
compliance of the visceral pericardium and degree of inflammation (Ntsekhe and Mayosi 
2013b; Shabetai 1976). 
Physical presentations include chest discomfort, tachypnoea, dyspnoea on exertion, 
progressing to orthopnoea. Occasionally there could be a cough with dysphagia (Roy et al. 
2007). Most patients become weak and anorectic with fainting and syncope (Roy et al. 2007). 
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Cardiac tamponade, a life-threatening slow or rapid compression of the heart due to the 
pericardial accumulation of fluid, can be a grave complication of pericardial effusion (Imazio, 
Mayosi, et al. 2010; Ristić et al. 2014; Roy et al. 2007). The clinical signs seen include the 
following: tachycardia, pulsus paradoxus (defined as an inspiratory decrease in systolic arterial 
pressure of 10mmHg during normal breathing), raised jugular venous pressure (JVP), low 
blood pressure (hypotension), muffled heart sounds, reduction in electrocardiographic voltage 
with electrical alternans and an enlarged cardiac silhouette on chest X-ray with slow-
accumulating effusions (Figure 1.5A & 1.6A). Pulsus paradoxus is a crucial finding in cardiac 
tamponade. The exaggerated ventricular interdependence occurring in cardiac tamponade 
when the overall volume of cardiac chambers becomes fixed is the reason for pulsus 
paradoxus. Changes in the volume of one side of the heart lead to changes on the other side 
(Adler, Charron, Imazio, Badano, Barón-Esquivias, Bogaert, Brucato, Gueret, Klingel, Lionis, 
et al. 2015) 
 
1.4.4.2 Constrictive pericarditis 
Though tuberculosis has become a rare cause of constrictive pericarditis in developed 
countries, it remains a significant cause in developing countries and most regions with high 
TB burden (Mutyaba et al. 2014) Other causes include purulent pericarditis from a bacterial 
cause, neoplasm, while it is rare in viral pericarditis. Factors such as duration of constriction, 
its severity and presence of ongoing pericardial inflammation can all influence the clinical 
presentation of constrictive pericarditis (Spodick 1997).  
Clinical signs of congestion will include engorgement of neck veins; peripheral oedema is 
uncommon. Liver enlargement leading to abdominal swelling and discomfort are typically more 
consistent with constriction rather than effusion (Strang, Kakaza, et al. 1988; Reuter et al. 
2007). Pulmonary oedema results in a cough and dyspnoea, while pleural effusion can be 
seen (Hageman, D'Esopo, and Glenn 1964). 
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1.4.4.3 Effusive-constrictive pericarditis 
Effusive-constrictive pericarditis refers to coexistent of features of pericardial effusion and 
constriction, with the signs of the later developing after fluid accumulation is removed (Ntsekhe 
et al. 2013a). It is said to result from thickened non-compliant visceral pericardium secondary 
to chronic inflammation (Hancock 1971; Russell et al. 2008). This finding occurs in up to 50% 
of tuberculous pericarditis and some reports have attributed it to a more severe outcome 
(Ntsekhe et al. 2012). Both clinical features of pericardial effusion and constrictive pericarditis 
can exist individually or both at the same time (Figure 1.7). During pericardiocentesis for a 
patient initially considered to have uncomplicated cardiac tamponade, the diagnosis often 
becomes apparent when clinical signs persist after removal of the fluid (Sagristà-Sauleda et 
al. 2004). Monitoring of right heart pressure, systolic arterial blood pressure and intra-
pericardial pressures are recommended whenever possible during elective pericardiocentesis. 
This is because, in some cases, pericardiocentesis can result in severe tricuspid regurgitation 
and right heart failure with persistently elevated right atrial pressure (Kuroda et al. 2016; 
Anguera, Paré, and Perez-Villa 1997; Klimis et al. 2018). Non-invasive imaging modalities 
may equally be used to reach a diagnosis of effusive-constrictive (Ntsekhe et al. 2012). The 
epicardial layer of the pericardium, which is responsible for the constrictive component of this 
process, is not typically thickened to the degree that is detectable in imaging studies. 
Following pericardiocentesis for cardiac tamponade, effusive-constriction can be diagnosed 
by careful detection of Doppler features of constriction; it can also be suspected in these cases 
without hemodynamic monitoring. Cardiac magnetic resonance imaging can be used in 
establishing the diagnosis of constrictive pericardial disease. Through it, the pericardial 
thickness can be evaluated, as well as cardiac morphology, and function. It can also be used 
to study the intrathoracic cavity structures and help in differentiating constrictive pericarditis 
from restrictive cardiomyopathy (Cosyns et al. 2014). In effusive-constrictive pericarditis, 
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definitive treatment is by visceral pericardiectomy because the visceral pericardial layer, rather 
than the parietal layer, is the cause of the heart constriction in this case (Cosyns et al. 2014; 
Strang 1984). However, this delicate surgery should be reserved for performance at hospitals 
with requisite experience in pericardiectomy for pericarditis as it is technically difficult requiring 
sharp dissection of many small fragments until an improvement in ventricular motion is 
observed (Adler, Charron, Imazio, Badano, Barón-Esquivias, Bogaert, Brucato, Gueret, 
Klingel, Lionis, et al. 2015). 
 
1.4.5 Diagnosing Tuberculous pericarditis 
1.4.5.1 Confirmation of the presence of pericardial disease 
The chest x-ray shows enlarged cardiac shadows (Figure 1) with up to 90% of those with 
constriction having a cardiac-thoracic ratio higher than 55%, and calcification noticed in less 
than 5% (Strang 1984). Up to 30% of patients may have features of active pulmonary 
tuberculosis, and another 50% with accompanying pleural effusion noticed on chest x-ray 
(Rooney, Crocco, and Lyons 1970).  In electrocardiography, the presence of microwaves 
(Figure 1.5B) with a QRS amplitude less than 5mm in the limb leads and less than 10mm in 
the chest leads are obvious findings. 
Echocardiography is an essential non-invasive tool in making a diagnosis of TBP. The 
properties of being sensitive, specific, non-invasive and readily available at bedside, make M-
mode and 2-dimensional Doppler echocardiography the gold standard and most effective 
technique for the diagnosis of pericardial effusion (Horowitz et al. 1974). Pericardial effusion 
appears as echo-free space surrounding the heart medial to the position of descending aorta 
in 2D echocardiography, often noticed to be swinging in cases of tamponade (Figure 1.5C 
&1.6D). A small collection of 25-50ml of pericardial fluid can be physiologic and may be visible. 
The size of the echo-free space has been used to grade the severity of pericardial effusion 
and is often used in determining the feasibility of percutaneous drainage; small effusion is less 
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than 1cm, moderate 1-2cm and large more than 2cm. Fibrinous strands in visceral pericardium 
are typical but not specific of TBP (Liu et al. 2001; Ku et al. 2003; Mayosi 2009). 
In pericardial tamponade, echocardiographic features include swinging heart, right 
ventricular/right atrial diastolic collapse as seen on the 2D image, increased respiratory 
variation of E wave velocity across mitral valve ( Figure 1.5D) more than 25% (Ha et al. 2002). 
The inferior vena cava (IVC) plethora with less than 50% collapse noticed in the presence of 
tamponade or severe constriction (Ha et al. 2002).  
In situations of a technically limited echocardiographic study, computed tomography (CT) or 
magnetic resonance imaging (MRI), may be used to identify the characteristics of pericardial 
effusion and tamponade (Maisch et al. 2004; Sagrista-Sauleda, Merce, and Soler-Soler 2011; 
Verhaert et al. 2010). MRI and CT scan (Figure 1.7) where available can give additional 
information, such as the degree of inflammation and accurate measurement of pericardial 
thickness (Yared et al. 2010; Feng et al. 2011). Given the central positive position of 
echocardiography in making a diagnosis and the safety concerns in acutely ill patients, the 
clinical utility of CT and MRI is questionable. However, they play adjunctive roles to 
echocardiography, especially in situations that show atypical hemodynamic states, where the 
presence and severity of tamponade are doubtful, or when there are other unexplained 
conditions (Verhaert et al. 2010). 
 
1.4.5.2 Confirmation of aetiology of tuberculosis 
Establishing tuberculosis as the aetiology of pericarditis may be difficult due to the 
paucibacillary nature of TBP and low diagnostic yield. The gold standard investigative modality 
for TB is a culture of tissue and fluid (Reuter, Burgess, et al. 2006b; Heller et al. 2010). 
However, this often takes time and is not readily available for use in most of the populations 
with a high TB burden, leading invariably to a delay in the commencement of treatment, 
ultimately affecting patient management and eventual outcome.  
26 
 
Diagnosis can be categorised as follows: 1) Definite TBP: Diagnosis confirmed on a pericardial 
sample made by finding positive acid and alcohol fast bacilli on microscopy, a positive 
microbiological culture of Mycobacterium tuberculosis, the presence of caseating granulomata 
in histology or positive mycobacterial DNA detected by PCR in tissue or fluid (Mayosi  et al. 
2014).  2) Probable TBP: Presence of a lymphocyte predominant pericardial exudate with 
increased ADA> 4OIU/L, positive polymerase chain reaction, positive isolation of 
Mycobacterium TB from other sites 3) Non-TBP where there is an alternate diagnosis for the 
cause of pericarditis. 
To prevent the challenge of early diagnosis, the World Health Organization and other research 
bodies have, in recent years, invested heavily in finding prompt and cost-saving diagnostic 
tools.  The emphasis has been on the development of point-of-care highly sensitive and 
specific diagnostic methods that can detect Mycobacterium TB in EPTB (Nema 2012).  
Currently, available modalities include adenine deaminase assay (ADA), polymerase chain 
reaction (PCR) based gene Xpert MTB/RIF, with a sensitivity of 25-96.6% (Lawn et al. 2013). 
These were initially developed for pulmonary TB, but now in use in other EPTB like TBP. 
However, lower sensitivity has been shown in pleural and pericardial fluids (Friedrich, von 
Groote-Bidlingmaier, and Diacon 2011). Also, they exhibit lower sensitivity in smear-negative 
compared to positive smear patients (Vadwai et al. 2011). Cost of these investigations is also 
a significant challenge in limited resource settings (Table 1.2). 
Interferon-gamma has been demonstrated in TB pericarditis compared to non-TB pericarditis 
with a cut-off of 50ng/ml resulting in 97% sensitivity, 100% specificity and diagnostic 
accuracy of 95% (Reuter, Burgess, et al. 2006b). The diagnostic efficiency is unrelated to 
HIV infection. Interferon-gamma release assays such as QuantiFERON-TB gold are 
currently in use in TB diagnosis in most developed countries. It has a pooled sensitivity of 
75% among patients with active TB (Pai and Menzies 2007) and high specificity of 94% 
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when tested against patients with non-TB Mycobacterium (Dewan, Grinsdale, and 
Kawamura 2007). 
 
1.4.6 Promoting Prompt Diagnostic Modalities for Tuberculous pericarditis 
The year 2015 marked the millennium development goals (MDG) and global TB target 
deadline of reduction of TB disease burden. Post-2015 WHO target is shifting to sustainable 
development goals (SDG) of ending TB as a public health problem (2016-2030).  This it plans 
to achieve by, among other things, the pursuance of strengthening of diagnostic and laboratory 
testing to achieve the stated objectives. WHO, in this renewed mandate, advocate for the early 
diagnosis of TB and universal drug susceptibility testing (DST).  They also highlight the critical 
role of laboratories in the post-2015 era for rapidly and accurately detecting TB and drug 
resistance (Uplekar et al. 2015).  
In keeping with this, WHO and different research bodies have been evaluating other modalities 
with the aim of ensuring early, prompt and cost-saving diagnosis. To achieve this, they are 
encouraging research at the development of point of care highly sensitive and specific 
diagnostic methods that can identify active Mycobacterium TB (Nema 2012). 
In 2016 the World Health Organization (WHO), reviewed and recommended four new 
diagnostic tests (one for TB) and (three for multi-drug resistant TB [MDR-TB]). A next-
generation cartridge called Xpert Ultra, and a new diagnostic platform called GeneXpert Omni 
is in development. The WHO assessed some of these emerging diagnostic modalities in 2017 
(Organization 2016) and the 2018 global tuberculosis report (Organization 2018), listing them 
as TB diagnostics under development (Table 1.3).   
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Table 1.3: Diagnosis of Tuberculous Pericarditis 
 
 
1.4.6.1 Xpert MTB/RIF   
One landmark event in TB research was the development in 2010 of Xpert MTB/RIF 
automated molecular assay (Cepheid CA the USA) for rapid TB diagnosis and rifampicin 
resistant detection of markers of MDR-TB (Purohit and Mustafa 2015). The laboratory 
technique was developed and endorsed specifically for detection of pulmonary TB using 
sputum. Its use has however recently been extended to EPTB and; in all but one study, the 
sensitivity ranged from 25%-96.6% (Lawn et al. 2013). However, lower sensitivity has been 
documented in CSF, pleural and pericardial fluids,(Friedrich, von Groote-Bidlingmaier, and 
Diacon 2011). Also, cost is a limitation as well as lower sensitivity in smear-negative compared 
to smear-positive (Vadwai et al. 2011). In an IMPI-1 diagnostic substudy on patients with TBP, 
Xpert MTB/RIF was shown to have a lower sensitivity and negative value compared to 
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unstimulated interferon gamma and adenine dinucleotide (Pandie et al. 2014). Also, in a 
Cochrane systematic review looking at the use of Xpert MTB/RIF in EPTB, eighteen studies 
with median sample size (IQR) of 13 (3-19) specimen were identified that evaluated pericardial 
fluid. Results of the review reported a TB prevalence of 20% with sensitivity and specificity of 
25-100% and 69-100% respectively. Reporting on seven studies (324 specimens), the pooled 
sensitivity and specificity at 95% confidence interval for Xpert in this review was 65.7 [46.3-
81.4) and 96.0% (85.8-99.3] (Kohli et al. 2018). 
 
1.4.6.2 Unstimulated Interferon assay 
Use of interferon gamma (IFN) to diagnose TB pericarditis has been demonstrated at a cut-
off of 50pg/ml,  with 92% sensitivity, 100% specificity and 95% diagnostic accuracy (Reuter, 
Burgess, et al. 2006b). This diagnostic efficacy is unrelated to HIV infection. The principle has 
led to the development of a highly sensitive and accurate enzyme-linked immunospot 
(ELISPOT) test that detects IFN producing T cells specific for Mycobacterium tuberculosis 
antigen (Ewer et al. 2003; Liebeschuetz et al. 2004). Currently, IFN related analysis (IGRA's), 
such as QUANTIFERON TB gold, are in use in TB diagnosis in most developed countries, 
with a pooled sensitivity of 75% among patients with active TB (Pai and Menzies 2007) and 
high specificity of 94% when tested against patients with non-TB Mycobacterium infection 
(Dewan, Grinsdale, and Kawamura 2007). However, WHO did not recommend it for use in 
diagnosis in LMICs because of its inability to differentiate active from latent infection (WHO 
2011). Also, very few studies have evaluated their use in pericardial and other extra-pulmonary 
TB, and there is also the concern over inconclusive results in immune-compromised due to 
anergy (Vincenti et al. 2007). 
 
30 
 
Table 1.4: Progress in the development of TB diagnostics (August 2018) a  
 
1 Lessem E. The tuberculosis diagnostics pipeline. Treatment Action Group; 2017 
 
1 UNITAID. Tuberculosis – diagnostic technology landscape, 5th edition. Geneva: World 
Health Organization; 2017 
 
 (Reproduced with permission from World Health Organization 
www.who.int/TB/publications/global_report/en) 
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1.4.7 Treatment options currently available  
The treatment of tuberculous pericarditis is aimed at treating the Mycobacterium and the 
hemodynamic sequelae of the pericardial syndrome. 
 
1.4.7.1 Medical treatment  
Treatment of TBP is by use of four anti-tuberculous drugs (Rifampicin, isoniazid, ethambutol 
and pyrazinamide) for a minimum of 6 months. They reduce the likelihood of developing 
constrictive pericarditis (Gooi and Smith 1978) and mortality among HIV negative subjects by 
8-17% (Bhan 1980). The delay in commencing treatment has been blamed on the difficulty in 
diagnosis, which may lead to late complications such as constrictive pericarditis and increased 
mortality. Despite complete treatment, pericardial constriction still occurs, having been 
reported to commence within two weeks of the bacilli invasion of the pericardium (Föll, Geibel-
Zehender, and Bode 2010), thus emphasising the need for prompt diagnosis and 
commencement of drugs. In a post-hoc study evaluating the effect of the use of anti-TB drugs 
among cohorts with tuberculous pericarditis, there was an overall mortality rate of 1.43 per 
100 person-month in a median follow-up of 11.97 months (Pasipanodya et al. 2015a). Follow-
up research reported inadequate antibiotics concentration in the pericardial fluid, with a finding 
that pericardial fluid rifampicin median peak concentration was lower than the minimum 
inhibitory concentration (MIC) (Shenje et al. 2015). Also, pyrazinamide peak concentration 
was 40 times smaller than pH-adjusted MIC, and isoniazid was the only drug that reached 
pericardial fluid concentration. These findings support the need to investigate alternative drug 
regimens in patients with EPTB, in whom poor drug penetration may contribute to poor 
outcome. Others have also expressed concern that the conventional dose of rifampicin 
(10mg/kg/day) may be too low, for treating both pulmonary TB  and EPTB (Chigutsa et al. 
2015). The current thinking and direction in the development of new drugs was summarized 
in the 2018 Global tuberculosis report (Table 1.5). 
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In the IMPI-1 trial, prednisolone led to a decrease in the rate of pericardial constriction and 
hospitalisation compared to placebo. However, among HIV positive patients, it was associated 
with an increased incidence of cancers [1.05 versus 0,32 cases per 100-person-years, hazard 
ratio 3.27; 95% confidence interval 1.07;10.03. p-value 0.03] (Mayosi et al. 2014). 
The same trial also reported that immunotherapy using mycobacterium indicus pranii did not 
influence the outcome in patients but, instead, increased the incidence of cancers (0.92 versus 
0.24 per 100 person-years, hazard ration 3.69, 95% confidence interval 1.03;13.24; p-value 
0.03). 
A Cochrane systematic review pulling together evidence from 6 trials on interventions for 
pericarditis, including the IMPI- trial, concluded there was a moderate level of evidence that 
corticosteroid probably reduced death from pericarditis among HIV negative patients, but that 
there was little evidence that it can reduce all-cause mortality and the need for 
pericardiocentesis (Wiysonge et al. 2017). However, for antiretroviral drug naïve HIV positive 
patients, they found low-level evidence that corticosteroids can reduce constrictive pericarditis 
and hospitalisation, with no effect on death. 
Use of corticosteroid and mycobacterium indicus pranii from the available evidence can 
increase the incidence of cancer but this conclusion, according to the review, needs further 
investigation to prove certainty. 
The place of fibrinolysis in pericarditis is the subject of the second investigation of the 
management of pericarditis (IMPI-2) trial and the pilot study to ascertain the feasibility of this 
randomised control trial is the focus of this thesis. 
1.4.7.2 Invasive management/surgery 
Echocardiographic or fluoroscopic guided needle pericardiocentesis is the treatment for 
cardiac tamponade to drain pericardial fluid. The European Society of Cardiology (ESC) 
Working Group on Myocardial and Pericardial Diseases have proposed a triage system 
33 
 
(Figure 1.4), following the opinion of experts, as a guide on deciding when to intervene and 
when to transfer the patient to a referral centre (Ristić et al. 2014). 
 
Table 1.5: New anti-TB drugs and regimens in global clinical development pipeline August 
2018 (From Global tuberculosis report 2018) 
 
A) Order of listing: New drug compounds, repurposed drugs, regimens. 
B) New chemical class. 
C) Optimised background regimen. 
 (Reproduced with permission from World Health Organization 
www.who.int/TB/publications/global_report/en) 
 
 
Pericardiocentesis is the most useful therapeutic procedure for early diagnosis and 
management of cardiac tamponade and symptomatic large pericardial effusion. It is indicated 
as a necessary emergency procedure even in hemodynamically unstable patients because 
removal of a small amount of fluid allows normal ventricular filling and restoration of adequate 
cardiac output (Adler, Charron, Imazio, Badano, Barón-Esquivias, Bogaert, Brucato, Gueret, 
Klingel, and Lionis 2015). The procedure was first described in 1653 by Napoleon’s Physician, 
Riolanus, as trephination of the sternum to relieve the pericardial compression caused by fluid 
surrounding the heart (Loukas et al. 2012). The procedure of pericardiocentesis was later (in 
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1840) explained in the literature by Schur; and the formal description of subxiphoid approach 
was, for the first time, given in 1911 by Marfan (Marfan 1911; Spodick 1970). For a long time, 
the procedure was done blindly with associated morbidity and mortality of up to 20% and 6% 
respectively (Moores and Dziuban 1995; Kil et al. 2008; Nguyen et al. 2011; Ainsworth and 
Salehian 2011). The introduction of fluoroscopic guidance was later to improve the outcome; 
however, the advent of ultrasound in the 1970's, popularised by Mayo clinic, remarkably 
revolutionised the diagnosis and management of pericardial effusion (Tsang et al. 1998; Ball 
and Morrison 1997). Currently echocardiography guided diagnostic and therapeutic 
pericardiocentesis is considered the standard clinical practice in the treatment of pericardial 
effusion (Osranek et al. 2003). It has more than 95% success rate in significant effusion, with 
a morbidity rate of 1-3% and procedure-related mortality of less than 1% (Nguyen et al. 2011). 
Indications for pericardiocentesis include symptomatic moderate to large effusion not 
responding to medical therapy, suspected tuberculous, bacterial or neoplastic effusion for 
diagnosis, chronic (greater than three months) large effusion more than 2mm in size at the 
end of diastole (Adler, Charron, Imazio, Badano, Barón-Esquivias, Bogaert, Brucato, Gueret, 
Klingel, Lionis, et al. 2015). Contraindications include aortic dissection and post-infarction 
rupture of the free wall (though it can still be used as a bridge where no immediate surgical 
management is available to maintain blood pressure around 90mmHg) (Cruz et al. 2015). 
Other relative contraindications include coagulopathy, anticoagulation treatment and 
thrombocytopenia (platelet count less than 50000/Mm3). 
As already alluded to, the advent of echocardiogram significantly improved the diagnosis of 
pericardial effusion (Poprawski, Pitisuttitum, and Tansuphasawadikul 2000; Martin et al. 1978; 
Van Trigt et al. 1993). However, opinions differ on the place of pericardiocentesis in the routine 
management of pericardial effusion (Krikorian and Hancock 1978; Van Trigt et al. 1993). The 
procedure has been in existence since antiquity (Marfan 1911; Spodick 1970) but, until lately, 
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its use remained controversial (Krikorian and Hancock 1978). Proponents point to the 
simplicity, convenience, avoidance of general anaesthesia and ability to combine it with 
catheterisation (Kuhn 1976; Hancock 1971). Those opposed to its use argue that routine 
pericardiocentesis is only justified in patients without hemodynamic compromise, provided it 
adds relevant diagnostic information or help avoid further complications (Kilpatrick and 
Chapman 1965a; Fowler 1976; Silber EN 1975).  
Other management options preferred due to the ability for closer visualisation and tissue 
biopsy for diagnosis include subxiphoid pericardiectomy, pericardial window and thoracotomy. 
Isolated studies and case reports involving small sample done decades ago have had 
conflicting conclusions on the diagnostic yield, symptomatic relief and outcome of 
percutaneous drainage compared to surgical drainage (Callahan, Seward, Nishimura, Miller, 
et al. 1985; Kopecky et al. 1986a). Some have also compared surgical drainage to 
pericardiocentesis focusing on diagnostic yield and outcome (Allen et al. 1999). However, 
these studies were done in developed countries and, to the best of our knowledge, no such 
studies have been done in Africa and low- and medium-income countries (LMICs) where most 
of the clinical condition is seen. There has also not been a large-scale randomised control 
study to evaluate the role of pericardiocentesis in pericardial effusion outcome. 
Identification of aetiology of pericardial effusion is usually made by the invasive collection of 
pericardial fluid or tissue. Indications for invasive procedures such as pericardiocentesis are 
large or symptomatic effusion, the presence of tamponade, questionable cause of the effusion 
(Jung 2012).  
In situations where aetiology is not precise, clinical clues can aid in providing useful suggestion 
on possible aetiology. These clinical indices include the size of effusion, the presence of 
inflammatory signs and cardiac tamponade (Sagrista-Sauleda et al. 2000). 
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In order to promote adherence of pericardial layers and prevent further accumulation of fluid, 
prolonged pericardial drainage of up to 30ml/24 hours following pericardiocentesis has been 
advocated based on expert opinions, retrospective studies and case reports (LeWinter 2014; 
Ristić et al. 2014). 
Sixty per cent (60%) of patients underwent pericardiocentesis in the IMPI-1 trial; there was 4% 
re-accumulation with the development of tamponade, 8 % progressed to constriction, with 
about 50% achieving full recovery (Mayosi  et al. 2014). One of the conclusions drawn was 
that offering pericardiocentesis in TBP was a good clinical practice that may reduce the 
incidence of complications. However, this conclusion requires further investigation by 
comparing the eventual outcome with the subject who did not have pericardiocentesis. 
 In the IMPI-1 trial, a subgroup analysis to evaluate if the use of adjunctive steroids made any 
difference on the composite outcome among patients who had pericardiocentesis compared 
to those who did not undergo pericardiocentesis; in chapter four of this thesis, the result of the 
analysis is presented.  
In those who already have features of advanced fibrinous TB effusion, pericardiocentesis is 
usually unsuccessful and pericardiectomy with complete open drainage is the only effective 
lifesaving procedure (Imazio 2011). Ultimately surgery is the definitive treatment for chronic 
constriction in the form of pericardiectomy. 
 Supportive medical therapy can prove favourable in improving the symptoms of congestion 
in situations where surgery is contraindicated. Anti-inflammatory treatment such as colchicine 
and NSAIDs have been shown to be useful in cases of transient constriction in leading to 
resolution of pericarditis (Haley et al. 2004; Imazio, Brucato, et al. 2010). Patients with 
potentially reversible forms of constriction may be detected by the presence of CRP and 
imaging evidence of pericardial inflammation by contrast enhancement on CT and CMR. In 
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such instances, empiric anti-inflammatory therapy should be considered and may prevent the 
need for pericardiectomy. 
 
Figure 1.3: Triage of diagnosing pericarditis  
(Reproduced with permission from Oxford University Press, first published in the 2015 
European Society of Cardiology guideline for diagnosis and management of pericardial 
disease. published in European Heart Journal 2015, 36; 2921) 
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Figure 1.4: 21-year old HIV negative young-man that presented in cardiac tamponade. A 
CHEST X-ray showing globular heart; B ECG with tachycardia and low QRS complexes 
(arrows); C 2D echo showing fibrinous large pericardial effusion; D Doppler flow tracing of 
same patient showing mitral E wave inspiratory (A) vs expiratory (B) variation >25%.  
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Figure 1.5: 24-year-old RVD positive young lady who presented in cardiac tamponade. A 
Chest x-ray at presentation showing globular heart shadow; B ECG, black arrows showing 
low QRS complexes with electrical alternans; C 2D chest x-ray images post 
pericardiocentesis; D 2D echocardiogram with large pericardial effusion [PE], with fibrinous 
strands, Vpd-visceral pericardium, Ppd- parietal pericardium, RA- right atrium, RV-right 
ventricle 
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Figure 1. 6: A 2D echocardiography image of a 56-year old patient with tuberculosis who 
presented with evidence of effusive-constriction; B MRI image of effusive-constriction (F-fat 
pad, LA-left atrium, LV-left ventricle, PE-pericardial effusion, RA- right atrium, RV-right 
ventricle. (Figure B with Copyright © permission of BMJ Publishing Group Ltd & British 
Cardiovascular Society. Mauro Santarone et al. Heart 2000; 83:556). 
 
 
Figure 1.7: Cardiac magnetic resonance images in TB pericarditis. (A) shows T2 weighted 
STIR imaging with thickened visceral and parietal pericardium and (B) shows fibrotic 
pericardial layers after administration of gadolinium (Reproduced with permission of 
Professor Ntusi NAB, et al. J Cardiovasc Magn Reson 2016;18(Suppl1): Q29.) 
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1.5 Summary of first Investigation of the Management of Pericarditis Trial (IMPI-I) and 
its relevance to IMPI-2 
Tuberculous pericarditis is a cause of cardiac mortality, especially in areas with high TB 
burden. Despite use of anti-tuberculosis treatment case fatality rate is up to 26%. The use of 
corticosteroids may reduce incidence of morbidity from cardiac tamponade and constrictive 
pericarditis and mortality, while immunotherapy by use of mycobacterium indicus pranii can 
aid cure in TB.  
The concept of the role of inflammation in the pathogenesis of pericarditis leading to 
constrictive pericarditis has been entertained over the decades. The research into how 
glucocorticoids can ameliorate the host inflammatory response in TBP and prevent the 
development of constriction was first documented in 1959 (Schrire 1959). In the study among 
28 patients, each group of 14 had either TB drugs with high dose steroid or only TB drugs, no 
difference was noticed in the two groups.  
The first investigation of the management of pericarditis trial (IMPI-1) was designed to 
investigate the efficacy and safety of adjunctive steroid and immunotherapy in patients with 
tuberculous pericarditis. The rationale for the trial was based on a number of observations and 
findings from other studies. 
(i) Reduction in occurrence of constrictive pericarditis and mortality following use of 
adjunctive steroid (Evans 2008; Mayosi 2002; Ntsekhe et al. 2003; Critchley et al. 
2013).  
(ii) The possibility for mycobacterium indicus pranii to reduce reduction in inflammation 
tuberculosis and increase in CD4 cell count among HIV infected patients judging from 
its noticed effect in leprosy (Saini et al. 2009; Mathur 2006; Talwar 1999; Nath 1998; 
Sharma et al. 2005). 
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(iii)  A concern about the safety of steroids because of the possible increased risk of 
cancers in HIV patients following glucocorticoid use (Elliott et al. 1992; Elliott et al. 
2004). 
 The first phase IMPI-1(2009-2014) was focused on tuberculous pericarditis (TBP), the leading 
cause of the disease in Africa and many places with high tuberculosis burden. It was a large 
scale RCT of 1400 patients (recruited from  19 hospitals from 8  African countries) with TBP 
randomised to 120mg of adjunctive steroid over six weeks, 5 doses of immunotherapy with 
subcutaneous injection of mycobacterium indicus pranii over three months or placebo (Mayosi 
et al. 2014).  
A total of 1400 participants were enrolled for comparison of prednisolone with placebo (706 in 
intervention arm and 694 in placebo, while 1250 participants were enrolled for comparison of 
mycobacterium indicus pranii with placebo (625 in each arm).  
Use of steroid and immunotherapy did not affect the combined primary outcome of all-cause 
mortality, cardiac tamponade requiring pericardiocentesis and pericardial constriction. Both 
therapies led to increased incidence of HIV-associated malignancies in those with very 
advanced immune suppression not on anti-retroviral medications. However, secondary 
outcome of the rate of constriction was reduced by 46% irrespective, of the HIV status without 
translating to a reduction in mortality.  
Given that the effect of adjunctive therapy on the primary outcome in the trial was neutral,  the 
ESC 2015 guidelines for diagnosis and management of pericardial disease puts the use of 
steroids in HIV negative patients on TBP in a class 2b level of evidence 
recommendation(Adler, Charron, Imazio, Badano, Barón-Esquivias, Bogaert, Brucato, 
Gueret, Klingel, Lionis, et al. 2015). Some authors have argued that subclinical cases of 
pericardial constriction could have been missed among IMPI-1 cohorts, since diagnosis of 
43 
 
constrictive pericarditis in most of the recruiting centres was based on clinical findings and use 
of such confirmatory modalities like Tissue Doppler imaging was not (*Kyriakakis 2016). 
The neutral result of IMPI-1 trial on the primary efficacy outcome, demands further search for 
interventions that can lead to reduction of adverse events in tuberculous pericarditis among 
our patient population. The second investigation for management of pericarditis (IMPI-2) trial 
is in answer to this quest. However, it will involve both tuberculous and non-tuberculous 
pericarditis and is set to investigate if the use of fibrinolysis can lead to a reduction in the 
primary outcome of persisting pericardial effusion leading to tamponade and pericardial 
constriction. The feasibility of the RCT to evaluate this question is the reason for the IMPI-2 
pilot study and one of the central themes in this thesis. 
1.6 The role of fibrinolysis in pericarditis  
More than 60 years ago physicians employed the use of intra-pericardial fibrinolysis in the 
management of purulent pericardial effusion as rescue therapy after other management failed 
(Adie and Childress 1951b; Wright et al. 1951). However not much was seen in the literature 
again on its use until in the 1980s when it was revisited (Bennett 1984). Following those 
documentations, there have been isolated case reports alluding to its role, both in humans 
and animal studies (Dybowska et al. 2015; Bigham et al. 2008).  
In exudative pericarditis such as post pneumonia and tuberculosis, the formation of fibrinous 
strands can lead to loculation. Use of fibrinolysis can, therefore, help in breaking these and 
allow complete evacuation. Open surgical drainage under general anesthesia with its 
attendant risk is usually the definitive way of managing persistent pericardial effusion to 
prevents its sequelae of constrictive pericarditis. However, the use of intra-pericardial 
fibrinolysis can be an effective and safe intervention in this condition. 
A randomised control trial among 94 Chinese patients with tuberculous and purulent effusion 
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concluded that early administration of intra-pericardial urokinase led to complete drainage and 
reduction in progression to pericardial constriction (Cui et al. 2005). A 2011 review of studies 
on the use of fibrinolysis in purulent pericarditis concluded that among 40 patients, there was 
a failure of pericardiocentesis requiring pericardiectomy in 2 patients, while in 36 patients with 
data, no constriction was found (Augustin et al. 2011). 
The concept of fibrinolysis to facilitate drainage is premised on the observation that 
inflammatory insults to the pericardial space attract leucocytes which, upon activation lead to 
the promotion of coagulation with resultant fibrin deposition (Figure1.1). The formation of fibrin 
bands limits the free flow of pericardial fluid during drainage because of adhesions, thus 
causing loculation.  Results from experimental models have been used to show that fibrin 
deposition form the cornerstone of the pathogenesis of inflammatory pericarditis and 
constrictive pericarditis and so is a potential target in inflammatory pericarditis such as 
tuberculosis, purulent and malignant effusion. 
 
1.6.1 The pharmacology of fibrinolysis. 
Plasmin is a cleaved product formed by activation of plasminogen by thrombolytic drugs 
leading to clot dissolution. (Figure 1.8). It a proteolytic enzyme with the ability to break cross-
links between fibrin molecules, responsible for the structural integrity of blood clots. This 
property of thrombolytic drugs is the reason why they are also referred to as "plasminogen 
activators" and "fibrinolytic drugs." 
Intrapericardial streptokinase has been the more frequently used agent although both 
urokinase and tissue plasminogen activator (t-PA) have also been used in pericardial 
fibrinolysis, with the latter two preferred due to lower risk of allergy. Other disadvantages of 
streptokinase include antibody formation, longer half-life, systemic thrombolysis due to the 
45 
 
creation of a complex with plasminogen and more complex dosing regimen. 
Natural occurring t-PA is a serine protease that converts the zymogen plasminogen into active 
serine protease plasmin, an enzyme responsible for removal of fibrin deposits. It drives 
intravascular fibrinolysis, and parenteral alteplase (recombinant t-PA) administration 
significantly increases t-PA concentration in plasma. It has a half-life of <5 minutes and binds 
to activated fibrin before binding to plasminogen. Different dosing regimen has been used from 
2mg to 50mg in the literature (Rahman et al. 1998; Bigham et al. 2008; Reznikoff, Fish, and 
Coursin 2003) with suggestions on retaining the drug for some time to aid distribution in the 
pericardium.  
 
Figure 1.8: Fibrinolysis pathway (t-PA: tissue plasminogen activator; pro-uPA: proenzyme 
form of urokinase plasminogen activator; tc-uPA: active form of urokinase plasminogen 
activator; PAI-1: plasminogen activator inhibitor-1) 
1.6.2 Adverse events of intra-pericardial Fibrinolysis 
Following repeated instillation of streptokinase, there could be allergic reactions, and this is a 
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well-known complication of fibrinolysis. However, treatment with urokinase or t-PA greatly 
reduces this risk (Augustin et al. 2011). There have been concerns with intra-pericardial 
bleeding. However, there has been only one case of haemorrhagic tamponade after 
fibrinolysis reported in the literature (Juneja et al. 1999) and may not be directly related to 
fibrinolysis. Bleeding events are not common with fibrinolysis for empyema in published case 
reports (Cameron and Davies 2008; Diacon et al. 2004) and studies from coagulation 
laboratories show that there is no proven systematic effect when fibrinolysis is used in purulent 
pericarditis (Ustunsoy et al. 2002). Cardiac tamponade is the other risk which can theoretically 
occur if the pericardial drain does not evacuate all the instilled volume. The addition of a small 
quantity of liquid may provoke cardiac compression (Refsum et al. 1981). However, no 
tamponade due to the intra-pericardial administration of fibrinolytic agents has been described 
(Augustin et al. 2011). The risk of tamponade could be lowered if the volume of fibrinolytic 
agent instilled is less than the amount of fluid drained immediately beforehand.  
Potential benefits of intra-pericardial fibrinolysis seem to outweigh the apparent low morbidity 
associated with the procedure based on case reports and a small clinical trial. 
 
1.7 The second Investigation of Management of Pericarditis Trial (IMPI-2) 
The second investigation of the management of pericarditis (IMPI-2) trial is a randomised 
controlled trial focused on the use of intrapericardial alteplase to facilitate complete drainage 
when indicated in patients with large pericardial effusion compared to routine care. The study 
will provide a definitive answer to the question of the use of fibrinolysis. In chapter 5 of this 
thesis, the proof of concept and feasibility study of the RCT is presented.  
CONCLUSION 
In this introductory chapter, we have highlighted the essential position pilot trials occupy in 
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planning for a randomised control trial; showing that if painstakingly designed and carried out, 
they can help refine and facilitate smooth conduct of all aspects of the main trial. 
Methodological reporting of the pilot studies is also an essential obligation with the potential 
of not only projecting such small works but can create awareness among researchers and 
help change the attitude of journal editors in the publishing of pilot trials.  
Subgroup analysis, another essential tool in unearthing non-obvious findings of RCT was also 
reviewed in the chapter, highlighting the criticisms and strengths of in their conduct. Subgroup 
analysis should be predefined at the design stage before the commencement of RCT to avoid 
bias and data mining; the results of such analysis should also be presented with caution. 
An overview of tuberculous pericarditis a significant cause of pericarditis in Africa was also 
discussed in this chapter; culminating in the review of the first investigation of the management 
of pericarditis trial in Africa (IMPI-1). The section discussed the rationale for the conduct of 
IMPI-1 trial, the summary of the trial results and why it was necessary to explore the question 
of interventions to reduce adverse events in pericarditis further through the second RCT (IMPI-
2 trial). The second investigation of the management of pericarditis trial focuses on the place 
of intrapericardial fibrinolysis in facilitating complete aspiration compared to conventional 
pericardiocentesis in adults with large pericardial effusion. So, in the last section of the 
chapter, the place of fibrinolysis in pericarditis is discussed. All the issues covered in this 
introductory chapter will shape the subsequent sections of the thesis. 
In chapter 2 and 3, the CONSORT extension for reporting of pilot trials is introduced in line 
with the objectives of the developers to aid reporting of pilot trials. This section of the thesis 
leverages on the concept to x-ray reporting of pilot trials in heart failure in order to improve the 
conduct and reporting of the IMPI-2 pilot trial presented in chapter 5. 
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CHAPTER TWO 
 Systematic Survey of Reporting Quality of Pilot Trials Protocol 
(Presented as a Published Manuscript) 
2.1 Introduction 
Scientific research publications have contributed enormously to improving the diagnosis and 
management of diseases. The gold standard for these researches is an appropriately 
designed, conducted and reported randomized control trial (RCT), as they usually function as 
the factory of breakthroughs in the biomedical world. However, often these trials result in 
failure and a monumental waste of resources, time and loss of unintended lives because of 
poor reporting.  
Wrongly reported RCTs can lead to bias and misleading results, conclusions, interpretations, 
and inferences with its attendant consequences to both patients and society in general. This 
has been the fate of some RCTs in the past and such happenings can be blamed on lack of 
methodological rigour (Ntala et al. 2013). The need to address such unfortunate problems led 
to the development of the consolidated standard for reporting of trials (CONSORT) checklist 
in 1996 (Moher et al. 2010) which has since then undergone two revisions in 2001 and 2010 
(Begg et al. 1996; Moher et al. 2010). The introduction of the CONSORT checklist, as attested 
to by some major journals, have led to standardization and improvement in the quality of 
reporting (Devereaux et al. 2002; Moher, Jones, and Lepage 2001; Plint et al. 2006).  
The CONSORT checklist initially intended for guidance on reporting of all types of RCTs, was 
not entirely applicable to most earlier phase trials and others such as cluster randomized trials 
and non-inferiority trials which require additional information (Schulz, Altman, and Moher 
2010). This led to the extension in the CONSORT checklist to accommodate trials that are not 
large, parallel arm clinical investigations (Dolgin 2013).  
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However, pilot trials which are an important prerequisite for the conduct of higher quality RCTs 
have not been addressed by available extensions. Evaluation of published pilot trials have 
consistently concluded that pilot trials are poorly reported due mainly to inappropriate focus 
(Arain et al. 2010b; Lancaster, Dodd, and Williamson 2004b; Shanyinde, Pickering, and 
Weatherall 2011), fuelling the fear that this important arm of research that provides information 
on the feasibility or otherwise of planned bigger studies run the risk of getting lost or redundant, 
a potentially disastrous consequence for clinical research (Thabane et al. 2010). 
In 2016, the CONSORT group introduced an extension for pilot and feasibility trials (Eldridge 
S 2016), to ensure accurate design conduct and reporting of pilot trials (Charlesworth et al. 
2013; Lancaster 2015). 
The second randomized controlled trial on the investigation of the management of pericardial 
disease (IMPI-2) trial, is a trial on the use of intrapericardial alteplase to facilitate complete 
aspiration compared to routine care in patients with large pericardial effusion. It is designed to 
be preceded by a pilot trial as a preparatory phase to evaluate the feasibility of the multicentre 
main study. This thesis uses the experience gained in the processes of the IMPI-2 pilot trial to 
discuss the role feasibility studies play in cardiovascular research. 
There is a need to lay a solid foundation for the main study by learning from what has been 
done previously and to improve on them.  To do this, we started by doing a systematic survey 
of the quality of pilot trials focusing on heart failure, due to its central role in cardiovascular 
disease, and the volume of trials it has recorded. In this chapter, we present the first phase of 
this evaluation (on abstracts) of quality of report in the form of publications. This chapter is a 
published protocol for the systematic survey. 
2.2 Publication Review 
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The publication describes the protocol of a systematic survey on heart failure pilot trials 
abstract. It gives the step-by-step account of the process and how we arrived at the selected 
publications. It also provides the rationale for choosing the CONSORT checklist for the 
assessment of the quality of reporting. 
2.2.1 Contribution of paper to the thesis novelty 
The survey provided the opportunity on skills to identify pilot trial publications, evaluate the 
methodology and questions asked. In developing the protocol, the general knowledge of 
processes in a pilot trial was gained in preparation for the IMPI-2 pilot trial. The teamwork also 
was a dress rehearsal for the administrative challenges of managing the trial team. 
2.2.2 Role of the candidate 
I was responsible for development and refining of the concept, designing of data extraction 
tool, conduction of the literature search, selection of eligible manuscripts for the survey and 
drafting/editing of the manuscript for publication. 
2.2.3 Roles of the co-authors 
LT and BM originated the idea, edited the manuscript at each stage, and approved the final 
draft for publication. LT was the guarantor and provided support and intellectual discuss at 
each stage. 
MZ and GC jointly drew up the process of paper review for eligibility and data abstraction. 
MZ reviewed the draft for scientific content. MC did the statistical work for the manuscript. 
2.2.4 Publication status 
The manuscript was published in 2017 in a peer review journal. 
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Introduction:  Pilot trials are initial small-scale studies done to inform the design of larger trials. Their ﬁndings like 
other studies are usually disseminated as peer-reviewed journal articles. Abstracts are used to introduce the contents 
to readers and give a general idea about the full reports and sometimes are the only source of in- formation available 
to readers. Despite their importance, the contents of abstracts of trial reports are usually not informative enough and 
lack the essential    details. 
Methods and analysis: This is a protocol for a planned systematic survey with a primary aim of analyzing the reporting 
quality measured as the completeness of the reporting of pilot trial abstracts in heart failure. The secondary aim will 
be to explore factors associated with better    reporting quality. 
Abstracts of heart failure pilot trials in humans (journal and conference abstracts) published in the English language 
from 1 January 1990 to 30 November 2016 will be assessed to determine the reporting quality, based     on the 
CONSORT 2010 statement extension to randomized pilot and feasibility trials. All non-pilot/feasibility trials and non-
human pilot trials will be excluded. We will search Medline (PUBMED), Cochrane controlled trials register, Scopus 
and African wide information databases for pilot trials in heart failure. Title and abstracts of identiﬁed studies will be 
screened for inclusion and data extracted independently by two reviewers in duplicate without using the full text. 
Reported and unreported items on the abstracts will be presented as frequencies and percentages, a descriptive 
analysis will be used to interpret the reporting quality and regression analysis used for characteristics associated with 
greater statistical reporting at 95% conﬁdence interval. 
Review registration number:  PROSPERO CRD42016049911.  
 
1. Introduction 
 
Abstracts are introductory summaries of full text that provide readers 
with a quick overview of the contents of the papers. They serve as an 
important aid in knowledge dissemination. Many researchers rely on 
abstracts as a concise source of information [1], helping them follow 
developments in the literature [2] and in reaching decisions on what 
articles to read in detail. Reasons advanced for the essential role of 
abstracts include the challenge of the large volume of literature, un- 
availability/inaccessibility of full text to some readers due to high cost 
[3,4], and the fact that some articles not published in English provide 
abstracts in English to reach a wider audience. These important roles of 
 
abstracts, therefore, require that they contain suﬃcient and accurate 
information that will guild the readers into contents of the full text [5]. 
Pilot trials refer to initial small studies that researchers use in reaching 
the decision on commencing larger conﬁrmatory trials [6–8]. They are 
comprised of a distinctive group of randomized controlled trials 
(RCT) often referred to as pilot and feasibility trials which do not have 
eﬀectiveness or eﬃcacy as their primary focus [9]. By the nature of their 
design, they are not powered for hypothesis testing, but rather should 
emphasize on conﬁdence interval estimation and are usually 
designed to support the development of a future deﬁnitive RCT. 
The consolidated standard for reporting of trials (CONSORT) statement   
(www.consort-statement.org)   originated   because   of  the
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concern raised over the years on the quality of report of RCTs [10]. It is a 
guideline that was designed to improve the quality of reporting, ﬁrst 
published in 1996 revised in 2001 and later updated in 2010 [11,12], to 
address this observation by providing a benchmark for complete re- 
porting of trials. This development has been well received by many peer 
review journals [13] and has been shown to improve the quality of 
reporting  of  trials [14–16]. 
The noted improvement has led to the extension of the checklist to 
various other forms of trials such as non-inferiority, equivalence, and 
cluster or pragmatic designs. There have also been extensions for dif- 
ferent types of interventions (non-drug treatments and herbal inter- 
ventions), Patient-reported outcomes, as well as extensions for re- porting 
harms. One major characteristic of the main CONSORT statement and all 
the current extensions is that they focus on trials for which the research 
question centers on the eﬀectiveness or eﬃcacy of an intervention. But as 
stated above pilot and feasibility trials are de- signed for a diﬀerent 
purpose, serving as a precursor to deﬁnitive trials and have been at 
various times described as a neglected arm of medical research [17]. In 
order to improve reporting of pilot and feasibility trials, a group of 
researchers recently developed a checklist extension to serve this function 
[18]. 
In this paper, we present a protocol for a systematic survey of quality of 
reporting in abstracts of pilot trials in heart failure, aimed at evaluating 
the completeness of such reports based on the checklist ex- tension. For 
the purpose of the survey, heart failure is deﬁned as a clinical condition 
often referred to as congestive heart failure (CHF), which occurs when 
the heart is unable to pump suﬃciently to maintain blood ﬂow to meet 
the body's needs [19]. We will be reviewing ab- stracts of journal 
publications and conferences focusing on all types of heart failure. We 
chose heart failure for this survey because of its role in the global burden 
of cardiovascular diseases [20,21] and the large volumes of trials in heart 
failure. 
In the last two decades, an increasing number of clinical trials in 
cardiovascular disease (CVD) have been conducted mainly due to the 
rising prominence of CVD as one of the leading causes of morbidity and 
mortality [21]. A sizable number of these clinical studies were preceded 
by pilot trials and their results disseminated to the public through 
publications. However, these pilot studies were not exempt from the 
inconsistency in quality reporting of most of the randomized control 
trials (RCT). The quality of reporting across journals is variable with some 
journal abstracts communicating adequate information and some grossly 
insuﬃcient for accurate interpretation [22]. The correct interpretation of 
abstracts can be enhanced if the reporting of the study design, methods, 
and results are complete and uniform across journals [23,24]. Similarly, a 
structured and detailed reporting of RCT helps guideline developers and 
policy makers as they rely on RCTs    [24,25]. 
2. Methods and analysis 
 
2.1. Primary Objective 
 
To evaluate the reporting quality of abstracts of pilot trials in heart failure 
in the past 26 years (1990–2016), using CONSORT extension for reporting 
of abstracts of pilot trials as the reference   standard. 
 
2.2. Secondary Objectives 
 
1 To identify aspects of the checklist consistently reported in pilot 
trials 
2 To identify factors associated with proper reporting of abstracts of 
pilot trials 
 
2.3. Inclusion criteria 
 
Type of studies: pilot/feasibility heart failure trial with a randomized 
control design (parallel or cluster) done in humans, Participants: reports 
on population with heart failure, 
Intervention: pharmacological and non-pharmacological interventions 
evaluating clinical outcomes, 
• Publications from 1st January 1990 to 30 November 2016. 
 
2.4. Exclusion criteria 
• Non-pilot trials in heart failure, 
• Animal studies. 
 
2.5. Study design 
 
The proposed survey will involve a systematic review of a sample of 
abstracts from all available publications on pilot trials in heart failure 
published from January 1990 to November 2016. We will systematically 
search Medline (PUBMED), Cochrane controlled trial register, Scopus, 
and African wide information electronic databases using search terms and 
medical subject headings (MESH) to identify heart failure pilot trials 
investigating pharmacological and non-pharmacological interventions 
(Table 1 and Appendix A). Articles will be restricted to those written in 
the English language. 
 
Table 2.1 
Medline search strategy. 
Incomplete information which may follow using a very small sample or    
not well-deﬁned outcomes [26,27] make it diﬃcult to trust the ﬁndings 
resulting in suboptimal use of these RCTs [28]. Other factors that have 
also been reported to inﬂuence the quality of report of trials include 
multi-center studies, trials involving pharmacological studies, industrial 
sponsored studies and those reporting positive results for their primary 
outcome [29]. Hence, it is imperative for authors to report complete 
details of their research and for journals to ensure proper reporting is 
adhered to by authors. 
The primary hypothesis in the planned systematic survey is that the 
quality of reports in abstracts of pilot trials in heart failure based on the 
CONSORT checklist extension for pilot and feasibility trials is poor. The 
exploratory hypothesis is that items in CONSORT extension for re- 
porting of pilot trials will be seen more in publications that contain the 
(((((Heart failure[MeSH Terms]) OR ((Heart failure OR paroxysmal dyspnea OR 
diastolic heart failure OR systolic heart failure OR Cardiac Failure OR Heart 
Decompensation OR Myocardial Failure OR Congestive Heart Failure OR Ventricular 
dysfunction OR cardiac insuﬃciency OR myocardial failure OR myocardial 
insuﬃciency)))) AND ((randomized controlled trial [pt] OR controlled clinical trial [pt] 
OR randomized controlled trials [mh] OR random allocation [mh] OR double-blind 
method [mh] OR single-blind method [mh] OR clinical trial [pt] OR clinical trials [mh] 
OR ("clinical trial" [tw]) OR ((singl* [tw] OR doubl* [tw]  OR trebl*  [tw]  OR  tripl*  
[tw])  AND  (mask*  [tw] OR  blind* [tw])) OR (placebos  [mh]  OR  placebo*  [tw]  OR  
random*  [tw]  OR  research design [mh:noexp] OR (comparative study) OR 
(comparative studies) OR (evaluation studies) OR (evaluation study) OR follow-up 
studies [mh] OR prospective studies [mh] OR controlled [tw]OR controls [tw]OR 
control [tw] OR prospectiv* [tw] OR volunteer* [tw]) NOT (animals [mh] NOT human 
[mh]))))) AND (((Pilot projects[MeSH Terms]) OR Feasibility Studies[MeSH Terms])   
OR 
((pilot OR feasibility))) 
characteristics mentioned above.    
• 
• 
• 
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Table 2.2 
Estimation of sample size based on 95% Conﬁdence    Interval. 
 
 P0  
0.50 0.55 0.60 0.65 0.70 0.75 0.80 0.85 0.90 0.95 
E    0.01 9604 9507 9219 8739 8067 7203 6147 4898 3457 1824 
0.05 384 372 368 349 322 288 245 195 138 73 
0.10 96 95 92 87 80 72 61 49 34 18 
P0 = Prior estimate of studies with adequate reporting. E 
= Margin of error for the estimate. 
 
3. Data extraction and synthesis 
 
Selected articles based on the key search words of pilot trials in heart 
failure from 1990 to 2016 will be exported to Endnote X7® reference 
manager software; duplicates will be identiﬁed and removed. Screening 
and data abstraction will be done independently and in du- plicate by two 
reviewers (GI and MZ) using a customized data extraction form in 
Microsoft Excel® format. Reviewer agreements will be measured using 
kappa statistics [30]. Discrepancies and diﬀerences of opinion will be 
resolved by consensus between reviewers or arbitration by a third 
reviewer. The abstracts (both journal and conference) will be evaluated 
using the 16 items of the CONSORT extension (Appendix B); where the 
item combines two or more pieces of information (e.g. eligibility and 
setting), each will be counted separately if it can stand alone. Where they 
are open to interpretation, the reviewers' interpretation of relevant 
information will be used. Reported items will be checked as yes and 
unreported items as no. Non-applicable items will be checked as NA. All 
“yes” responses will be assigned the number 1, while “no” and NA will be 
assigned 0. The overall quality of the ab- stracts will be calculated as a 
proportion of y e s . 
 
3.1. General characteristics 
 
Information to extract from the publications will include names and 
addresses of authors, journal names, impact factor, Journal policy on the 
endorsement of CONSORT statement (by checking on the website of the 
journal), year of publ icat ion . 
 
3.2. Assessment of abstract using CONSORT extension for pilot and 
feasibility trials checklist 
 
Title identiﬁcation as trials will be checked, and abstract format noted as 
structured or unstructured. Trial design (Cluster/parallel), participant's 
characteristics such as eligibility and setting of pilot trial conduct, type of 
intervention in each group, Single or multiple centers, as well as deﬁned 
pre-speciﬁed objectives. Other things to be checked will include pre-
speciﬁed measurements to determine the outcome, method of 
randomization and blinding, the number of participants screened and 
randomized. There will also be an evaluation of analysis done in each 
group including study outcome, explanation of harm re- porting and 
general interpretation of result discussing risk and beneﬁt. Finally, we 
will check the conclusions drawn from the study, implications for future 
deﬁnitive trial, trial registration and funding information. 
 
4. Deﬁnition of adequate reporting 
 
The CONSORT extension for reporting of abstracts has 16 items which 
are expected to be in an abstract. In this survey, a publication abstract will 
be judged as adequate if all the items are   reported. Ta
b
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4.1. Sampling scheme and sample size   calculation 
 
We will consider for inclusion in the systematic survey, all sampled 
studies described as pilot or feasibility randomized control trials (RCT) 
from the general sampling population of RCTs in heart failure. Eligible 
trials will be those done in humans from 1 January 1990 to 30 November 
2016 and reported in the English language. Nonrandomized trials and 
crossover studies will not be included in the survey. For purposes of the 
survey, adequate reporting of abstract will be determined by considering 
the proportion of studies reporting up to 16 items in the checklist. Using 
a 95% conﬁdence interval approach, the number of required pilot trials 
abstracts (n) for the survey will be given by: 
n     1.962(P0 (1     P0)/E2) 
where 1.96 is the z-score associated with a 95% conﬁdence interval, P0 is 
the prior estimate of the proportion of studies with adequate re- 
porting of abstract and E is the target margin of error for the estimate. 
With a margin of error of E = 0.10, our expectation is that the number of 
studies with an adequate report of abstracts will be calculated at P0  = 
0.60  [31,32]  (Table 2). 
 
4.2. Statistical analyses 
 
As shown in Table 3, the analysis will be divided into two sections. 
 
4.2.1. Primary outcome measures 
Reporting quality by presenting reported and unreported items on the 
checklist as frequencies and percentages using descriptive analysis. 
 
4.2.2. Secondary outcome measures 
Negative binomial regression analysis will be used to determine the study 
characteristics associated with greater statistical reporting. Count of 
adequately reported items on the checklist will be the dependent variable. 
The independent variable will include the following characteristics 
linked to reporting quality in previous publications [11,23,24,26,27,29]; 
journal impact factor, endorsement of CONSORT, sample size, single or 
multiple sites, type of study (pharmacological or non-pharmacological), 
abstract format (structured or unstructured). Incident risk ratio (IRR) will 
be calculated to evaluate factors associated with better reporting. The 
result will be presented as IRR with 95% conﬁdence interval and 
associated p-values. The criterion for statistical signiﬁcance will be set at 
alpha = 0.05. We will use SPSS software version 23 (Chicago, IL) for all 
a n a l y s e s . 
5. Ethics and dissemination 
 
Formal ethical approval is not required for the proposed survey as data 
collection is based on publicly available reports. This protocol was written 
according to the Preferred Reporting Items for Systematic Reviews and 
Meta-Analysis extension for Protocols (PRISMA-P) [33]. We will submit 
this systematic survey when completed to a peer-re- viewed journal for 
publication, and the ﬁndings will also be presented at an upcoming 
conference. 
 
6. Discussion 
 
This planned systematic survey of quality of abstracts of pilot trials was 
registered prospectively in PROSPERO (CRD42016049911) and the 
protocol was written in line with PRISMA-P. It is to the best of our 
knowledge the ﬁrst of such review using the CONSORT extension for 
reporting abstracts of pilot trials. The heart failure trials to be analyzed 
were published before the introduction of the CONSORT extension. 
However, the work will serve as the basis to evaluate improvement when 
the extension is fully in operation. 
 
7. Authors' data sharing and c o n t r i b u t i o n s  
 
All authors contributed to the protocol and approved the ﬁnal 
manuscript. LT and BM were responsible for the conception of the 
survey. GI was involved in the search strategy. GI and LT designed the 
survey. GI, MZ, MC were involved in designing and testing of the data 
extraction form. GI wrote the initial draft, GI and LT contributed to 
improvements in the manuscript and BM and LT critically revised the 
ﬁnal draft. 
All authors approved the ﬁnal written manuscript. Responsibility for 
statistical analysis Plan: MC. 
Guarantor of the systematic survey; Prof. Lehana Thabane. 
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Appendix A 
 
Heart failure Pilot Trial Search Strategy. 
 
PubMed search 
 
Heart failure [Mesh] OR. 
Heart failure OR paroxysmal dyspnea OR diastolic heart failure OR systolic heart failure OR Cardiac Failure OR Heart Decompensation OR 
Myocardial Failure OR Congestive Heart Failure OR Ventricular dysfunction OR cardiac insuﬃciency OR myocardial failure OR myocardial in- 
suﬃciency. 
AND. 
 
Filters for RCT's in PubMed courtesy University of Cape Town    Library 
 
Randomized controlled trial [pt] OR controlled clinical trial [pt] OR randomized controlled trials [mh] OR random allocation [mh] OR double- blind 
method [mh] OR single-blind method [mh] OR clinical trial [pt] OR clinical trials [mh] OR (“clinical trial” [tw]) OR ((singl* [tw] OR doubl* [tw] OR 
trebl* [tw] OR tripl* [tw]) AND (mask* [tw] OR blind* [tw])) OR (placebos [mh] OR placebo* [tw] OR random* [tw] OR research design [mh:noexp] 
OR (comparative study) OR (comparative studies) OR (evaluation studies) OR (evaluation study) OR follow-up studies [mh] OR pro- spective studies 
[mh] OR controlled [tw]OR controls [tw]OR control [tw] OR prospectiv* [tw] OR volunteer* [tw]) NOT (animals [mh] NOT human [mh]) 
AND. 
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Pilot projects [MeSH] OR Feasibility Studies [MeSH] OR pilot OR feasibility. Filter by 
years. 
Filter by years (1 January 1990–1 May 2016) 
 
Africa-Wide (Ebsco) and Web of Science 
 
Heart failure OR paroxysmal dyspnea OR diastolic heart failure OR systolic heart failure OR Cardiac Failure OR Heart Decompensation OR 
Myocardial Failure OR Congestive Heart Failure OR Ventricular dysfunction OR cardiac insuﬃciency OR myocardial failure OR myocardial in- 
suﬃciency. 
AND. 
Clinical trial OR randomized controlled trial OR randomized controlled trial OR random allocation OR double-blind OR single-blind OR placebo OR 
random research OR comparative study OR evaluation study OR follow up OR follow-up OR prospective OR control OR volunteer OR single mask OR 
double mask OR treble mask OR triple mask OR single blind OR double-blind OR treble blind OR triple bl ind. 
AND. 
Pilot OR feasibility. 
Filter by years (1 January 1990–1 May 2016) 
 
Scopus- 
 
Heart failure OR paroxysmal dyspnea OR diastolic heart failure OR systolic heart failure OR Cardiac Failure OR Heart Decompensation OR 
Myocardial Failure OR Congestive Heart Failure OR Ventricular dysfunction OR cardiac insuﬃciency OR myocardial failure OR. 
Myocardial insuﬃciency. 
 
AND 
 
Clinical trial OR randomized controlled trial OR randomized controlled trial OR random allocation OR double-blind OR single-blind OR placebo OR 
random research OR comparative study OR evaluation study OR follow up OR follow-up OR prospective OR. 
Control* OR volunteer OR single mask OR double mask OR treble mask OR triple mask OR. 
Single-blind OR double-blind OR treble blind OR triple blind AND pilot OR feasibility. 
 
Appendix B. CONSORT extension for reporting abstracts of pilot trials 9 
 
Item Extension for pilot trials Judgment   Score 
 
Yes   No 
Title Identiﬁcation of study as a randomized pilot trial 
Trial Design Description of pilot trial design (e.g.  parallel, cluster 
METHODS 
Participants Eligibility criteria for participants and the settings where the pilot trial   was conducted 
Interventions Interventions intended for each group 
Objective Speciﬁc objectives of the pilot   trial 
Outcome Pre-speciﬁed assessment or measurement to address the pilot trial objective(s)1 
Randomization How participants were allocated to the interventions 
Blinding (masking) Whether or not participants, caregivers, and those assessing the outcomes were blinded to group 
assignment 
RESULTS 
Numbers 
randomized 
Number of participants screened and randomized to each group for the pilot trial   objective(s)1 
Recruitment Trial status2 
Numbers analyzed Number of participants analyzed in each group for the p i l o t  objective(s)1 
Outcome Results for the pilot objective (s); including any expressions   of uncertainty1 
Harms Important adverse events or side-eﬀects 
Conclusion General interpretation of the results of pilot trial and their implications for the future deﬁnitive trial 
Trial Registration Registration number for pilot trial and name of trial r e g i s t e r  
Funding Source of funding for pilot trial 
1 Space permitting, list all pilot trial objectives and give the results for each. Otherwise, report those, which are a priori, agreed as the most important (main) to the decision to proceed with the 
future deﬁnitive trial. 
2 For conference abstracts. 
 
Appendix A.  Supplementary data 
 
Supplementary data related to this article can be found at    http://dx.doi.org/10.1016/j.conctc.2017.11.004. 
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CHAPTER THREE 
 Result of Systematic Survey on Quality of Pilot Trial Abstracts in 
Heart Failure (Presented as a Published Paper) 
3.1 Paper Review  
In this publication we present the findings of the first part of our survey on the quality of heart 
failure pilot trials, focussing on abstracts. It provided the opportunity to systematically sieve 
the literature and the experience revealed the details of missing information and how it relates 
to quality and perception of pilot trials. 
3.1.1 Contribution of paper to the thesis novelty 
The survey provided the opportunity to find out what is reported in the pilot trials, the processes 
and challenges in conducting pilot trials, as well as the errors. The experience gained was a 
good preparation for conducting an IMPI-2 pilot trial and a rich source of information on how 
to report the findings in order to ensure it guides the development of a definitive trial 
3.1.2 Role of the Candidate 
I did the data extraction, paper reviews, manuscript development and implementation and 
incorporation of co-authors inputs. I also was responsible for the production of the final edition 
of article publication. 
3.1.3 Roles of the co-authors 
LT and BM provided the intellectual substance and constant supervisory support. 
MZ, MC and GC jointly reviewed the papers for eligibility and data abstraction. MZ reviewed 
the draft for scientific content. MC conducted and wrote up the statistical   
LT approved the final edition of the manuscript for publication. 
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3.1.4 Publication status 
The manuscript was published 2018 in a peer review journal. 
Isiguzo GC, Zunza M, Chirehwa M, Mayosi BM, Thabane L. Quality of pilot trial abstracts in 
heart failure is suboptimal: a systematic survey. Pilot and Feasibility Studies. 2018;4(1):107.
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Quality of pilot trial abstracts in heart 
failure is suboptimal: a systematic survey 
Godsent C.  Isiguzo1,2     , Moleen Zunza3, Maxwell Chirehwa3, Bongani M. Mayosi1  and  Lehana    Thabane4,5* 
 
Abstract 
Background: Pilot trials are miniature researches carried out with the sole aim of acting as the precursor for larger 
more definitive studies. Abstracts are used to summarize and introduce the findings to the reading audience. There   is 
substantive empirical evidence showing that abstracts, despite their important roles, are not informative enough, lacking 
the necessary details. This systematic survey was designed to assess the quality of reporting of heart failure pilot trial 
abstracts. The quality of reporting was defined as the completeness of reporting based on adherence to 
the CONSORT extension for reporting of pilot trial abstracts. We also identified factors associated with reporting 
quality. 
Methods: We searched MEDLINE (PubMed), Cochrane Controlled Trials Register, Scopus, and African-wide 
information databases for abstracts from heart failure pilot trials in humans published from 1 January 1990       to 
30 November 2016. These were assessed to determine the extent of adherence to CONSORT extension 
checklist for reporting of abstracts of pilot trials. We screened identified studies for inclusion based on title and abstract. 
Data were independently extracted by two reviewers using the checklist. We used regression analysis to assess the 
association between completeness of reporting (measured as the number of items in the   CONSORT 
extension checklist for reporting of abstracts in pilot trials contained in each abstract) and factors influencing the 
quality of the reports. 
Results: Two hundred and twenty-eight (228) articles were retrieved, of which 92 met the inclusion criteria. The mean 
CONSORT extension score was 8.3/16 (standard deviation 1.7); the least reported items were the source of 
funding (1% [1/92]), trial registration (13% [12/92]), randomization sequence (13% [12/92]), number randomized to each 
arm (16% [15/92]), and number analyzed in each arm (16% [15/92]). Multivariable regression analysis showed that 
pharmacological intervention pilot trials [incidence rate ratio (IRR) = 0.88; 95% confidence interval (CI), 0.81–0.97] 
were significantly associated with better reporting. Other factors such as structured abstract (IRR = 1.10; 95% CI, 0.99–1.23) 
and CONSORT endorsement (IRR = 1.10; 95% CI, 0.99–1.23) only showed minimal relationship with better reporting quality. 
Conclusion: The quality of reporting of abstracts of heart failure pilot trials was suboptimal. Pharmacological 
intervention was significantly associated with better reporting. These findings are consistent with previous 
research on reporting of   trials. 
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Background 
Numerous challenges confront readers while  accessing the 
literature; these include but are not limited to the enormous 
volume of published work, the high cost of obtaining articles 
especially in resource-limited settings [1], and language 
constraints when articles are not writ- ten in users’ language 
[2]. The outcome of this has been an over-reliance on 
abstracts for articles as a one-stop point for most researchers. 
Abstracts of journal articles o r  scientific papers often 
provide readers with an over- view of the content of the full 
article. As a result, researchers tend to rely on abstracts as a 
concise source   of information [3] and in making decisions 
on which publications to read in detail [4]. Furthermore, 
researchers rely largely on the abstract when deciding 
whether to include an article in a systematic review [5]. All 
these factors make the abstract a key section of the scientific 
publication. It is, therefore, important that abstracts of 
articles are consistent with what is reported   in the text and 
capture essential   information. 
Randomized control trials (RCT) constitute a       significant 
portion of clinical studies and most times are the core 
component for systematic reviews. However, the quality of 
reporting of RCTs have over the years attracted many 
questions, mostly related to consistency and completeness of 
reports [6]. The Consolidated Standard for Reporting of 
Trials (CONSORT) checklist was conceptualized in 1996 to 
address these issues. Its publication and instant acceptance 
led to revisions in 2007 and 2010 [7, 8]. Many journals have 
adopted the CONSORT checklist, and it has been shown to 
improve the quality of reporting RCTs [9–11]. 
The overwhelming acceptance of CONSORT checklist has 
led to the development of extensions to incorporate other 
types of RCTs. Due to the need to widen the scope of the 
checklist, in 2016, the CONSORT extension checklist for 
abstracts of pilot trials was developed to aid adequate 
reporting of pilot trials [12], an important but often neglected 
arm of medical research  [13]. 
We conducted this systematic survey to evaluate the quality 
of reporting of abstracts of pilot RCTs in heart failure 
published 1990–2016. Heart failure, defined as a clinical 
condition in which the heart does  not  pump blood 
sufficiently or does so at a higher pressure to maintain the 
body’s need [14, 15], has been a prominent cause of 
cardiovascular disease burden in Africa in the last two 
decades [16, 17]. It has also attracted many    clinical trials 
in the last two decades (1990–2016), most of which were 
preceded by pilot trials [17]. The quality reporting is defined 
as complete reporting of the 16 items in the CONSORT 
extension checklist. 
The aims of this survey are to (1) evaluate the quality of 
reporting of abstracts of pilot RCTs in the past 26 years 
(1990–2016), using the CONSORT extension 
for reporting of abstracts of pilot trials; (2) identify aspects 
of the checklist that are consistently   reported; 
(3) identify factors associated with better reporting of 
abstracts; and (4) determine the quality (completeness) of 
abstracts of pilot trials. 
 
Methods 
Randomized controlled pilot trials in heart failure published 
from 1 January 1990 to 30 November 2016 were searched for 
in line with the systematic survey method as previously 
described [17]. Abstracts were selected if they were de- scribed 
as random, randomly allocated, and randomized.  We searched 
the MEDLINE (PubMed), Cochrane Con- trolled Trials 
Register, Scopus, and African-wide information databases 
(search strategy in the Additional file 1). We limited our search 
to pilot trial reports written in English language only. Two 
reviewers independently screened the identified papers and 
those finally selected to assess the quality of reporting of 
abstracts using the 16 items of CONSORT extension for 
reporting of abstract of pilot trials. We assigned a score of one 
to an item on the CONSORT checklist if the item was reported 
in the abstract. The overall quality of abstract was calculated as 
the proportion of “yes” responses. We classified abstracts that 
re- ported all the 16 items in the CONSORT checklist as 
adequate quality reporting. 
We hypothesized that pilot trials published in high impact 
journals [18], published in CONSORT-endorsing journals  [19, 
20], those on pharmacological interventions [20],      studies with 
large sample sizes [21], and industry-funded   studies 
[22] would have better reporting quality. 
The protocol for this systematic survey [17] was     registered 
with PROSPERO (CRD42016049911) and written 
according to the Preferred Reporting Items for Systematic 
Reviews and Meta-Analysis Extension for Protocols 
(PRISMA-P) [23]. 
 
Statistical analysis 
The analysis was with IBM statistical package for social 
sciences (IBM SPSS) version 24 (IBM Corp., Armonk, NY) 
and STATA 9.0 (College Station, TX). We calculated the 
percentage of trials that scored yes on each of the 16 items 
and the associated 95% confidence interval (CI). 
We reported categorical variables as count and          
percentages; continuous variables are summarized as mean 
(standard deviation (SD)) or median (interquartile range 
(IQR)). Incidence risk ratio (IRR) was calculated to identify 
factors associated with better reporting. Negative binomial 
regression was conducted to determine factors associated 
with better reporting quality. 
 
Results 
Our search identified 228 articles; after the screening one 
hundred and thirty-six articles were found to be 
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ineligible based on several reasons (Fig. 1). A total of 92 
articles from 48 journals were eligible; among these, 12 were 
conference presentations. The three highest contributing 
journals were European Journal of Heart Failure (9 articles; 
9.8%), American Heart Journal (8 articles; (8.7%), Journal 
of American College of Cardiology (7 articles; 7.6%), and 
Journal of Cardiac Failure (7 articles; 7.6%). 
 
Study characteristics 
The estimate of Kappa statistic for inter-rater agreement for 
screening publications for eligibility was 0.82 [95% 
confidence interval (CI), 0.76–0.87]. A majority (71%) of 
the   studies   were   published   between   2001   and 2016 
 
(Table 1). Both pharmacological intervention studies and 
non-pharmacological intervention studies were 45 (49%), 
respectively; two studies (2%) had both pharmacological and 
non-pharmacological interventions. The abstract 
presentation was structured in 80% of the studies. In 62   of 
92 (67%) of the studies, the CONSORT statement was not 
endorsed by the publisher. Most (74%) of the studies were 
conducted at a single site. 
 
Quality of reporting of abstracts of pilot trials 
None of the studies reported all the 16 items in the check- list 
(Table 2), the maximum reported number of items was 12, 
with a mean (SD) of 8.3 (1.7) items. The most reported item 
was the type of intervention intended for each    group 
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Table 3.1 Characteristics of included papers: n = 92 
Characteristic Count (%)/median (Q1; Q3) 
Year of publication 
1990–2006 26 (28%) 
2007–2016 66 (72%) 
Intervention type (n = 90) 
Pharmacological 45 (49%) 
Non-pharmacological 45 (49%) 
 
99% (95% CI 91; 99), followed by specified objectives of the 
pilot trial 94% (95% CI 89; 99) and pre-specified   outcome 
to address pilot trial objectives 97% (95% CI 90; 98). 
The least reported item was funding source 1% (95% CI 0.16; 
6.9); however, 21 of 92 (22.8%) studies re- ported funding 
source in the main manuscript but not in the abstract. 
Inadequately reported items include the randomization method 
used 13% (95% CI 8; 19), trial registration information 13% 
(95% CI 7; 21), and the number of 
Both pharmacological and non-
pharmacological 
Abstract format 
2 (2%) participants screened in each arm 16% (95% CI 9; 26). 
Recruitment status, an item in the CONSORT checklist that 
addresses conference presentation, was low with   2% 
• Structured 74/92 (80%) 
• Unstructured 18/92 (20%) 
CONSORT endorsement 
• Yes 30/92 (33%) 
• No 62/92 (67%) 
Number of sites 
• Single 61/82 (74%) 
• Multiple 21/82 (26%) 
Study duration in months (n = 68) 3.0 (2.6; 6.1) 
Sample size (n = 88) 41 (24; 88) 
CONSORT Consolidated Standards    of Reporting Trials, Q1 first quartile, Q3 
third quartile 
(95% CI 5; 8) among the 12 conference abstracts. 
Multivariable analysis (Table 3) of factors associated with 
reporting quality showed pharmacological intervention is 
significantly associated with better reporting quality (IRR 
0.88; 95% CI 0.81; 0.97; p value 0.01), while 
structured abstract (IRR 1.10; 95% CI 0.99; 1.23; p value 
0.5) did not have a strong association. Journals which 
endorsed CONSORT was not a significant factor (IRR 
1.10; 95% CI 0.99; 1.23; p value   0.06). 
 
Discussion and conclusions 
The CONSORT extension for reporting of abstracts of pilot 
trials was introduced in 2016 to standardize the reporting of 
abstracts of such studies. We undertook    this 
 
Table 3.2 Publication adherence to CONSORT checklist for abstract of pilot trials   n = 92 
 Item Criteria Count Percent (95% CI) 
Title Identifier Title identifies the study is a randomized controlled pilot   trial 65 71 (60; 79) 
Description Trial design Description of pilot trial design (e.g., parallel or cluster) 30 33 (23; 44) 
Method Eligibility Eligibility criteria for each participant 81 88 (78; 94) 
 Settings Setting where pilot was conducted 29 32 (22; 47) 
 Interventions Interventions intended for each group 91 99 (91; 99) 
 Objectives Specific objectives of the pilot trial 89 94 (89; 99) 
 Outcomes Pre-specified assessment or measurement to address the pilot 
trial objectives 
89 97 (90; 98) 
 Randomization sequence 
generation 
Describe how participants were allocated to the   interventions 12 13 (8; 19) 
 Blinding (masking) Whether or not participants, caregivers, and those assessing the 
outcomes were blinded to group   assignment 
20 22 (15; 31) 
Results Number randomized Number of participants screened 15 16 (9; 26) 
  Number randomized to each group for the pilot    objectives 41 45 (36; 53) 
 Recruitment Trial status (for conference abstracts) 2 2 (5; 8) 
 Numbers analyzed Number of participants analyzed in each group of pilot   objectives 15 16 (11; 24) 
 Harm Important adverse events or side effects 28 30 (23; 39) 
Conclusion Result interpretation General interpretation of results of pilot trial 80 87(76; 93) 
 Plans Any implication for future trial 20 22 (15; 30) 
Registration Trial registration Registration number of trials 12 13 (7; 21) 
 Funding Source of funding 1 1 (0.16; 6.9) 
CI confidence interval 
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Table 3.3 Univariate and multivariable analysis of factors 
associated with reported items 
Item Univariate Multivariable 
 
 
IRR (95% CI)    p value    IRR (95% CI)    p value 
Year of publication 
Many of the articles were also silent on the blinding, and 
when used, some failed to state the group blinded in the 
studies. Not being explicit about blinding erodes the integrity 
and internal validity of the reports, and it is a potential  
source  of   bias  among  the  readers  [33,    34]. 
• 1990–2006 
• 2007–2016 
Intervention type 
• Pharmacological 
• Non-pharmacological 
Abstract format 
• Structured 
• Unstructured 
CONSORT endorsement 
• Yes 
• No 
Number of sites 
• Single 
• Multiple 
0.99 
(0.91; 1.08) 
 
 
0.93 
(0.86; 1.01); 
 
 
1.11 
(0.99; 1.24) 
 
 
1.07 
(0.98; 1.16) 
 
 
1.08 
(0.97; 1.22) 
0.86 1.07 
(0.91; 1.13) 
 
 
0.07 0.88 
(0.81; 0.97) 
 
 
0.08 1.10 
(0.99; 1.23) 
 
 
0.12 1.10 
(0.99; 1.23) 
 
 
0.14 1.02 
(0.92; 1.15) 
0.74 
 
 
0.01 
 
 
0.05 
 
 
0.06 
 
 
0.62 
Reporting on harm was low at 28%; this is an essential item 
as it informs the design and applicability of intended larger 
trials. Previously, this safety reporting has often been 
inadequate or neglected [35]. And, in literature, there is 
highly variable adherence to reporting of harm [36, 37]. 
Methodological aspects reported include intervention type, 
specific objective, and outcomes to be assessed. Many of the 
articles identified them as pilot trials; this was despite the 
constraint of word limit by journals, a reason often adduced 
as responsible for  not  including  this [10, 26, 29]. Also, pilot 
trials with pharmacological intervention, those with 
structured abstracts, and those published in the journal that 
endorses CONSORT were more likely to report on the items 
on the checklist. The last point brings to fore why it is 
important for journals   to have stipulated reporting format 
to ensure that the quality of abstracts’ report is improved. 
 
 
IRR incidence rate ratio, CI confidence   interval 
*Incident rate for change in 1 unit on the log scale 
 
survey to gauge the current practice using heart failure 
pilot trials as a sample to track reporting quality 
improvement expected with introduction and adherence 
to the extension. We found inadequate reporting quality 
in keeping with previous articles evaluating adherence to 
CONSORT checklist on abstracts [8, 24, 25]. 
The least reported item was the funding source      like 
findings in a previous study [26]. The full declaration of 
funding source in a publication can give the reader the 
opportunity to make their own assessment regarding 
potential conflict of interest. However, we noticed that 22/96 
of the articles had information on funding in other places 
rather than the abstract, and this our study is limited in scope 
by using only articles published in the English language. We 
also used a recently produced checklist to evaluate 
publications done by authors who at the time of writing of the 
articles probably had no reporting checklist to f o l l o w . 
In conclusion, the reporting quality of abstracts of heart 
failure trial measured by the number of items reported was 
suboptimal; the need to guard against this was the reason 
that informed the introduction of CON- SORT extension 
checklist. The desire is that increasingly journals will 
demand adherence to the checklist by authors. Ultimately, 
we hope that there will be a marked improvement in the 
quality of report of abstracts in the coming years. 
 
Additional file
may not be unrelated to word count stipulation by indi-    
vidual journals. Often, this poses a challenge to authors on 
what to include in abstracts, and there may be the 
need for CONSORT extension checklist developers to 
consider this limitation. 
The randomization sequence was also poorly re- ported. It 
is an item that can provide acceptable comparability between 
groups if properly reported. Some previous studies have 
commented on this  methodological flaw [10, 27–29], 
explaining that this could be because of attachment of  more  
relevance  to  clinical than the methodological aspect of  
RCTs.  There has been corroborating evidence in other 
studies  supporting a correlation between deficient reporting  
and  poor trial  methodology  [30–32]. 
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Abstract 
Background 
Corticosteroids, by dampening the immune response to tuberculous antigens within the 
pericardium may reduce the size of the inflammatory effusion and reduce major adverse 
pericarditis related outcomes in those with effusive TB pericarditis who are unstable. However, 
in the first investigation of the management of pericarditis trial (IMPI-1) adjunctive corticosteroids 
had a neutral effect on the composite outcome of death, recurrent tamponade requiring 
pericardiocentesis and constrictive pericarditis. In the trial, a large proportion of the randomised 
study cohort underwent pericardiocentesis at the discretion of the responsible clinician, as part 
of their initial management. By evacuating the pericardium of compressive pericardial fluid, 
pericardiocentesis may have an impact on the subsequent incidence rate of constrictive 
pericarditis, recurrent tamponade and death. Whether the procedure modified the effectiveness 
of adjunctive steroids in the trial is not known. 
Objective: Our aim in this subgroup analysis is to explore whether performing pericardiocentesis 
modified the effects of prednisolone among patients with effusive TB pericarditis.  
Hypothesis: We hypothesised that among patients with tuberculous pericarditis, the effects of 
prednisolone would be similar among those who received pericardiocentesis at baseline and 
those who did not (because it was not indicated).   
Method 
Outcomes: The primary efficacy outcome was the composite of death, constrictive pericarditis 
or cardiac tamponade requiring pericardiocentesis. Secondary outcomes include death, 
constrictive pericarditis, cardiac tamponade requiring pericardiocentesis, constriction or 
cardiac tamponade, and hospitalisation.  
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Analysis: The subgroup analysis was performed by adding an interaction term between 
pericardiocentesis (yes vs no) and treatment group (prednisolone vs placebo) to the main 
effects model using the Cox proportional-hazard model for all outcomes. We used forest plots 
to report the effect estimate as a hazard ratio (95% confidence interval) for each subgroup and 
a p-value for the test of interaction. The criterion for statistical significance was set at alpha = 
0.05, and this was not adjusted for multiple testing since these analyses are exploratory.  
Results 
Two-thirds of the study population presented with large pericardial effusion, and 60.5% 
(847/1400) had pericardiocentesis at physician discretion. There was no statistically significant 
reduction in composite outcome with pericardiocentesis (p-value for the interaction with 
prednisolone was 0.71). Effects on the secondary outcomes were similar in both groups with no 
significant risk reduction. 
Conclusion 
Among participants presenting with tuberculous pericarditis, the effect of adjunctive steroid on 
the primary efficacy outcomes of death, constrictive pericarditis and cardiac tamponade 
requiring pericardiocentesis were similar among those who received pericardiocentesis 
procedure at baseline because it was indicated and those who did not receive it.  This finding 
would need to be confirmed in future non-inferiority trials.  
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4.1 Introduction 
A comprehensive summary of the background, rationale, trial design, research questions 
addressed, results and conclusion of the IMPI-1 trial is provided in chapter one. In the trial, 
patients who were randomised to receive adjuvant corticosteroids did not experience a 
reduction in the composite outcome of death, constrictive pericarditis and pericardial tamponade 
requiring pericardiocentesis at the prespecified time of six months compared to those 
randomised to receive standard therapy. Corticosteroids, by dampening the immune response 
to tuberculous antigens within the pericardium may reduce the size of the inflammatory, 
exudative pericardial effusion and therefore reduce major adverse pericarditis related outcomes 
in those with effusive TB pericarditis who are unstable. Approximately 60% of the trial 
participants in both arms underwent pericardiocentesis before randomisation. The decision to 
undergo pericardiocentesis was left to the discretion of the treating physician but was 
encouraged where there were clinical or echo features of significant cardiac compression. 
There is a reason to suspect that the outcome of the study may have been influenced by the 
high proportion of participants who underwent pericardiocentesis, precisely because it is 
possible that pericardiocentesis may have modified the potential impact of corticosteroids on 
the composite outcome. There are theoretical reasons to believe that patients with large 
inflammatory, exudative effusions are at higher risk of major adverse events and that evacuation 
of the fluid alone may alter the natural history of the condition and, therefore, the response to 
steroids. 
Pericardiocentesis is a life-saving procedure following cardiac tamponade as it reduces the 
raised intrapericardial pressure leading to lower intracardiac pressure; thereby improving 
patient’s outcome and ultimately a reduction in mortality (Krikorian and Hancock 1978; Kopecky 
et al. 1986b; Callahan, Seward, Nishimura, Miller Jr, et al. 1985). Pericardiocentesis followed 
by use of anti-tuberculosis medication leads to favourable results irrespective of HIV status of 
patients (Reuter, Burgess, Louw, et al. 2006). Intermittent drainage and early initiation of anti-
tuberculosis therapy are associated with a low risk of constriction and death (Reuter et al. 2007). 
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The presence of fluid in the pericardial space is proinflammatory, and fluid accumulation 
develops as an inflammatory response to tuberculoproteins (Fowler 1991). The bacillary load is 
a determinant of the adverse event in pericardial effusion (Pasipanodya et al. 2015b) and 
reduction of the fluid through pericardiocentesis can reduce the bacillary load and thus lead to 
a reduction in the rate of constriction and theoretically reduce the rate of major adverse events. 
However, the influence of pericardiocentesis on long-term complications such as constrictive 
pericarditis is not apparent. For example, in effusive-constrictive pericarditis, pericardiocentesis 
relieves the pericardial tamponade and aids in making the diagnosis by finding the persistent 
elevation of right atrial end-diastolic pressure and interventricular end diastolic pressure after 
reduction of intrapericardial pressure. However, the removal of the fluid does not prevent 
subsequent development of constrictive pericarditis or need for pericardiectomy later (Hancock 
2004; Kolek 2011).  
Observational studies in patients who had 80-100mls of pericardial fluid aspirated before high 
dose oral prednisolone and anti-tuberculosis medication administration showed good outcome 
(Strang et al. 1987). Following open surgical drainage and use of prednisolone in 240 patients 
with TBP, a good outcome was shown with the anti-tuberculosis regimen, and it was neither 
dependent on the administration of prednisolone nor drainage. In the study, open drainage at 
admission had no effect on pericarditis related death or need for pericardiectomy following 
administration of corticosteroids (Strang, Gibson, et al. 1988).  
While there is evidence that pericardiocentesis relieves immediate tamponade, there have been 
no randomised controlled studies to test the impact of pericardiocentesis on re-accumulation of 
pericardial fluid and recurrence of tamponade, constrictive pericarditis and death.  In a 10-year 
follow-up of 383 patients who were randomised to prednisolone compared to placebo in addition 
to anti-tuberculous therapy; corticosteroids reduced adverse events of death from pericarditis, 
pericardiectomy, the need for repeat pericardiocentesis and subsequent open drainage. In the 
subgroup analyses, of these relatively small studies, the outcome following use of prednisolone 
was better in those who had drainage than those who did not (Strang et al. 2004). Furthermore, 
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for every adverse event, there was treatment interaction between open drainage and 
prednisolone (11% in prednisolone and drainage, 19% in prednisolone and no drainage). Also, 
prednisolone conferred a significant survival advantage compared to placebo after adjusting for 
age and sex (HR 0.64; 95% C. I 0.41-0.99).  
A systematic review of corticosteroid uses in all forms of tuberculosis included six trials focusing 
on pericarditis and reported that there was a significant principal reduction in mortality of 17% 
(RR 0.83; 95% C. I 0.74-0.92) (Critchley et al. 2013).  
Cellular immunity plays a significant role in TBP, as shown by the enhanced type1 T-helper cells 
(TH-1) response, leading to high interferon gamma which suppresses type 2 T-helper cells (TH-
2) responses. There is also a lower level of interleukin 10 (IL-10) compared to the level in 
bacterial effusion, due to the suppression effect of IL-10 on TH-I (Burgess et al. 2002). 
Therefore, use of prednisolone may attenuate the inflammatory response leading to the better 
outcome; however, pericardiocentesis will lead to the removal of the profibrotic and 
proinflammatory modulators, raising a question on whether the use of steroids will still have the 
same effect following pericardiocentesis. Conclusive research has not provided this answer as 
it is not certain whether the effects of steroids work better in patients with large tuberculous 
pericardial effusions compare to patients with small pericardial effusions. 
To address the possibility that the impact of adjuvant corticosteroids compared to placebo may 
have been modified by pre-randomization pericardiocentesis we performed a subgroup analysis 
of the IMPI-I trial.  
 
4.1.1 Hypothesis 
The specific hypothesis to be tested was; among participants presenting with large pericardial 
effusions, the effect of adjunctive steroids on the composite outcome of death, pericardial 
tamponade requiring pericardiocentesis and constrictive pericarditis corticosteroids will be 
similar irrespective of pericardiocentesis status at baseline. The rationale for the study 
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hypothesis is based on the premise that because patient selection for pericardiocentesis by the 
Physician in the IMPI-1 trial, was on individual indications (this may have selected out the 
patients who were most likely to develop the composite endpoint and benefit from adjuvant 
corticosteroids). This is as opposed to a protocol that mandated either routine pericardiocentesis 
for all patients or no pericardiocentesis for all patients (not feasible or ethical) presenting with 
pericardial effusion   (Kilpatrick and Chapman 1965b; Sagrista-Sauleda, Merce, and Soler-Soler 
2011). 
 
4.1.2 Aims and Objective 
The main aim of this subgroup analysis was to determine if pericardiocentesis at baseline 
modified the impact of adjuvant corticosteroid therapy on the composite outcome of death, 
constrictive pericarditis and recurrent pericardial tamponade in patients with large tuberculous 
pericardial effusions. 
Further objectives were to determine if pericardiocentesis at baseline modified the impact of 
adjuvant corticosteroids on each component of the composite outcome in the same patients. 
4.2. Methods 
The IMPI-1 trial enrolled 1400 patients with either definite or probable tuberculous pericarditis 
to participate in the trial from 19 hospitals in 8 African countries, from January 2009 to February 
2014. The patients were randomised to six weeks of 120mg prednisolone and five doses of 
intradermal Mycobacterium indicus pranii over three months as compared with placebo. The 
median follow-up period was 636.5 days (IQR, 317.5 to1085.5). In this predefined subgroup 
analysis, patients in both treatment arms (prednisolone versus placebo) were divided into two 
groups (Figure 4.1), depending on their baseline pericardiocentesis status (performed versus 
not performed). The primary efficacy outcome (composite of death, cardiac tamponade requiring 
pericardiocentesis and constrictive pericarditis) was compared for each group using a Cox 
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proportional-hazard model with an interaction term for treatment effect across the subgroup. 
The point effect estimate was reported as hazard ratio with 95% confidence interval and 
presented with a forest plot. The analysis was exploratory, so the P-value was not adjusted for 
multiple testing. Continuous variables are represented as median with interquartile range unless 
otherwise specified; nominal variables are presented as counts (%). Cox proportional hazard 
model for the outcome was used to add an interaction term between pericardiocentesis 
(performed and not performed) and the treatment group (prednisolone and placebo) to the 
primary effect model. The effect estimate for each subgroup was reported as Hazard ratio at 
95% confidence interval and presented with a forest plot. Level of significance was determined 
using p-value for test of interaction with alpha value=0.05. The p-value test for interaction 
described whether a history of performing pericardiocentesis at baseline or not interacts with 
the overall treatment effect of prednisolone on the primary efficacy outcome. The analysis was 
performed using STATA 14 (StataCorp. 2013. Stata Statistical Software: Release 14. College 
Station, TX: StataCorp LP). 
 
4.3. RESULTS 
4.3.1 Study Population Characteristics 
The prednisolone arm had 706 participants and the placebo arm 694, with a median follow-up 
of 635 days (Figure 4.1). Sixty-seven per cent (933/1400) of the study population were females, 
48% presented in NYHA stage III and IV, 67% were HIV positive, and 67.3% had CD4 cell count 
less than 200. 
Eight hundred and forty-seven (847) of the study population (60.5%) underwent 
pericardiocentesis. There was no difference in age, sex and weight between the groups. Of the 
847, approximately half (428, [50.7%]), received prednisolone, while 416 (49.5%) received 
placebo. Of the 553 patients who did not undergo pericardiocentesis 278 (50.2%) were 
randomised to receive prednisolone. Table 4.I provides the differences in baseline 
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characteristics stratified by pericardiocentesis status and whether they were in the active or 
placebo arms.  Overall a more significant proportion of patients who received pericardiocentesis 
had a heart rate higher than 100, compared to those who did not ((60.5% vs 46.9%). Similarly, 
the proportion of participants who underwent pericardiocentesis with systolic blood pressure 
less than 90, was almost double the proportion ((9.9 vs 4.2%) who did not undergo 
pericardiocentesis. Furthermore, a much larger proportion of the group that underwent 
pericardiocentesis had large effusions (85.7% versus 39.9%) and had NYHA Class III and IV 
heart failure symptoms compared to those who did not undergo the procedure (43.8% versus 
40%). Also, a slightly higher proportion in the performed group tested positive for HIV (68.6% 
versus 64.9%) and had a higher CD4 cell count, compared to the other group (39.6% versus 
37.2%). At presentation, the proportion of participants in the performed group who were on anti-
tuberculosis medications was more than in the not performed group - 96.2% versus 94.9% 
(Table 4.1).  
 
4.3.2 Impact of Corticosteroids by pericardiocentesis at baseline 
The outcome status was known in 1371/1400 participants at the end of the trial. The primary 
composite outcome occurred in 25% (107/428) of those that had pericardiocentesis and 14.6% 
(61/419) of the participants who did not have pericardiocentesis; secondary outcomes were 
recorded in 28.3% (121/428) following pericardiocentesis and 17.9% (75/419) without 
pericardiocentesis. 
Compared to those patients who did not undergo pericardiocentesis at baseline, those 
participants who underwent pericardiocentesis had a non-significant risk reduction of 7% for the 
primary outcome (HR 0.93, 95% C.I 0.71-1.2, p-value for interaction 0.709). Those who 
underwent pericardiocentesis had 18% risk reduction in tamponade (HR 0.82, 95% C. I 0.45-
1.43, p-value for interaction 0.583), 47% risk reduction in constriction (HR 0.53, 95% C.I 0.30-
0.93, p-value for interaction 0.759) and 12% increase in the risk of death over the follow-up 
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period (HR 1.12, 95% C. I 0.82-1.54, p-value for interaction 0.776). However, none of these 
effects in the secondary outcome was statistically significant. 
 
4.4. DISCUSSION 
The main findings from this subgroup analysis include that: a] amongst patients in the IMPI trial, 
the use of pericardiocentesis as part of the initial management strategy did not modify the 
neutral impact of adjuvant corticosteroids on the composite outcome of death, recurrent 
tamponade needing pericardiocentesis or constrictive pericarditis compared to placebo. 
Pericardiocentesis did not modify the impact on of corticosteroids on the secondary individual 
outcomes of death, tamponade and constrictive pericarditis at six months compared to placebo; 
and c] pericardiocentesis may be a marker for sicker more hemodynamically compromised 
patients at baseline and worse outcomes at six months. 
In this subgroup analysis, the baseline clinical characteristics show that more participants who 
underwent pericardiocentesis at baseline had tachycardia, systolic blood pressure lower than 
90mmHg, NYHA functional class III and IV, and presented with a larger size of effusion. The 
group, therefore, had more likelihood of presenting in cardiac tamponade and it is not surprising 
that the clinical condition influenced the managing physician's decision for pericardiocentesis (a 
life-saving intervention for patients who present with cardiac tamponade) for patients in this 
group. Removal of even a minimal amount of fluid in emergencies can improve the survival of 
patients who present in cardiac tamponade. 
Observational evidence on the impact of the evacuation of the pericardium in patients with large 
tuberculous effusion who were randomised to receive steroids or placebo is not clear (Strang et 
al. 1987). However, in this analysis pericardiocentesis at baseline did not have any significant 
modification of the effect of adjunctive steroid on the study outcomes and is in keeping with our 
hypothesis. It is possible that amongst patients presenting with larger effusions and more 
evidence of significant cardiac compression; corticosteroids may have led to improved 
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outcomes compared to placebo in the absence of pericardiocentesis because of its effect in 
halting the immune response within the pericardium and reducing the amount of inflammatory 
exudates. However, by performing the pericardiocentesis and removing the target of the 
steroids, the two patient groups (pericardiocentesis and no pericardiocentesis) were rendered 
almost equal regarding the effectiveness of adjunctive steroids.  
Tuberculous pericarditis is paucibacillary and large pericardial fluid accumulation is said to be 
an inflammatory response to tuberculo-proteins (Fowler 1991); tuberculous pericardial effusion 
is proinflammatory, an assertion that has been scientifically proven by the establishment of the 
role of cellular immunity pathogenesis of TBP. Evidence for this is the finding of raised interferon 
gamma in TBP due to TH-I response leading to suppression of TH-2 response, and reduction 
in IL-10 compared to the level in bacteria effusion as the later suppresses TH-1(Burgess et al. 
2002). Another study also reported on the elaboration of such inflammatory markers such as 
interleukin 10 and interferon gamma in the pericardial fluid of patients with pericardial effusion 
(Ntsekhe et al. 2013b). The implication of this could be that if the cause of the inflammation is 
adequately addressed by pericardiocentesis, the impact of corticosteroids may not have any 
influence on the long-term outcome in patients.  
Amongst patients who do not have tuberculous pericarditis the long term impact  of 
pericardiocentesis and steroids are not known, In a study to evaluate if conventional 
pericardiocentesis should be carried out in patients who present with large pericardial effusion, 
the result among the 71 patients showed that pericardiocentesis did not play an essential role 
in the long-term outcome (Mercé et al. 1998). There was documentation of a previous 
pericardiocentesis in 80% of patients that had persistent effusion; 38 of the 40 patients offered 
conservative drainage had a resolution of effusion within weeks without intervention. However, 
higher than 98% of the patients had idiopathic pericarditis. The condition is benign with low rates 
of constrictive pericarditis recurrent pericarditis and death because none of these patients had 
tuberculous pericarditis or purulent pericarditis where the rates of constrictive pericarditis and 
recurrent tamponade are high. Therefore, these results may not apply to the understanding of 
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the role of pericardiocentesis the IMPI-1 results. 
It is notable that pericardiocentesis in IMPI-1 did not prevent subsequent repeat accumulation 
of pericardial effusion requiring repeat pericardiocentesis as 4% of participants had re-
accumulation with tamponade. Also, pericardiocentesis did not influence the outcome of 
constriction; 8% of the trial patients who had the pericardiocentesis progressed to constriction 
(Mayosi et al. 2014). However, in the trial, the overall rate of constrictive pericarditis and 
recurrent pericardial tamponade and death was low compared to historical studies where the 
rate of pericardiocentesis is low. In the IMPI Registry (Mayosi, Wiysonge, Ntsekhe, Volmink, 
Gumedze, Maartens, Aje, Thomas, Thomas, and Awotedu 2006) pericardiocentesis was 
undertaken in 37% of patients, and the rate of major adverse pericardial outcomes was between 
32 and 44% depending on baseline variables (Mayosi et al. 2008b; Ntsekhe et al. 2008).  
 The subsequent progression of some patients to constrictive pericarditis despite 
pericardiocentesis could be explained by the fact that despite pericardiocentesis, significant 
amounts of fluid remained in the pericardial space, and as already explained, this fluid is 
proinflammatory and a stimulant of pericardial fibrosis. While the analysis suggests that 
pericardiocentesis did not modify the effectiveness of steroids, what is still unclear is whether 
adjuvant corticosteroids given to patients with compressive hemodynamic where 
pericardiocentesis is not available would be effective. Our analysis was not designed to answer 
this question, which is unlikely ever to be tested given the mortality and morbidity benefits of the 
procedure under those circumstances. (ESC guideline). A possible interpretation of the study is 
that following pericardiocentesis, profibrotic and inflammatory cytokines rich fluid are removed; 
and evacuating compressive pericardial fluid in unstable patients with large pericardial effusion, 
may mitigate the potential effectiveness of corticosteroids in unstable patients, rendering them 
as neutral as they are in patients who are stable and do not need pericardiocentesis. 
 
Conclusion 
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In this subgroup analysis, pericardiocentesis performed at baseline had no significant interaction 
with the effectiveness of prednisolone on the primary composite outcome or the secondary 
outcomes. This is in keeping with our hypothesis that the removal of inflammatory profibrotic 
pericardial fluid from patients who are hemodynamically unstable and unwell, may have 
neutralized the impact of corticosteroids in the study. A non-inferiority trial may be necessary to 
evaluate this concept further; while addressing the inflammation by use of fibrinolysis - the focus 
of the second investigation of the management of pericarditis (IMPI-2) trial may provide 
additional answers to tackling the complications of tuberculous pericarditis. The findings of this 
study are important because they indicate that even though pericardiocentesis may identify a 
high-risk group for adverse outcomes, the impact of adjuvant corticosteroids did not differ by 
pericardiocentesis status. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1: Study Flow 
Total study population N=1400 
Prednisolone arm 
n=706 
Routine arm  
n= 694 
 
n=42
8 n=419 
n=278 
n=275 
Follow up for 12 months for outcomes 
(composite, death, tamponade, constrictive pericarditis) 
No pericardiocentesis Pericardiocentesis 
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Table 4.1: Baseline Characteristics of the Subgroup¶ 
Variable  Pericardiocentesis  
n=847 
No pericardiocentesis  
n= 553 
 Overall 
N=140
0 
Prednisolon
e n=428 
Placebo 
n= 419 
Prednisolon
e n=278 
Placebo 
n=275 
Age – year 1400 34.9 35.3 37.2 35.7 
Weight - Kg 1377 57.4 57.9 57.2 58.5 
Female sex – no. (%) 616 192 (44.9) 172 (41.1) 125 (44.8) 127 (46.2) 
Systolic BP - mmHg 1399 110 110 110 112 
Diastolic BP -mmHg 1399 70 72 70 73 
Systolic BP<= 90mmHg-no. (%) 106  45 (10.6) 38 (9.1) 14 (5.0) 9 (3.3) 
Heart rate >100beates/min- no. 
(%) 
680 167 (60.7) 253 (60.4) 132 (47.3) 128 (46.6) 
Duration of symptoms- days 1400 30 21 30 30 
NYHA Class** – no. (%) 
  I 
  II 
  III 
  IV 
1397  
71 (16.6) 
169 (39.6) 
132 (30.9) 
55 (12.9) 
 
60 (14.4) 
183 (43.8) 
127 (30.4) 
48 (11.5) 
 
66 (23.7) 
173 (62.2) 
31 (11.2) 
8 (2.88) 
 
59 (21.5) 
169 (61.7) 
40 (14.6) 
6 (2.2) 
Size of effusion**- no. (%) 
  Small <1cm 
  Medium 1-2cm 
  Large >2cm 
1359  
14 (3.39) 
45 (10.9) 
354 (85.7) 
 
10 (2.5) 
50 (12.3) 
346 (85.2) 
 
36 (13.3) 
127 (46.9) 
108 (39.9) 
 
46 (17.1) 
109 (40.5) 
114 (42.4) 
HIV Status- no. (%) 
  Positive 
  Negative 
  Unknown 
1400  
293 (68.6) 
125 (29.3) 
9 (2.1) 
 
274 (65.4) 
135 (32.2) 
10 (2.4) 
 
181 (64.9) 
93 (33.3) 
5 (1.8) 
 
191 (69.5) 
78 (28.4) 
6 (2.2) 
Anti-tuberculosis medication at 
randomization**- no. (%) 
1083 202 (96.2) 
 
318 (96.9) 320 (94.9) 185 (96.9) 
Antiretroviral medications at 
randomization**- no. (%) 
927 50 (11.7) 48 (11.5) 49 (11.6) 56 (20.4) 
CD4 cell count>200 cells/mm3-
no. (%)  
776 106 (39.6) 96 (40.0) 51 (37.2) 60 (45.8) 
Haemoglobin>10g/Dl -no. (%) 1393 188 (44.2)  131 (46.9)  
White blood cell 
count>10×109/L- no. (%) 
1396 27 (6.35) 41 (9.8) 15 (5.38) 16 (5.8) 
¶ Median values are reported for continuous variables due to the presence of extreme values in 
some. No significant differences were seen on the baseline characteristics except for those with ** 
with p<0.005.  HIV- Human immunodeficiency virus 
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Figure 4.2: Forest plot of modification effect of prednisolone of primary efficacy outcomes by 
pericardiocentesis status at baseline 
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Figure 4.3: The cumulative hazard curves for pericardiocentesis on Primary and secondary 
outcomes 
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Abstract 
Background: Effusive pericarditis is a cause of cardiovascular morbidity and mortality in Africa 
and other regions with high tuberculosis and HIV burden. The Investigation for Management of 
Pericarditis (IMPI)-2 is a trial designed to determine whether intrapericardial alteplase [IA] can 
facilitate pericardiocentesis to improve outcomes.  
Objectives: The primary objectives are: Phase1: to determine the safe dose of IA for complete 
drainage of pericardial effusion; and Phase 2: to evaluate the feasibility of a large randomized 
controlled trial [RCT] to assess the effects of a safe dose of IA vs usual care in reducing 
tamponade or pericardial constriction over 12 months. 
Study design: This was a two-phase study design—phase 1 is an open-label one arm dose-
finding study, followed by phase 2 which is a pilot RCT. 
Population: For both phases, we recruited adult patients ≥18 years with confirmed pericardial 
effusion and no contraindication for fibrinolysis. 
Methods: Phase 1: Interventions: We allocated patients in sequence to 3 escalating doses of 
IA based on safety profile—1mg, 10mg, and 50mg. 
Outcome: Maximum dose, with no minor or major bleeding.  
Phase 2: Patients were randomised using 1:1 ratio to pericardiocentesis by use of 50mg of IA 
(Intervention) vs usual care, defined by pericardiocentesis at the discretion of the treating 
physician (Control). The primary feasibility outcomes (criteria for success of feasibility) include 
recruitment rate (3-5/month), adherence rate to study protocol (≥95%), completion of case 
report forms (CRF) within 24 hours of recruitment (≥95%), and adherence to follow-up (≥95%).  
Results: Phase 1: We recruited 12 patients—mean (standard deviation [SD]) age of 38 (16) 
years, and sequentially them to allocated 1mg (3 patients), 10mg (3 patients), and 50mg (6 
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patients) of AI. Zero out of 12 (0%): 95% confidence interval: (0%,3%) had no minor or major 
bleeding in all three doses. 
Phase 2: 132 patients randomized to 50mg IA (n=64) and usual care (n=68). The median (SD) 
of age was 45 (14) years, 45% (58/132) female, and 52% (68/132) HIV positive. Recruitment 
rate was 4-5 patients/month over the 16 months with 97% adherence to protocol, CRF 
completion rate was 88.5%, and overall adherence to follow-up was 81%. 
Conclusion: 50mg IA was safe for complete drainage of pericardial effusion.  The results also 
show that it will be feasible to recruit, randomise, completely drain the effusion, and follow up 
patients over 12 months in the main trial.  
Trial Registration: Clinical Trials. gov (NCT02673879). 
Funding: South African Medical Research Council.  
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5. Introduction 
5.1.1 The burden of tuberculous pericarditis and lessons from IMPI-1: 
Tuberculous Pericarditis is a recognised cause of heart diseases especially in Africa and in 
regions with a high tuberculosis burden (Lange and Hillis 2004; Imazio, Mayosi, et al. 2010).  As 
much as up to 10% of hospital admissions for heart failure in Africa is due to pericarditis 
(Maharaj 1991; Oyoo and Ogola 1999), and over 90% of these are related to tuberculosis (Adler, 
Charron, Imazio, Badano, Barón-Esquivias, Bogaert, Brucato, Gueret, Klingel, Lionis, et al. 
2015). The epidemics of HIV/AIDS have further increased the prevalence of tuberculous 
pericarditis worldwide (Mayosi, Wiysonge, Ntsekhe, Volmink, Gumedze, Maartens, Aje, 
Thomas, Thomas, and Awotedu 2006).  The two common complications of pericarditis are 
cardiac tamponade and pericardial constriction. Management of these complications often 
requires cardiothoracic surgery which is not readily available in most of the high burden 
communities. 
The Investigation for management of pericardial disease in Africa (IMPI) trial was 
conceptualised to research for interventions to improve outcomes of patients with pericarditis.  
IMPI-1 the first randomised control trial (RCT) was conducted in 19 hospitals from 8 African 
countries between 2009 and 2014 (Mayosi  et al. 2014). It was an investigation of the role of 
adjunctive steroid and immunotherapy in reducing the primary composite outcome of death, 
constrictive pericarditis and cardiac tamponade requiring pericardiocentesis among patients 
with tuberculous pericarditis (Mayosi  et al. 2014). 
At the end of the study, among patients with definite or probable TB pericardial disease, four 
broad conclusions were drawn: (a) The use of Prednisolone and Mycobacterium indicus pranii 
had no significant effect on the combined outcome of death from all causes, cardiac tamponade 
requiring pericardiocentesis or constrictive pericarditis. (b) Both therapies led to an increased 
risk of HIV-associated malignancy; (c) The use of prednisolone reduced the incidence of 
constrictive pericarditis and hospitalisation; (d) The beneficial effects of prednisolone on 
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constriction and hospitalisation were similar in HIV-positive and negative and HIV-negative 
patients. 
 
5.1.2 Why is there a need for another Randomised Control Trial? 
Despite the growing body of knowledge on pericarditis, the disease remains a great source of 
morbidity and mortality in the world, especially among the more impoverished communities 
(Mayosi et al. 2008b). The result of IMPI-1 trial immensely contributed to science and 
understanding of tuberculous pericarditis. However, the finding of increased incidence of HIV 
related malignancies and the inability of either corticosteroid use or mycobacterium indicus 
pranii immunotherapy to reduce the primary composite outcome gave rise to a need to look for 
an alternative intervention which could improve major adverse pericardial outcomes.  
Well-designed randomised control trial (RCT) provides the best source of evidence to influence 
practice; therefore, we reasoned that asking further questions through well-structured RCT was 
the right way to go in the quest to find answers to intervention to reduce pericarditis outcomes.  
 
5.2 What is the rationale for using a fibrinolytic agent to facilitate pericardiocentesis? 
Chapter one of the thesis provides a comprehensive review of the literature on evidence of the 
use of fibrinolysis in pericarditis, the rationale for its use, its mechanism of action and potential 
side effects. In summary, the reaction of the body's immune system to fight insults to the 
pericardium is the cause of exudation of fluid which ultimately results in the accumulation of fluid 
in the space (Burgess et al. 2002; Maisch, Maisch, and Kochsiek 1982). These inflammatory 
insults to the pericardial space attract leucocytes; and activated leucocytes promote 
coagulation, leading to the formation of fibrin (Roberts 2005). The deposition of fibrin in the area 
is the cause of pericardial adhesion, thickening, and loculation of effusion (Brockington, Zebede, 
and Pandian 1990; Mayosi, Burgess, and Doubell 2005). 
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The use of fibrinolysis in pericarditis was first documented in the literature over 60 years ago 
(Adie and Childress 1951a; Barnett et al. 2011;), and there is research evidence which suggests 
that the formation of fibrin is the cornerstone of the pathogenesis of both persistent inflammatory 
pericarditis and constrictive pericarditis (Mayosi, Burgess, and Doubell 2005). Inflammation and 
fibrin deposition are, therefore, a central theme in the aethio-pathogenesis of pericardial 
constriction and persistent loculation of fluid in the pericardial space. Fibrin may be a potential 
target in the management of exudative inflammatory pericarditis, such as tuberculous, purulent, 
neoplastic and auto-immune pericardial effusion.  Finding a way of addressing fibrin deposition 
may, therefore, provide the answer to persisting pericardial effusion and its sequelae of 
constriction. 
There are Isolated case reports on the use of intrapericardial fibrinolytic agents as rescue 
therapy for pericarditis in both animal studies and humans (Bigham et al. 2008; Dybowska et al. 
2015). However, there has not been a large-scale randomised control trial to establish their role 
in a large population.  
 
5.3 The rationale and design of IMPI-2 and the reason for a two-phased study 
The second investigation of the management of pericarditis (IMPI-2) trial, is an RCT designed 
to test the efficacy and safety of complete percutaneous pericardial drainage facilitated by 
intrapericardial tissue plasminogen activator (t-PA) compared to conventional 
pericardiocentesis when indicated in adults with a large pericardial effusion due to tuberculous 
and non-tuberculous pericarditis. IMPI-2 uses a generic form of t-PA called alteplase in the trial. 
The IMPI-2 trial hypothesizes that among patients with large pericardial effusion who receive 
treatment for the underlying cause of pericardial disease, those who are randomised to receive 
intrapericardial alteplase (IA) to ensure complete pericardial drainage, will have a 35% reduction 
in the combined endpoint of cardiac tamponade requiring pericardiocentesis and constrictive 
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pericarditis, compared to conventional pericardiocentesis when indicated. The RCT addresses 
two broad research questions:  
a) among patients with large pericardial effusion due to tuberculous and non-tuberculous 
causes, is complete pericardiocentesis facilitated by use of intrapericardial fibrinolysis effective 
in reducing the combined outcome of death, cardiac tamponade requiring pericardiocentesis 
and constrictive pericarditis compared to standard percutaneous pericardiocentesis when 
needed over 12 months?  
 b) among patients with large pericardial effusion due to TB and non-TB causes, does complete 
pericardiocentesis using intrapericardial fibrinolysis increase the incidence of significant 
bleeding, other non-major bleeding and other adverse events compared to standard 
pericardiocentesis when required over 12 months. 
 We structured this study in two phases; Phase 1 was a dose-finding study to determine a safe 
and appropriate dose of IA to facilitate complete percutaneous pericardial drainage. Phase 2 
was a pilot RCT designed to evaluate the feasibility of conducting a large multicenter trial and 
being able to recruit adults with pericardial effusion at an appropriate rate and to follow them up 
for 12 months (IMPI-1 Pilot trial).  
Phase 1 was a prelude for the pilot RCT and was like phase 1 of a clinical trial (the foundation 
of any successful drug development process used to establish adequate dose and schedule for 
efficacy). In this study, the phase was used to evaluate the scientific basis for the study 
hypothesis by first ascertaining the safety and efficacy of IA in patients with large pericardial 
effusion. Through the dose-finding study, we determined the correct dose for IA in patients with 
pericardial effusion. Parameters under the purview of the dose-finding study included the 
starting dose, rate of dose increment, the dose escalation method, number of patients needed 
per dose level, specification of dose-limiting toxicity, the definition of maximum tolerated dose 
(MTD) and patient selection.  
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The goal of the pilot was to lay the foundation for the larger trial, by providing information for 
planning and justification of a planned randomised control trial. We did this through evaluation 
of the organisational readiness on such parameters as the number of participants expected, the 
willingness of these participants and their referring physicians to be part of the trial, and the rate 
of recruitment. Also, the pilot is planned to provide an opportunity for test running the trial 
processes such as randomisation, compliance with the protocol, data collection 
tool/questionnaire, recruitment and consent process. Other parameters will include the 
acceptability of the intervention, selection of the most appropriate primary outcome measures 
as well as the ability to identify events of interest and follow-up related to the process. 
 
5.4 Study research questions 
Phase-1: What is the safe dose of intrapericardial alteplase (IA) that can effectively facilitate 
complete pericardiocentesis in patients presenting with large pericardial effusion without a] 
altering systemic markers of coagulation, and b] causing clinically detectable minor or major 
bleeding? 
Phase-2: Is it feasible to recruit participants with large pericardial effusion, adhere to all 
aspects of the study protocol and follow up the participants for 12 months, well enough to 
meet the standards required to complete the randomised controlled trial? 
 
5.5 Objectives 
Phase 1: The primary objective is to determine the safe dose of IA for complete drainage of 
pericardial effusion. 
Phase 2: The primary objective is to evaluate the feasibility of a large randomised controlled 
trial [RCT] to assess the effects of a safe dose of IA vs usual care in reducing tamponade or 
pericardial constriction over 12 months. 
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The secondary objectives of Phase 2: Identification of all intervention related and other adverse 
events, such as bleeding, adverse reaction from trial medication, unexpected adverse events, 
re-accumulation of effusion and hospitalisation. 
 
5.6 Study Population 
 For both phases, we recruited adult patients ≥18 years with confirmed large pericardial 
effusion ((i.e. ≥1cm echo-free space anterior to the right ventricle in diastole) and no 
contraindication for fibrinolysis. Eligible patients were also required to express willingness to 
participate for the full duration of the trial and provide written informed consent. Participants 
were excluded in the presence of uremic pericarditis (patients undergoing dialysis or urea 
level more than 21.4 mmol/L), the presence of thrombocytopenia pregnancy and any 
contraindication to use of fibrinolysis. 
 
5.7 Study design and Methodology 
A two-phase study design—phase 1 is an open-label one arm dose-finding study, followed by 
phase 2 which is a single blinded (participants) pilot randomised control trial. 
5.7.1 Methods: 
 Phase 1 (Dose-finding): Interventions: We allocated patients in sequence to 3 escalating doses 
of IA based on safety profile—1mg, 10mg, and 50mg. 
Outcome: Maximum dose, with no minor or major bleeding.  
Phase 2 (Pilot RCT): We randomised patients using 1:1 ratio to pericardiocentesis by use of 
50mg of IA (Intervention) vs usual care, defined by pericardiocentesis at the discretion of the 
treating physician (Control).  
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The primary feasibility outcomes (criteria for success of feasibility) include recruitment rate (3-
5/month), adherence rate to study protocol (≥95%), completion of case report forms (CRF) 
within 24 hours of recruitment (≥95%), and adherence to follow-up (≥95%).  
The secondary safety outcomes for Phase 2 include all intervention related and other adverse 
events, such as bleeding, adverse reaction from trial medication, unexpected adverse events, 
re-accumulation of effusion and hospitalisation. Information on the detailed efficacy and safety 
of intervention were meant exclusively for the trial safety monitoring board.  
Managing physicians from different referring centres sent patients for the trial based on clinical 
suspicion of pericardial effusion. They were screened to confirm eligibility by 2-D 
echocardiography, electrocardiogram, full blood count, electrolyte, creatinine, urea estimation 
and pregnancy test if female (see study flow diagram). Eligible patients provided informed 
consent, and we used the University of California San Diego Brief Assessment of Capacity to 
Consent (UBACC) questionnaire modified for the IMPI pilot trial to evaluate their comprehension 
of the consent information (Jeste et al. 2007). Randomisation using 1:1 ratio to 
pericardiocentesis by use of 50mg of IA (Intervention) vs usual care, defined by 
pericardiocentesis at the discretion of the treating physician (Control).  The trial team was 
automatically alerted to the outcome of randomisation and pericardiocentesis was arranged and 
carried out at either the catheterisation laboratory or procedure room. Pericardiocentesis was 
done using the subcostal approach and aspiration to dryness confirmed by echocardiography 
(less than 1cm echo-free space over the right ventricle at the end of diastole). Samples were 
sent out for analysis and those in the intervention arm were given 50mg of intrapericardial 
alteplase and catheter flushed with 7ml of normal saline while those on routine arm had the 
catheter removed as per local site practice 
Patients subsequently had a chest x-ray and post-procedure haemoglobin estimation; we then 
transferred them to the ward for observation and appropriate treatment. Those in the routine 
arm were discharged within 24 to 48 hours if stable, while those on alteplase arm had another 
2-D echocardiography at 2 hours post procedure and repeated aspiration to dryness. The 
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protocol stipulated that, if at 2 hours post-aspiration, 2-D echocardiography revealed significant 
re-accumulation of fluid and aspiration to dryness is not achieved, the second dose of 50mg 
alteplase should be given and the entire steps repeated.  
We managed all participants in liaison with the medical unit and discharged them if stable, in 
24-48 hours with a detailed follow-up plan and appropriate referral were made based on the 
clinical status. 
 
5.7.2 Ethical Review 
The IMPI-2 trial is approved by the Faculty of Health Sciences Human Research Ethics 
Committee of the University Cape Town (HREC REF 370/2015) and the South African Health 
Products Regulatory Authority [formally Medicine Control Council of South Africa] (20150723). 
The IMPI-2 trial is registered with clinical trials.gov (NCT02673879). 
 
5.7.3 Data analysis 
For phase 1, using a previously validated dose-finding sample size calculation method (Le 
Tourneau, Lee, and Siu 2009), we arrived at 12 participants as the  required sample size to 
ascertain the safe dose of IA to facilitate complete drainage. Simple descriptive analysis was 
used to present the data. The required sample size for Phase 2 of the study is 218; however, 
we based the sample size of this preliminary report on a convenient sampling for feasibility 
evaluation. We analysed all clinical measures on an intention-to-treat basis. Descriptive 
statistics were calculated for all variables over the six-time points (baseline, two weeks, six 
weeks, three months, six months and twelve months). Continuous variables were reported as a 
median and interquartile range (IQR) and compared using student T-test for continuous 
variables, while categorical variables were reported as count (%) and analysed using Chi-
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square test for categorical variables. Statistical significance was taken at the p= 0.05 level. Data 
analysis was performed using Stata version 14.2 (StataCorp, College Station, TX, USA). 
 
5.8 Results 
In figures 5.1 and 5.3 the study flow charts for both phases of the study are presented, while 
Table 5.3 shows the key findings of the study. 
Phase 1 
We recruited a total of twelve patients with a mean age (standard deviation) of 38 (16) years, 
58.3% (7/12) were females, and approximately 42% (5/12) were HIV positive (See Table 5.1 for 
the timing of recruitment).  
The patients were systematically allocated to escalating doses of IA, starting at a minimal dose 
of 1mg (3 patients) 10 mg (3 patients) and 50mg (6 patients). None of the 12 patients (0%) [95% 
confidence interval (0%,3%)] had minor or major bleeding. Only one patient had systemic IA 
concentration of 0.5ng/ml (excess of 10ng/ml is required to induce systemic plasmin generation) 
[Figure 5.2]. The baseline alteplase values following intrapericardial administration remained 
unchanged for all the study participants different from what obtains following parenteral 
administration. 
 
Phase 2 
We screened 300 patients in the two active sites (Cape Town and Mthatha); 132 (44%) patients 
were recruited, which was 60% of projected recruitment in 16 months; 48.5% (64/132) into 
alteplase arm and 51.5% (68) into the routine arm. Cape Town began recruitment four months 
before Mthatha and achieved 118% of our planned recruitment, at an average of 4-5 patients 
per month (Figure 5.4 and Figure 5.5). Four of the patients in the alteplase arm could not get 
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the intervention due mainly to the failure of pericardiocentesis, and ultimately 46.2% had 
intrapericardial alteplase. The median age (standard deviation [SD]) was 45 (14) years, and 
females constituted 44.6% (58/132) of the study population. There were no significant 
differences in the baseline characteristics between the two arms. 
There was a failure to administer the drug in 3% (4/130) of participants. The primary reason for 
this deviation from protocol was a failure of percutaneous pericardiocentesis and none 
placement of pigtail catheter in the pericardial space. In one case excessive bleeding intra-
procedure made the physician abandon alteplase administration. Inadequate history from 2 
participants resulted in the wrong recruitment of patients who were ineligible for the trial; 
however, no harm occurred. These alterations resulted in 97% adherence to study protocol. The 
timing between randomisation and intervention was within 24 hours in over 90% of participants. 
The increasing re-accumulation of effusion especially in the alteplase arm within 24-48 hours 
post pericardiocentesis led to slight modification of the protocol concerning patients on the 
alteplase arm. Instead of removal of pigtail catheter after repeat echo and aspiration at 2 hours, 
we left the catheter for 24 hours and re-evaluated patients next day for evidence of re-
accumulation and re-aspiration if indicated before removal of the catheter. 
The overall adherence to follow-up was 80.9% (We This percentage was based on a ratio of 
the actual number of visits recorded versus expected follow-up visit [364/450]). It was maximum 
at two weeks and three months (85.6% and 83.3% respectively). By twelve months there was 
a significant drop-out rate and adherence to follow-up was 62.9% (Table 5.2). There was better 
adherence in the routine arm compared to intervention. At the time of this preliminary report, we 
lost 10% of the study population to follow-up (13/130). Three of the patients relocated to other 
provinces, two left the republic being foreign nationals, while another three were alive and 
receiving anti-tuberculous medications from other hospitals but refused to present for trial follow-
up.  We contacted participants by telephone or used field workers to trace the participant's 
contact address when they missed a follow-up visit despite prior reminders. A patient is deemed 
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to have been lost to follow up if he/she fails to turn up for appointment consecutively after 
repeated telephonic reminders and confirmation that the patient is alive. 
CRF completion rate was 88.5%; it varied between the two study sites as shown in Figure 5.6. 
Cape Town site had no personnel to enter data from patients’ files, resulting in 80% CRF 
completion rate compared to 97% in Mthatha. 
 
Secondary Safety Assessment: 
 We recorded no case of minor or major bleeding attributable to IA was, and there were no 
recorded adverse events. 
 
Other Pilot Trial Results: 
Approximately 52.7% (68/130) were HIV positive, TBP accounted for 91% of the presumptive 
diagnosis in the study population but was only conclusively proven in 26% (33/130) [15.4 % had 
culture-positive TB, and 10% were culture negative respectively].  
Tuberculosis was the cause of pericarditis in 91.5% based on the finding of the culture-positive 
specimen in 15.4% (20/130), gene expert positive in 10%, ADA> 30 IU/L in 34.1% and 
suspected TB based on history in 31.8% (41/130). We obtained a histological diagnosis in six 
of the eight patients who had malignancy (four small cell lung adenocarcinoma, one blast phase 
Non-Hodgkin's lymphoma, one primary cardiac tumour).  
 
5.9 Discussion 
The results of Phase 1 of this two-phase study showed that at a dose of 50mg, intrapericardial 
alteplase was safe in facilitating complete drainage in patients presenting with large pericardial 
effusion. No adverse events such as minor bleeding occurred at any of the doses employed in 
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the phase, and the trial process was adjudged to be safe for the commencement of phase 2 of 
the study. 
In Phase 2, the target of recruitment was surpassed at an average of 4-5 patients per month, 
and we established that the study was feasibility (Figure 5.4 and Figure 5.5). However, we could 
not meet the projected adherence rate to study protocol with 3% deviation. Also, the CRF 
completion rate fell short of expectation in one of the sites. The longer the participants were in 
the trial, the less likely they were to continue follow-up. 
The following observations were drawn from this preliminary report to allow improvement of 
design and conduct of the main study: The administration of IA during pericardiocentesis; 
retention of pigtail catheter for up to 48 hours after IA administration to prevent patients 
representing with re-accumulation. Others include the combined use of electronic and paper 
CRFs, reviewing randomisation of patients with malignant effusion and use of data capturers to 
enter data. 
The study in the first 16 months covered by this preliminary report recorded a high attrition rate, 
like findings in the IMPI-1 study (Mayosi  et al. 2014), though in it, injection side effect from 
mycobacterium indici was given as the reason. The CRF completion rate was also reduced, 
especially in the Cape Town trial site. One reason for this finding was the switch from originally 
intended electronic data capture to use of paper case report forms without making provision for 
any staff to capture the data. We hope that in the main trial adequate funds are mapped out to 
engage desk officers to capture the data so that the research fellow can devote more time to 
trial-related procedures. We introduced some measures to improve follow-ups such as 
telephonic reminders and contact tracing.  A substudy, the Informed Consent Comprehension 
study (ICC study), was also initiated to improve consent comprehension.  
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5.10 Conclusions 
Analysis of IMPI-2 trial dose-finding study and the review of the experience from the first 132 
patients recruited to the IMPI-2 pilot trial led us to the following conclusions towards the 
conduct of the main IMPI-2 trial: 1) At 50mg, intrapericardial alteplase was safe in facilitating 
complete pericardiocentesis with no compromise of patient's safety measured by the 
occurrence of minor or major bleeding. 2) Conduct and completion of the IMPI-2 randomised 
controlled trial is feasible. Based on the findings of this preliminary study, it is possible to 
recruit, randomise completely drain and follow up patients in line with the protocol of the study. 
However, to minimise the incidence of re-accumulation of pericardial fluid following the use of 
IA, initial monitoring before removal of pigtail catheter should be delayed for 48-72 hours. In 
recruiting patients, consideration should be given towards exclusion of patients in terminal 
stages of malignancies as such may not have a good outcome with IA. Also, the patient's 
education and reiteration of consent information, as well as using contact tracing, can improve 
adherence to protocol.   
The need to ensure the later led to development of the informed consent comprehension 
study through the use of University of California Brief Assessment of Capacity to Consent 
(UBACC), with primary objective of evaluating the feasibility (defined as the acceptance of the 
use of UBACC among at least 50% of IMPI-2 pilot trial participants for informed consent 
comprehension evaluation) and the utility of the UBACC as a training tool for iterative consent 
administration among participants. This study is presented in chapter 6. 
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Figure 5.1: The dose escalation flow chart, IMPI-2 dose-finding scheme highlighted in bold 
(DLT= Dose-limiting toxicity; MTD= Maximum tolerated dose) 
 
 
 
Figure 5.2: Alteplase concentration in the dose-finding study 
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Table 5.1: Baseline characteristics of Dose-finding 
study participants 
Variables  N=12 
Female sex-no. (%) 7 (58.3) 
Age- mean (SD)      38 (16) 
Referral Hospitals-no. (%)  
• New Summerset Hospital 3 (25.0) 
• Groote Schuur Hospital 3 (25.0) 
• Mitchel’s Plain District Hospital 2 (16.7) 
• Hiedeveld Emergency Centre     1 (8.3) 
• Khayelitsha District Hospital      1 (8.3) 
Co-morbidities- no. (%)  
• Human immunodeficiency (HIV) 5 (41.7) 
• Malignancy-related 2 (16.7) 
• Diabetics Mellitus 2 (16.7) 
Mortality- no. (%) 
• Cerebrovascular accident 
• Pulmonary Embolism 
• Metastatic diseases                           
 
1 (8.3) 
1 (8.3) 
1 (8.3) 
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                                                                                                                                                 3 months Follow-
up 
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                                                                                                                                              12 months Follow-up 
                                                                                                                                                
Screened for eligibility N= 300 
Recruited into the pilot n=130 
Excluded n= 170 
Routine arm n= 68 Alteplase arm n= 64 
Missed n=3 
Dead n= 3 
Missed n= 2 
Dead n=2 
Attended Follow-up n=57 Attended Follow-up n=50 
Attended Follow-up n= 40 
Attended Follow-up n= 39 
Attended Follow-up n= 26 
Attended Follow-up n= 10 
Attended Follow-up n= 54 
Attended Follow-up n= 46 
Attended Follow-up n= 30 
Attended Follow-up n= 12 
Missed n= 5 
Dead n= 2 
 
Missed n= 1 
Dead n= 2 
 
Missed n= 1 
Dead n= 2 
Missed n= 4 
Dead n= 3 
Missed n=3 
Deas n= 4 
Missed n= 1 
Dead n= 1 
Missed n= 2 
Dead n= 2 
Missed n= 7 
Dead n= 1 
Dose-
finding 
study 
Figure 5.3: Study flow diagram 
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Figure 5.4: IMPI-2 Pilot Screening (Projected versus actual) 
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Table 5.2: Baseline Characteristics of the Subgroup¶ 
Variables 
 
Alteplase 
n=64 
Routine 
n= 68 
 
Female sex – no. 
(%) 
 
32 (50.0) 26 (39.4) 
 
Age -year 
 
47 (34-60) 44 (33-57)  
BMI – Kg/m2 
 
22.4 (15.8-55.0) 21.8 (14.6-34.2)  
NYHA Class – 
no. (%) 
Class I 
Class II 
Class III 
Class IV 
 
 
 
 
 
 
14 (21.9) 
11 (17.2) 
19 (29.7) 
20 (31.3) 
 
14 (21.1) 
21 (31.8) 
17 (25.8) 
14 (21.2) 
 
 
 
Systolic Blood 
Pressure - mmHg 
 
 
 
116 (106-125) 
 
114 (105-122) 
 
Diastolic Blood 
pressure - mmHg 
 
 
 
74 (66-81) 
 
74 (68-83) 
 
Pulse rate – 
beats/min 
 
 
 
106 (93-120) 
 
103 (92-113) 
 
Duration of 
symptoms – days 
no. (%) 
<30 days 
>30 days 
 
 
 
 
 
 
 
 
46 (71.9) 
18 (28.2) 
 
 
 
51 (77.3) 
                       15 (22.7)  
 
 
Left ventricular 
function – no. (%) 
Normal 
Impaired 
 
 
 
 
 
 
51 (83.6) 
10 (16.4) 
 
 
   59 (93.7) 
4 (6.4) 
 
 
HIV Status 
Positive 
Negative 
 
 
 
 
33 (52.4) 
30 (47.6) 
 
35 (53.6) 
31 (47.0) 
 
 
Size of effusion- 
no. (%) 
Large >2cm 
Medium1-2cm 
Small <1cm 
 
 
 
 
 
 
 
50 (82.0) 
10 (16.4) 
1 (1.6) 
 
 
53 (85.5) 
8(12.9) 
1 (1.6) 
 
 
 
Characteristics of 
Fluid – no. (%) 
Bloodstained 
Serosanguinous 
Serous 
Purulent 
 
 
 
 
 
 
 
 
35 (62.5) 
12 (21.4) 
8 (14.3) 
1 (1.8) 
 
 
34 (55.7) 
17 (27.9) 
9 (14.8) 
1 (1.6) 
 
 
 
The total volume 
of fluid aspirated 
- ml 
 
 
 
1.1 (0.84-1.65) 
 
0.89 (0.60-1.30) 
 
CD4 cell count 
<200 cells/mm3  
>200 cells/mm3 
 
 
 
 
14 (63.6) 
8 (36.4) 
 
17 (70.8) 
7 (29.2) 
 
 
Total WBC 
 
6.8 (4.7-9.6) 7.2 (5.7-9.9)  
Haemoglobin 
 
10.7 (9.0-11.7) 10.7 (9.4-11.9)  
Mortality – no. 
(%) 
 
11 (17.2) 8 (14.7) 
 
¶ Continuous variables presented as median (IQR). BMI-Body mass index;  
NYHA- New York Heart Association; WBC- White Blood Cell Count  
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Table 5.2: Continues 
Variables  
 
Alteplase 
n=64 
Routine 
n= 68 
 
Cause of Effusion- no. (%)     
Tuberculosis 
  Confirmed (Culture or GXP) 
  Probable (ADA>30 IU/L) 
  Suspected  
Malignancy  
Purulent pericarditis 
Connective tissue disease 
 
 
 
17 (26.6) 
19 (26.7) 
22 (34.4) 
4 (6.25) 
1 91.56) 
0 (0.0) 
 
16 (24.6) 
25 (38.6) 
19 (29.2) 
4 (6.15) 
1 (1.54) 
1 (1.54) 
 
 
 
 
Adherence to Follow-up no. 
(%) 
- Two weeks 
- Six weeks 
- Three months 
- Six months 
- Twelve months 
 
 
 
 
 
50 (83.3) 
40 (74.1) 
39 (79.6) 
26 (76.5) 
        10 (58.8) 
 
 
57 (87.7) 
54 (88.5) 
46 (86.8) 
30 (76.9) 
12 (66.7) 
 
 
 
ADA-Adenosine deaminase assay; GXP- Gene expert 
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Figure 5.5: Recruitment performance 
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Figure 5.6: CRF completion rate July 2018 
 
 
 
Table 5.3 Study Key Messages 
Phase 1 Key findings on dose-finding 
• Zero percentage of patients had minor or major bleeding 
• 50mg of intrapericardial alteplase is a safe dose for complete drainage of 
pericardial effusion.   
 
Phase 2 Key findings on feasibility (criteria for success of feasibility) 
• Recruitment rate was 4-5 patients/month over the 16 months (3-5/month),  
• 97% adherence to protocol (≥95%),  
• CRF completion rate was 88.5% (≥95%), and  
• Overall adherence to follow-up was 81% (≥95%). 
It is feasible to recruit, randomise, completely drain the effusion, and follow up patients 
over 12 months in the main trial.  
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ABSTRACT 
Background 
Informed consent (IC) is critical for research involving humans. In the pilot study for the second 
investigation of the management of pericarditis (IMPI-2), we used the University of California 
Brief Assessment of Capacity to Consent (UBACC) to determine the feasibility of administering 
the UBACC during the IC process for IMPI-2. We also explored the potential impact of UBACC 
to improve informed consent comprehension (ICC) over time, and factors associated with ICC. 
Methods 
Consenting trial participants were administered the UBACC four times over six months; we 
recorded responses at each visit. A UBACC score of ≥25 was considered adequate 
comprehension.  
Outcomes 
The primary feasibility outcome was acceptance of UBACC evaluation, with success measured 
by ≥50% of participants accepting the tool. The secondary outcome was ICC defined by UBACC 
score ≥25. We used univariate logistic regression to explore comprehension over time and 
factors associated with UBACC score ≥25. 
Results  
Eighty-one participants (91% of invited participants) accepted use of the UBACC. 
Comprehension improved with time, the odds of passing the evaluation at six months compared 
to baseline was higher by 39% (OR 1.39, 95% C.I 1.17-1.65, p <0.001). Factors associated with 
a lower ICC were the use of interpreters and low education level (OR 9.17; 95% C.I 2.11;39.8; 
p-value 0.003). 
Conclusion 
Use of UBACC as a tool to evaluate ICC in a randomised clinical trial is feasible; using it as a 
training tool repeatedly during follow-up has the potential to improve ICC over time. 
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6.1 INTRODUCTION 
Informed consent (IC) is a voluntary agreement by participants to be part of a research project, 
following the presentation of sufficient information by a qualified member of the research team 
(Health, principles, and research 1975). It is a crucial component of research, involving availing 
the participant with accurate information on their condition, purpose, risks and benefits of the 
study, the current standard of care and available alternative methods. A robust informed consent 
process ensures that participants understand the information provided, give a voluntary decision 
and suffer no negative consequences should they refuse to participate (Emanuel, Wendler, and 
Grady 2000; Marshall et al. 2006) However, the extent to which these requirements are 
achieved often remains a matter of researcher judgement in which empirical evaluation during 
the consent process has little place (le Roux-Kemp 2011). Balancing completeness versus 
simplicity is a real challenge in the preparation of patient information materials, especially in low 
and medium-income countries (LMICs). Social factors such as poor literacy and increased 
vulnerability confront the population when asked to participate in research they do not fully 
understand. The Declaration of Helsinki requires researchers to ensure the comprehension of 
information they give to potential participants (Association 2013).  
A range of tools have been developed in clinical research to assess the understanding of 
informed consent, such as structured questionnaires (Flory and Emanuel 2004) and quizzes 
(Lindegger et al. 2006). In evaluating comprehension, any instrument used should enhance the 
decisional capacity of participants through an understanding of the critical elements of the 
research process.   
One such tool is the University of California San Diego Brief Assessment of Capacity of Consent 
Questionnaire (UBACC). It is a screening tool consisting of 10 items scored on a scale of 1 to 
3, with 1 reflecting an inadequate response and 3 indicating an intelligent response. An 
intermediate score of 2 may be used for partially appropriate responses or uncertainty even 
after re-explanation [The original UBACC (Jeste et al. 2007) tool's scale was from 0 to 2, 
however, in our current study we shifted the scale for ease of analysis]. The UBACC was initially 
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designed for use in evaluating capacity to comprehend during recruitment into psychiatric 
research and could be a helpful tool in ensuring understanding of informed consent through 
repeated teaching and evaluation of comprehension among research participants. The UBACC 
tool screens for participants’ appreciation and understanding of research study elements 
including purpose, protocol/procedure, risk-benefit and voluntary nature of participation (Jeste 
et al. 2007). It has been used in research on schizophrenia (Jeste et al. 2008), neurocognitive 
conditions (Duron et al. 2013), HIV (Doyle et al. 2016) and, recently, in genomics of 
schizophrenia research in South Africa (Campbell et al. 2017), and shown to be a useful tool for 
improving understanding of research elements. We decided to evaluate the feasibility of 
administering the UBACC as a training tool among participants being enrolled in the second 
Investigation of Management of Pericardial disease pilot trial (IMPI-2). A randomised control 
trial (RCT) of Complete Percutaneous Pericardial Drainage Facilitated by Intrapericardial 
Alteplase Compared to Conventional Pericardiocentesis When Indicated in Adults with Large 
Pericardial Effusion due to Tuberculous and Non-Tuberculous Pericarditis. The study will test 
whether participants randomised to the intervention arm will have a reduction in major adverse 
pericardial diseases outcomes compared to those in the placebo arm. The pilot phase of the 
trial which was used to assess UBACC was designed to evaluate the feasibility of recruiting and 
retaining participants and assessing adherence to the study protocol in preparation for the larger 
multicenter trial. 
The current study, named the Informed Consent Comprehension study (ICC study), was 
designed to evaluate the feasibility (defined as the acceptance of the use of UBACC among at 
least 50% of IMPI-2 pilot trial participants for informed consent comprehension evaluation) and 
the utility of the UBACC as a training tool for iterative consent administration among participants. 
Specifically, the study tested to see if participants will allow the use of UBACC to evaluate their 
comprehension and if their comprehension of information obtained during the IMPI- 2 consent 
process improves over time using the ‘teach to goal’ method (Isles 2013; Kripalani et al. 2008; 
Paasche-Orlow et al. 2005). The study will also examine factors associated with better consent 
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comprehension. To the best of our knowledge, this is the first time this kind of research has 
been done on clinical trials in Africa. 
The hypothesis is that the use of the UBACC as a training tool will improve consent 
comprehension among participants of the IMPI-2 pilot trial. The primary objective of the study 
is the determination of the feasibility of use of the tool defined as the acceptance of the use of 
UBACC among at least 50% of IMPI-2 pilot trial participants for informed consent 
comprehension evaluation. The secondary objectives include evaluating if its comprehension 
improves with use of UBACC as a training tool, if informed consent comprehension improves 
over time and identification of factors associated with the improvement in comprehension.  
The primary outcome of the ICC study is number of participants that accepted the use of UBACC 
for informed consent evaluation at baseline. It is important to note that the ICC substudy was 
conceived and approved after the IMPI-2 pilot trial had already begun. For regulatory reasons, 
a low UBACC score could not be used as an exclusion criterion for enrolment.  
 
6.2. METHODOLOGY 
6.2.1. Data Collection 
Patients referred to the IMPI-2 pilot trial were screened for eligibility based on the inclusion and 
exclusion criteria outlined in the trial protocol (NCT02673879 clinical trials.gov). This includes 
age 18 years and above, no contraindication to fibrinolysis and presence of large pericardial 
effusion. Demographic data information and any previous history of involvement in a clinical trial 
were also collected. 
Once eligibility was established, participants were taken through the IMPI-2 consent process 
using a standardised consent form (available in English, Xhosa and Afrikaans) [Appendix 1]. 
This included information on details of the study, currently available treatment, the purpose of 
the study, randomisation, risk and benefit of participating, follow-up plan, duration of the study, 
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confidentiality, voluntary participation and freedom to withdraw. An opportunity was given for 
questions and clarifications. We used a flow diagram to illustrate the basic concepts of 
pericardial effusion, pericardiocentesis, potential complications randomisation and follow-up. 
Those who did not understand the English language had interpreters to assist in the process.  
Once the participant had no further questions, we administered the UBACC to evaluate their 
comprehension and recorded the total UBACC score following the first consent. Items on which 
the participant scored 1 or 2 were then re-explained and a further opportunity for questions 
given, after which the UBACC was re-administered (Figure 1). Where this was administered 
more than once; an average score was taken. In some situations, patients declined the UBACC 
evaluation after giving consent to enrolment in the IMPI-2 trial. In such instances, we evaluated 
them at the two weeks follow-up visit. UBACC was used as an iterative training tool and not a 
screening tool, and no comparison to baseline was done for people who had a UBACC greater 
than 25 at baseline. 
At each follow-up visit (two weeks, six weeks, three months and six months), we provided the 
patients with all information given in the initial consent process, but without formally re-
consenting. This was then followed by inquiring about new symptoms, drug use and general 
well-being. The patients were subsequently examined, and echocardiography was performed, 
followed by an assessment of comprehension using the UBACC. Where incorrect answers 
suggested gaps in comprehension, relevant information was provided verbally to the patients 
again. At the end of the process, we conducted repeat evaluations and recorded the average 
UBACC score for that visit. This sequence of events was a product of the fact that the ICC study 
was introduced as a substudy only after the pilot trial had already been approved and started.  
 
6.2.2. Sample Size  
Sample size estimation was based on the feasibility outcome of recruiting 50% of eligible pilot 
trial participants. Using the confidence interval (C. I) approach (Cocks and Torgerson 2013) at 
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95% C.I. with a prior estimate of 0.80, and a margin of error of 0.10, we would require at least 
61 participants in assessing the feasibility of use of the UBACC for informed consent 
comprehension among IMPI-2 pilot participants (Appendix 2).  
6.2.3. Statistical Analysis 
Data analysis were done using STATA 14 (Stata Statistical Software College Station, TX). We 
reported age as a categorical variable in groups and presented all categorical variables as count 
(%). Bivariate logistics regression was performed for baseline and subsequent UBACC scores 
to identify the relationship between factors such as age, sex, level of education, use of 
interpreters and different UBACC scores at baseline (Appendix 3), and to determine the odds 
of having UBACC score ≥25 at each follow-up visit compared between baseline, as well as odds 
of passing the question by the interval since the last evaluation. Identification of significant 
predictors of outcome was done using bivariate regression models at 95% CI and p-value <0.05. 
 
6.3 Ethical Review  
The IMPI-2 trial and patient information documentation were approved by the Faculty of Health 
Sciences Human Research Ethics Committee of the University Cape Town (UCT HREC 
370/2015) and the South African Health Products Regulatory Authority (20150723). It was 
registered with clinical trials.gov (NCT02673879). The ICC substudy reported in this paper was 
approved through an amendment to the parent study. 
 
6.4. RESULTS 
6.4.1 Data Included 
From April 2017 to August 2018, we screened 300 participants for eligibility into the IMPI-2 pilot 
trial and recruited 128 participants in the two centres (89 from Cape Town and 39 from Mthatha). 
This ICC study was conducted at the Cape Town study site.  
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Eighty-nine participants were invited to take part in the informed consent comprehension 
evaluation with the UBACC. Ninety-one per cent (81/89) [95% confidence interval: 1.42; 1.65] 
of eligible IMPI-2 participants accepted the evaluation, with complete data for analysis available 
for 71 participants.  
 
6.4.2 Descriptive Data 
The demographic characteristics of the study population are displayed in Table 1. Of the 71 
participants included in the analysis, there was a slight male preponderance (54.9%) and the 
median age (IQR) was 42 (19-77) years. Forty-nine per cent of the cohort had at least secondary 
level of education, 67.6% were of South African Xhosa origin and 33% needed interpreters for 
the interviews. 
 
6.4.3 Comprehension of different aspects over time 
The average UBACC score at baseline was 23.8. This increased with iterative learning 
(Appendix 4) at subsequent follow-up visits compared to baseline as shown by significant 
improvement at six months (Table 2). The average score for Question 1 was lowest at baseline 
(Table 3). 
We recorded high UBACC scores in questions exploring the reason for accepting to participate 
in the trial (question 2), voluntariness (question 4) and financial responsibility in cases of harm 
resulting from participation (question 10) [Table 3].  
Knowledge of the primary purpose of participation in the trial (question 3) and right of withdrawal 
(question 5) had a marked increase in UBACC scores at six months. 
Understanding of risk of participation (question 7) either resulting from the procedure or as a 
side-effect of the trial intervention, remained poor. The reduced comprehension was shown by 
the low UBACC score throughout the study duration, which was worse at six months despite 
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reiteration. Comprehension of the uncertainty about the effect of the trial intervention (question 
9) was low, but at six months there was a slight improvement. We did not compute the estimates 
of effect for the association between covariates and UBACC score 
 
6.4.4 Factors associated with lower UBACC score 
Use of interpreters ( ES 0.9; 95% C.I 0.44; 1.50) and having lower than a secondary level of 
education (ES -0.04; 95% C.I -0.58; 0.50) was associated with a low UBACC score, most 
marked at six months (appendix 5). However, the study was hypothesis-generating and not 
powered to test significance.  
 
6.4.5 Understanding of Specific Questions 
Most participants correctly answered the question “who will pay for your medical care cost in 
case of trial related injuries", with a 78-90% correct response over the follow-up period. 
However, most participants failed to correctly answer the question “Is it possible that the 
treatment planned in the study may not have the expected result” despite repeated correction. 
Improved comprehension was most marked with regards to their understanding of the trial 
concept, the benefits and that the primary focus.  
 
6.5 DISCUSSION 
Identified challenges during informed consent processes may include absence of a conducive 
environment, the presence of pain/distress (Britz and le Roux-Kemp 2012), poverty, low levels 
of education (Lavery 2007; Minnies et al. 2008) and health literacy (Adams et al. 2005) Others 
are the presence of investigation intervention only in the trial (Hawkins and Emanuel 2008; 
Mystakidou et al. 2009), insistence on signatures rather than oral agreement (Vischer et al. 
2016), use of legality driven voluminous and complex consent forms (Commission 2001; 
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Bioethics 2005), language barriers and foreign accents of researchers (Adams et al. 2005). 
These challenges are worse in LMICs due to low literacy and over the years’ researchers have 
introduced the use of tests to evaluate and improve consent comprehension in a bid to reduce 
the impact of the challenges. 
Informed consent materials can be improved through an iterative learning process of presenting 
the study information, assessing a participant’s understanding of the study elements, and 
revisiting and revising poorly understood aspects. 
Tools that have been used in different studies to improve comprehension include: brief informed 
consent evaluation protocol (BICEP) (Sugarman et al. 2005) quality of informed consent test 
(QuIC) (Joffe et al. 2001) Deaconess Informed Consent Comprehension Test (DICCT) (Miller 
et al. 1996) Digitised Informed Consent Comprehension Questionnaire (DICCQ)(Afolabi et al. 
2014) and the UBACC. Each of these tools has its challenges and is subject to different 
interpretations.  
In this preliminary study, we showed that it was feasible to use the UBACC as a tool to track 
and improve ICC in an RCT. Furthermore, the use of the UBACC as a training tool was 
acceptable to IMPI-2 pilot trial participants. This provides further evidence to support the use of 
tools like the UBACC in clinical trial situations in LMICs, as previously suggested in a study in 
Africa among patients with schizophrenia (Campbell et al. 2017). 
The purpose of the trial was not well understood at baseline, however, the level of 
comprehension measured by the UBACC scores improved with iterative learning over time and 
with repeated reinforcement over the follow-up period. The finding is evidence that reiteration 
improves comprehension, as seen in a study among HIV patients in Botswana (Chaisson et al. 
2011). We used pictures and flow diagrams to explain different aspects of the trial and emphasis 
was placed on the reiteration of areas that showed low levels of comprehension, resulting in the 
improvement we noticed over time.  
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Information consistently understood about the trial were the primary purpose of recruitment 
being research, voluntary participation, liberty to withdraw and culpable party in events of harm. 
The comprehension of these aspects could enhance research integrity and strengthen 
adherence to follow-up in the trial.  
Comprehension of information on the risk of study, randomisation and effect of the intervention 
was repeatedly low, despite most of the participants knowing that the primary purpose was 
research (question 2). We attributed this to therapeutic misconception and the complexities with 
explaining randomisation in LMICs; alluded to by other studies (Appelbaum et al. 1987; Joffe et 
al. 2001). Immediate relief from pericardiocentesis rather than the long-term complications of 
TB pericarditis, which the trial was designed to investigate, could be responsible for such 
persistent therapeutic misconceptions. Reiteration of trial information was used to improve 
comprehension, and this could be the reason for the marginal increase in UBACC score on 
question 9 at six months. The preliminary IMPI-2 pilot data result shows that visit adherence at 
six weeks, three months, six months and twelve months were 78%, 80%, 75% and 60% 
respectively. The likely explanation for the reduction in adherence with longer duration of the 
study, judging from the findings of the ICC study, could be that non-adherence to follow-up is 
related to consent comprehension. At six months the proportion of participants with high UBACC 
score increased, despite the reduced number of participants. Meaning that those who had poor 
comprehension dropped out with clinical improvement; while those who stayed on had better 
comprehension.  
A higher level of education and non-use of interpreters for UBACC administration were 
associated with a higher score, consistent with what has been reported previously in the 
literature (Campbell et al. 2017; DuBois, Bante, and Hadley 2011; Dunn 2006).  
The low UBACC score for participants who took the evaluation in Xhosa could have been due 
to the difficulty in explaining concepts like randomisation and research risk to the participants 
by the interpreters. Reasons could be due to lack of correct local words to convey the 
information (Adams et al. 2005), or loss of meaning due to use of inadequately trained 
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interpreters for the purpose or the influence of limited education on the understanding of 
concepts related to the study (Vasquez and Javier 1991). It has previously been observed that 
use of investigators who use a language or accent different from that of research participants 
can affect informed consent comprehension (Escobedo et al. 2007; Musmade 2013). The 
finding could also imply the need for the development of culturally and linguistically appropriate 
tools for informed consent comprehension in communities, as advocated by some (Afolabi et 
al. 2014). 
We attributed the low UBACC score seen with the low level of educational attainment to bias 
that could be shown by such participants to being tested. The task of memory recall could be 
didactic and embarrassing, a situation that has previously been shown to be a challenge to 
informed consent comprehension (Sudore et al. 2006). 
We noticed some secondary effects during this study for which we did not primarily design it. 
The use of UBACC led to improvement in the skill and ability of the researcher in the 
administration of IC to participants during the trial. With time the process became more 
structured and intuitive leading to prompt completion. It was beneficial especially in emergencies 
such as when patients presented in cardiac tamponade and time to intervention was crucial in 
achieving a good outcome. Also, the participants displayed knowledge of the trial concepts and 
took ownership of the process because of the iterative learning.  
Our study was limited by the fact that although the sample size was adequate to test the 
feasibility of the use of UBACC tool, it was not adequately powered to test for association 
between identified factors and comprehension. This explains the large confidence interval in the 
results. Therefore, our findings are mainly exploratory, and we will need to confirm them in a 
larger similar trial, if not the main IMPI-2 trial, should the pilot trial be positive. Our use of 
bivariate logistic regression to examine the significance of the association between each 
baseline characteristics and comprehension at each time point is prone to false significance due 
to influence of type 1 error. Using longitudinal models like generalized estimating equation or 
mixed-effect models to examine the impact of these predictors on changes in comprehension 
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over time is a better method and we intend to use this in subsequent stages of the trial.  
Secondly, UBACC was conceived to be a screening tool, but in this study, we used it as a 
teaching tool for improving comprehension of informed consent. Participants with low scores at 
baseline were not eliminated, whereas in the original UBACC concept, having low scores would 
have been understood as not having the capacity to consent – again something that could be 
corrected in the larger trial, also, baseline values were not collected at the same time for 
everyone.  
Another limitation of the study is having the researcher administer the evaluation which could 
have been a source of bias. The ICC study was conceptualised to improve the dropout rate 
noticed in the IMPI-2 trial follow-up, however, as shown in the results despite the improvement 
in participants understanding, many missed their follow-up the longer the trial lasted leading to 
missing data. This is a potential limitation of the study; however, in the main trial we hope to 
improve the adherence to follow-up by iterative learning using the UBACC. To report the findings 
better, we will use of repeated measure anova for the analysis. 
 
Conclusion 
The use of an iterative learning tool such as UBACC is feasible in a randomised control trial in 
Africa and could lead to improved informed consent comprehension among participants. 
However, it may be better to use trained native language speakers to administer informed 
consent and evaluate comprehension. There is also a need to develop culturally and 
linguistically appropriate tools for informed consent comprehension based on local peculiarities.  
In the main trial, to better understand the impact of predictors on changes in comprehension 
over time, we will explore the use of such longitudinal models as mixed-effect regression models 
and generalised estimating equation in analysing the data. 
 
 
 120  
Table 6.1: Baseline characteristics of the ICC study population 
Characteristics Count (N=7) Percentage (%) 
Age groups (years) 
 <20 
 20-29 
 30-39 
 40-49 
 50-59 
 60-69 
 >70 
 
1 
10 
21 
15 
11 
10 
2 
 
1.4 
14.3 
30.0 
21.4 
17.7 
14.3 
2.9 
Sex 
 Female 
 
32 
 
45.1 
Level of Education 
 None 
 Primary† 
 Secondary 
 Tertiary 
 
4 
21 
31 
9 
 
5.6 
29.6 
43.7 
12.7 
Population group 
 South African Blacks‡ 
 Other South Africans§ 
 Foreign Nationals¶ 
 
48 
13 
10 
 
67.6 
18.3 
14.1 
Marital status 
 Married 
 Single 
 Widow 
 
34 
35 
2 
 
47.9 
49.3 
2.8 
Previous trial 
 No 
 Yes 
 
68 
3 
 
95.8 
4.2 
Use of Interpreters 
 No 
 Yes 
 
47 
24 
 
66.2 
33.8 
†Grouped with informal education, ǂ Mostly Xhosa, § White and Afrikaans, ¶ Other African 
Black immigrants 
ICC-Informed Consent Comprehension 
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Table 6.2: Odds of passing UBACC at subsequent visits compared with baseline  
Visit n Proportion 
passing (UBACC 
Score>25) 
OR 95% C. I P 
(Interaction) 
Baseline 64 44.0%    
6 weeks 61 59.0% 1.17 1.01; 1.34 0.033 
3 months 50 64.0% 1.28 1.09; 1.46 0.001 
6 months 35 69.0% 1.39 1.17; 1.65 <.001 
OR-Odd Ratio; C.I- Confidence interval; UBACC- University of California Brief Assessment of 
Capacity to Consent 
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Table 6.3: Proportion of passing the UBACC questions at baseline and follow-up 
UBACC Questions Baseli
ne 
n= 64 
6 weeks 
n=61 
3 months 
n=50 
6 months 
n=35 
 % Pass %Pass % Pass % Pass 
Question 1     
What is the purpose of the study 
that was just described to you? 
36% 55% 60% 51% 
Question 2     
What made you agree to 
participate in this study? 
75% 79% 68% 83% 
Question3     
Do you believe that this is 
primarily research or treatment? 
53% 57% 54% 74% 
Question 4     
Do you have to be in this study if 
you do not want to participate? 
78% 85% 84% 80% 
Question 5     
If you withdraw from this study, 
will you still be able to receive 
regular treatment? 
58% 57% 58% 74% 
Question 6     
What are the things you are 
required to do while in this study? 
66% 59% 54% 60% 
Question 7     
Please mention some of the risk 
and discomfort that people in this 
study may experience 
45% 41% 42% 37% 
Question 8     
Please mention the benefits of 
being in this study 
50% 59% 56% 54% 
Question 9     
Is it possible that the treatment 
planned in study may not have 
the expected result? 
42% 39% 38% 60% 
Question 10     
Who will pay for the medical cost 
if you are injured as a direct result 
of being in the study? 
78% 84% 90% 80% 
OR-Odd Ratio; C.I- Confidence interval; UBACC- University of California Brief Assessment of 
Capacity to Consent 
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Figure 6.1: The ICC Study Flow (IMPI- Investigation for management of pericarditis in Africa; 
UBACC- University of California San Diego Brief Assessment of Capacity to Consent; ICC- 
Informed consent comprehension) 
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Appendix 6.1:  
UBACC English Version 
No Question Score 
1 What is the purpose of the study that was just described to you?  
Response:  
3 = To compare between using a drug in the pericardium to facilitate 
drainage and routine care in patients with pericardial effusion 
2= Incorrect answer 
1= Don’t know or not sure 
1 
2 
3 
2 What made you agree to participate in this study? 
 Response: 
3 = Find intervention that is best for me, help others 
2= Incorrect answer 
1= Don’t know or not sure 
 
1 
2 
3 
3 Do you believe this is primarily research or primarily treatment?  
Response:  
3 = Both Research and treatment 
2= Incorrect answer 
1= Don’t know or not sure 
 
1 
2 
3 
4 Do you have to be in this study if you do not want to participate?  
Response:  
3 = No I don’t have to 
2= Incorrect answer 
1= Don’t know or not sure 
 
1 
2 
3 
5 If you withdraw from this study, will you still be able to receive regular 
treatment? Response:  
3 = Yes 
2= Incorrect answer 
1= Don’t know or not sure 
1 
2 
3 
6 What are the things you are required to do while in this study?  
Response:  
3 = At least 2 of the following: Sign consent, answer some question to 
see if you understood what you signed for, take your medications, come 
back at weeks 2 and 6, months three, six and twelve for follow up 
2= Incorrect answer 
1= Don’t know or not sure 
 
1 
2 
3 
 125  
7 Please mention some of the risk and discomfort that people in this study 
may experience.  
Response:  
3= At least 2 of the following: the discomfort of the procedure, risk of 
bleeding, the intervention may not help me, the risk of coming repeatedly 
to follow up 
2= Incorrect answer 
1= Don’t know or not sure 
1 
2 
3 
8 Please mention the benefits of being in this study. 
Response: 
3 = Might learn more about my health, closer follow up, may help the 
larger society know how to treat the condition better 
2= Incorrect answer 
1= Don’t know or not sure 
1 
2 
3 
9 Is it possible that the treatment planned in study may not have the 
expected result? 
Response:  
3 = Yes, it is possible 
2= Incorrect answer 
1= Don’t know or not sure 
1 
2 
3 
10 Who will pay for the medical care cost if you are injured as a direct result 
of being in the study?  
Response:  
3 = This will be covered by the insurance held at UCT through its no-fault 
insurance policy which covers the trial 
2= Incorrect answer 
1= Don’t know or not sure 
1 
2 
3 
 Total score  
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UBACC Xhosa Version 
No  Umbuzo  Score  
1  Yintoni injongo yesifundo esigqityakucaciswa kuwe?  
Impendulo:  
3=Kukuthelekisa Phakathi kokusebenzisa kwamayeza akwi  
(pericardium)ekufunxeni incindi ekuxilongeni izigulane ezinoxinezelelo lwe 
(pericardium) effusion.  
2=Yimpendulo engeyiyo  
1=Andiyazii okanye andiqinisekanga  
1  
2  
3  
2  Yintoni ekwenze ukuba uvume ukuthabatha inxaxheba koluphando?  
Impendulo:  
3 Kukufumana ulwazi olungcono kum, kuzoncedakala  nabanye abantu  
2=Yimpendulo engeyiyo  
1=Andiyazi okanye andiqinisekanga  
1  
2  
3  
3  Ingaba ucinga ukuba olu luphando okanye lunyango?  
Impendulo:  
3= Luphando nonyango zombini   
2=Yimpendulo engeyiyo  
1= Andiyazi okanye andiqinisekanga  
1  
2  
3  
4  Ingabo kunyanzelekile na ukuba ube koluphando nokuba awufuni?  
Impendulo  
3 = Hayi andinyanzelekanga   
2=Yimpendulo engeyiyo  
1=Andazi andiqinisekanga  
1  
2  
3  
5  Ukuba uye wayeka ukuthabatha inxaxheba koluphando, ungakwazi 
ukufumana unyango lwakho njengesiqhelo?  
Impendulo:  
3= Ewe   
2=Ympendulo engeyiyo  
1=Andiyazi okanye andiqinisekanga  
1  
2  
3  
6  Ukuba uthe wathatha inxaxheba koluphando, zeziphi ezinye zezinto 
ozakucelwa uzenze?  
Impendulo:   
3=Nokuba zimbini kwezi zilandelayo :   
Ukutyikitya (ukusayina) isivumelwano, uphendule imibuzo ubonisa ukuba 
uyayiqonda into oyisayineleyo,uthathe amayeza akho ,uphinde ubuye 
emva kweveki ezimbini ,ezintandathu ,inyanga ezintathu ezintandathu 
ukuya kunyaka  
2= Yimpendulo engeyiyo  
1=Andiyazi okanye andiqinisekanga  
1  
2  
3  
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7  Ndicela uchaze ubungozi okanye ubunzima onokubufumana ukuba uthe 
wathatha inxaxheba koluphando?  
Impendulo:  
3= Nokuba zimbini kwezi zilandelayo:   
Ukungahambi kakuhle kwenkqubo leyo uzobe uyenziwa, umngcipheko 
wokopha, yonke lenkqubo isenokungabiluncedo kum, umngcipheko 
wokuza ngokuphindelela kutyelelo lwakho. 2=Yimpendulo engeyiyo  
1  
2  
3  
 1=Andazi okanye andiqinisekanga   
8  Ndicela uxele inzuzo/amanye amancedo anokufumaneka koluphando? 
Impendulo: Ndinokufunda lukhulu ngempilo yam, utyelelo  
olusondeleleneyo,kuncedwe uluntu oluninzi lwazi lukhulu (ncono ) 
ngendlela yolunyango   
2= Yimpendulo engeyiyo  
1=Andazi okanye andiqinisekanga  
1  
2  
3  
9  Ingaba ingenzeka into yokuba oluphando lungangabi luncedo kuwe?  
Impendulo:  
3=Ewe kunokwenzeka.   
2=Yimpendulo engeyiyo  
1=Andiyazo okanye andiqinisekanga  
1  
2  
3  
10  Ngubani ozakuhlawulela unyango lwakho xa uthe walimala usephantsi 
koluphando?  
Impendulo:  
3= Oko kuyakubazindleko ze inshorensi yase yunivesithi yekapa (UCT)            
akunamgaqo nkqubo we-inshorensi ejongene noPhando      
2=Yimpendulo engeyiyo  
1= Andiyazi okanye andiqinisekanga  
1  
2  
3  
  
                                                                                                         Uvavanyo 
lokuqala 
                                                                                                       Uvavanyo 
lwesibini 
 
Uvavanyo lwesithathu 
  
                                                              
 Amanqaku eziphumo                                                                                                 
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UBACC Afrikaan’s Version 
No Question Score 
1 Wat is die doel van die studie wat vir u  beskryf was?  
Antwoord.  
3 = Om te vergelyk tussen ‘n drogeiy/medisyne wat in die perikardium 
gespuit word of routine behandeling. Om dreinering te verbeter in 
patiente met  
perikardiale effusie. 
2=verkeerde antwoord 
1=ek weet nie 
1 
2 
3 
2 Hoekam sal jy dit oorweeg om aan die studie deel te neem. 
Antwoord 
1= Om beste behandeling vir my te kry  en ook sodoente andere te help 
2=verkeerde antwoord 
3=Weet nie, nie seker 
 
1  
2 
3 
3 Glo jy dit is eerstens navorsing of primere behandeling 
Antwood: 
3= altwee Navorsing en Behandeling 
2=Verkeerde antwoord 
1=Weet nie ;nie seker 
  
1 
2 
3 
 
4 Moet jy in die studie wees al wil jy nie deelneem nie  
Antwoord 
3=Nee ek hoef nie 
2=Verkeerde antwoord 
1= Weet nie; nie seker nie 
 
1 
2 
3 
 
5 Indien jy onttrek van die studie,sal jy nog steeds dieselfde  behandeling 
kry  
Antwood: 
3=Ja 
2=Verkeerde antwoord 
1=Weet nie;nie seker nie 
 
1 
2 
3 
6  
Indien jy deelneem aan die studie is daar sommige goed wat van jou 
verwag sal word. 
Antwoord: 
3= Ten minste (2) twee van die volgende (i) toestemming te teken  
(ii) sommige vrae te beentwoord om te sien of jy verstaan waarvoor jy 
teken (iii) Medisyne te neem soos voorgeskryf. 
(iv)die kliniek by te woon op 2weke;6weke;3maande;6maande en 1jaar. 
2= Verkeerde antwoord 
1= Nie seker;weet nie 
 
 
1 
2 
3 
 129  
7  
Beskryf sommige risikos of ongemak patiente kan ondervind indien 
hulle aan die studie deelneen 
Antwoord 
3=ten minste 2 van die volgende; 
(i) Die ongemak van die procedure 
(ii) Risiko van bloeding 
(iii) Die intervensie mag nie help nie 
(iv) Die ongerief om gereeld die kliniek by te woon 
 
1 
2 
3 
 
8  
Beskryf  sommige voordele van die studie? 
Antwoord:  
3= Mag meer leer van my gesondheid;gereelde opvolg 
Mag die groote gemeenskap help met beter behandeling. 
2=verkeerde antwoord 
1=weet nie ;nie seker nie 
 
1 
2 
3 
 
9 Is dit moonthlik dat hierdie studie geen vooideel vir jou inhou nie ? 
Antwood:  
3= Ja 
2=verkeerde antwoord 
1=Weet nie;nie seker nie 
 
1 
2 
3 
 
10 Wie sal betaal vii mediese sorg? 
Indien jy beseer word as direkte oorsaak van die deelname aan die 
studie. 
Antwooid 
3= Die assuransie van UCT sal betaal deur die geen skuld assuransie 
polis wat die studie dek. 
2=Verkeerde antwoord 
1=Weet nie;nie seker nie 
 
1 
2 
3 
 
 Totale Puntetelling 
 
 
 Evaluasie 1 
Evaluasie 2 
Evaluasie 3                                                                                                                 
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Appendix 6.2: Sample size calculation table for estimating the proportion of patients who will 
accept UBACC evaluation using a 95% confidence interval for different values of the margin of 
error (E) and prior estimate (P) 
 
 
 
E 
                             Prior estimate (P) 
 0.50 0.55 0.60 0.65 0.70 0.75 0.80 0.85 0.90 0.95 
0.01 9604 9507 9219 8739 8067 7203 6147 4898 3457 1824 
0.05 384 372 368 349 322 288 245 195 138 73 
0.10 96 95 92 87 80 72 61 49 34 18 
P = prior estimate of the proportion of eligible patients that would accept UBACC evaluation 
E= Margin of error of estimate 
Sample size (n) = 1.96^2*P(1-P)/E^2
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Appendix 6.3: ICC study analysis plan 
Objective Outcome Explanatory variable if 
applicable 
Criteria for feasibility/ hypothesis Method of analysis 
Primary feasibility: To 
determine the feasibility of 
using the UBACC as 
training tool in improving 
and evaluating 
comprehension of the IC 
process among participants 
in a clinical 
Acceptance of use 
of tool, measured as 
percentage of 
patients who agree 
to using the tool to 
evaluate the 
comprehension of 
the IC process 
N/A Criteria for success of feasibility: At least 
50% of eligible trial patients will accept 
the evaluation  
Descriptive statistics expressed as 
percentage (95% confidence 
interval) 
Secondary feasibility 
objectives: 
1. If the biological 
intervention in the form of 
using UBACC as an 
educational tool improves 
the response 
 UBACC score of 
≥25 
Time: comparing baseline 
performance with 6 weeks, 
3 months and 6 months 
IC comprehension will improve over time Logistics regression 
2. Determine if there are 
factors associated with 
response 
UBACC score of ≥25 • Sex 
• Age 
• Educational level 
• Use of interpreters 
• Language of 
administration of 
UBACC 
 
 
Sex, age  
Low level of education, use of 
interpreters and not 
administering the IC in English 
Language will be associated 
with comprehension. 
Logistics regression 
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     Appendix 6.4: Progression of consent comprehension with Follow-up 
 
 
 
(UBACC- University of California Brief Assessment of Capacity to Consent) 
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Appendix 6.5: Bivariate model showing the odds of different variables in relation to UBACC score with 
Follow-up 
            Baseline             6 weeks            3 months               6 months 
 OR        95% C. I          p value OR      95% C. I     p value OR          95% C. I             p value OR               95% C. I         p value 
Sex† 
 
            
Female 0.42 0.15;1.19    0.10 0.29 0.10-0.85 0.03 0.42 0.13-1.37 0.15 0.48 011-2.10 0.33 
Education ǂ 
 
            
Secondary 1.20 0.40-3.59  0.74 2.00 0.65-6.19 0.23 9.17 2.11-39.8 0.00 1.78 0.32-10.0 0.51 
Origin¶ 
 
            
Xhosa 
 
2.43 0.57-10.4  0.23 0.89 0.21-3.62 0.86 1.53 0.34-6.87 0.58 1.71 0.23-12.6 0.59 
Foreign 
nationals 
2.13 0.33-13.8  0.43 1.33 0.20-8.17 0.76 1.60 0.24-10.8 0.63 1.00 0.08-12.6 1.00 
Use of 
Interpreter# 
 
            
Yes 0.34 0.11-1.04 0.06 0.42 0.14-1.26 0.12 0.42 0.12-1.42 0.162 1.75 0.40-7.58 0.45 
OR- Odd Ratio; C.I- Confidence Interval ICC-Informed Consent Comprehension 
†Female compared to male, ǂ Secondary level and above compared to Primary level and below, ¶ Afrikaans not shown, 
#compared to without an interpreter 
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Appendix 6.6: UBACC scores over the study period 
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CHAPTER SEVEN 
 CONCLUSIONS 
 
“A wise man is not one that gives correct answers, but rather the one that poses the right questions 
because the wise learn much more from foolish questions than the fool from wise answers” African 
Proverb  
This thesis began by ruminating over an old African proverb from the Ashanti people in Ghana, that 
“you do not test the depth of a river with both feet”. The central theme was on how smaller studies 
lead to larger ones. Each chapter of the thesis dwelt on one aspect of asking a scientific question, 
coalescing in the pilot trial of the second investigation of the management of pericarditis in Africa 
(IMPI-2 Trial). 
The IMPI project brings to fore the maxim that local challenges are only better tackled with homemade 
solutions. Pericarditis, the focus of the IMPI trial, is a common cause of cardiac morbidity and 
mortality.  However, the peculiarities in Africa and most of the low- and medium-income countries 
make tuberculosis a prominent cause of pericarditis, a situation that has not been made any better by 
the scourge of human immunodeficiency virus. It is for this reason that the thesis devoted a prominent 
part of the introduction on tuberculous pericarditis. Pilot trials a fundamental concept in raising, 
refining and trying scientific research questions, formed the foundation for the subsequent chapters 
by arming our understanding going into the IMPI-2 pilot trial. 
Several factors make it very challenging to conduct and complete large, expensive randomised control 
trials in Africa and most resource-limited settings. Some of these include readiness and capacity of 
the centres to undertake the processes, funders confidence, the cooperation of the physicians to refer 
potential participants, patients understanding of the trail information and commitment to follow-up. 
Pilot studies are essentials tools as the first step in the conduct of large RCT, and if correctly done, 
they could help in providing the solution to most of the challenges above and thus set the stage for 
definitive trials. The thesis uses Investigation of Management of Pericarditis (IMPI) trials to explore 
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and describe the potential use of pilot studies and subgroup analyses in limited resource 
environments. It uses the pilot phase of the IMPI-2, to describes practical challenges and lessons 
learned which will prepare the IMPI-2 investigators for the main phase of randomised controlled trial.   
The Strengths/Merit of this Work 
There were several fundamental lessons learned from performing the research for this thesis: 
1. Inadequate reporting of pilot trials identified by critical appraisal of the literature can lead to 
loss of valuable information emanating from randomised control trials. To mitigate against this, 
it is imperative that one insists on complete and thorough reporting with the aid of checklist 
such as the Consolidated Standards of Reporting Trials (CONSORT).  
2. Subgroup analysis is an essential statistical tool that can be used to effectively and reliably 
answer critical clinical questions which may be glossed over in large RCTs and thus obviate 
the need to conduct another expensive and resource intensive clinical trials.  
3. There is a vast difference between planning and implementation in clinical trials. In the conduct 
of clinical studies, it is essential to ensure the smooth running of all the processes. The IMPI-
2 pilot study allowed for the ascertaining of such parameters as data collection tools, potential 
recruitment sites, measures of outcome and protocol needed several changes during the pilot 
trial. Though these steps were daunting, therein lay the beauty of a pilot trial, as we learnt in 
the IMPI-2 trial. Our result showed that randomised control trial of patients with large 
pericardial effusion was feasible based on our recruitment rate; however, this was not without 
challenges and required several meetings, re-strategizing and adjustments. A good 
percentage of the study population was between 39-59 years, these are the core of workforce 
for any nation, and a sad reminder to the horrifying impact of diseases such as tuberculosis 
and HIV/AIDS on the economic development of Africa. 
4. Reducing attrition is essential in achieving success in a trial. We saw this as a significant 
challenge in the successful conduct of IMPI-2 trial. Ensuring informed consent 
comprehension, we learnt could improve follow-up. The Informed Consent Comprehension 
Study presented in chapter six first showed that it was feasible to use tools such as UBACC 
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to evaluate consent comprehension in the context of clinical trials in Africa. Its use also 
assisted in gaining the confidence of trial participants in the trial process, leading to 
improvement in adherence to follow-up. There was also a subjective improvement in informed 
consent delivery skills of the researcher. These effects will require more solid confirmation in 
future trials. 
 
Implications of outcomes of the thesis for future research in low- and middle-income 
countries 
The findings in this thesis lead us to recommend that in resource-limited settings, researchers and 
clinical trialists should explore using pilot studies, subgroup analyses, more thorough critical 
appraisal of the literature, as effective means of preparation for trial, answering important questions 
and getting clinical results before conducting the main study. 
The concepts discussed in this thesis serves as veritable tools in the planning of future trials as it 
highlights significant areas such as the impact on the design, conduct, analysis and presentation of 
main studies. It explores and describes the potential use of pilot studies and subgroup analyses in 
resource-limited environments.  
The findings of IMPI-1 trial on use of corticosteroids in tuberculous pericarditis continue to shape 
clinical management in this disease. The implication of the subgroup analysis presented in chapter 4  
may infact be that amongst patients presenting with effusive pericarditis, evidence of hemodynamic 
instability who are unwell, while corticosteroids may not be needed in those who undergo 
pericardiocentesis, the same may not be true who are unable to receive the procedure. This finding 
also provides an important knowledge gap about 1) the optimal management of patients who are 
unable to access pericardiocentesis and the potential role of corticosteroids and 2) the potential 
impact of role routine complete pericardiocentesis compared to usual care in pericardial effusion. The 
IMPI-2 trial is set to provide part of the answer to this later question. The preliminary findings of the 
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initial phase of the pilot as presented in chapter five of the thesis will help prepare the IMPI-2 
investigators and others to be able to conduct a large simple randomised controlled trial effectively. 
 
 
Limitations of the thesis 
Several challenges delayed the commencement and completion of the pilot trial. These contributed 
to the prolongation of the duration of the pilot study and non-commencement of the main. It was a 
limitation in the thesis as ideally one would have loved to practically see the impact of the pilot study 
on the main trial processes.  
During the conceptualisation of the IMPI-2 feasibility study, 218 participants were calculated as the 
required internal pilot study population to inform the commencement of the main trial. However, the 
pilot report presented in this thesis used 130 participants. At the planning stage, 11 sites were to be 
involved in the recruitment for the pilot; this was later reduced to eight locations. However, only two 
study sites participated in the pilot study for the 16-18 months covered by the report due to logistical 
challenges. As a result, the robust experience that would have accrued from a multi-centre pilot study 
was lost resulting also in a low study population. These were significant limitations.  
Also, we noted a high drop-out rate during follow-up, and the informed consent comprehension (ICC) 
substudy presented in chapter six was a response to this.  
Despite the noble intentions, the findings of the ICC study would have been more objective if trained 
interviewers were engaged to conduct the interviews rather than the clinical researcher. Not doing so 
could have been a source of bias, as already alluded to in chapter six.  Use of the tool also was not 
formerly part of the IMPI-2 pilot trial, and it could not, therefore, be administered on all participants, 
thus limiting its conclusions. Also, the original intended use of the tool for screening was different from 
its current use for teaching and evaluation of consent comprehension. 
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